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Chronic fatigue syndrome (CFS) is a complex disorder where neurological symptoms 
are common. Historically, this illness was first recognised in its epidemic form, often 
in proximity with an epidemic of polioclastic illness and was called myalgic 
encephalomyelitis (ME). Most cases of CFSIME now occur sporadically. Patients 
usually present with a wide range of physical and neuropsychiatric problems without 
abnormal physical signs. Occasionally, fatigue, angina-like chest pain and sweating 
may be the presenting symptoms and these features are similar to that described in 
patients with cardiological syndrome X. 
Although viral infections are known to precipitate CFS, persistence of known viruses 
does not explain the symptoms. In the initial studies of CFS patients, non-specific 
activation ofthe immune system was observed (Chronic Fatigue Immune Dysfunction 
Syndrome). There was also some evidence to suggest -an impairment of the aerobic 
metabolism in the skeletal muscle of these patients. Muscle biopsy findings and 
isolated muscle cell culture studies were suggestive of subtle mitochondrial 
dysfunction. Multifocal perfusion defects were reported in the cerebral SPECT 
(Single Photon Emission Computed Tomography) scans of a small number of patients 
who were studied. In the neuroendocrine studies of CFS, impaired activation of the 
hypothalamic-pituitary-adrenal (HPA) axis and relative hypocortisolemia were 
observed. Despite these interesting research developments, attempts to treat fatigue in 
CFS pharmacologically have been largely unsuccessful. There is still no specific 
diagnostic marker for CFS. _ 
Metabolic functions are one of the principal determinants of energy expenditure and 
are exquisitely susceptible to the effects of circulating hormones and chemical 
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changes. Consequently, clinical experiments based on energy expenditure and 
metabolic functions were considered to be valid approaches to the present research. 
Significant abnormalities were found in the proton magnetic resonance spectroscopy 
of basal ganglia in CFS patients. Autonomic cardiovascular responses to exercise are 
also impaired in a subset of CFS patients. Finally, plasma membrane injury appears to 
be a possible explanation for a range of observations made in this research. 
SUbjective fatigue is a complex symptom. It is the outcome of a variable combination 
of physiological and neuropsychological changes induced by the primary disease 
process. Downstream links between brain, neuromuscular and the cardiorespiratory 
functions are implicated in the neural control of force output during exercises in 
health and disease. Higher perceived fatigue in CFS is probably caused by the central 
mechanisms while the sensory input to these neural regulatory mechanisms may limit 
endurance to maximal and submaximal exercises. Based on these findings and more 
indirect evidence from other studies, changes in cell membrane properties affecting 
neuronal signalling in the basal ganglia seem to emerge as one of the likely 
,.. 
pathophysiological mechanisms in CFS. There is also evidence of an imbalance of the 
central autonomic tone in a subset of CFS patients. Surely, research in CFS has the 
potential to unravel the biology of central fatigue and may bridge the gap that exists 
between the borderland of neurology and psychiatry. 
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1. INTRODUCTION 
"It was the best of times, it was the worst of times, it was the age of wisdom, it was the 
age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the 
season of light, it was the season of darkness, it was the spring of hope, it was the 
winter of despair, we had everything before us, we had nothing before us" 
(Charles Dickens, A tale of two cities) 
,. 
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Chronic fatigue syndrome (CFS) is characterised by otherwise unexplained, 
overwhelming persistent or relapsing fatigue of new onset in variable combination 
with post-exertional malaise, unrefreshing sleep, self-reported impairment in short 
term memory, headache, muscle and joint pain (Table 1). For research purposes, case 
definition of CFS is based on the modified international criteria proposed by the 
Centers of Disease Control (CDC), Atlanta in 1994 [1]. CFS is recognised worldwide, 
is common and occurs in all age groups, usually affecting more women than men [2]. 
Because of its chronicity, lack of effective therapy and consequent disability in adults, 
a diagnosis of CFS has a significant socio-economic impact. Since CFS lacks any 
specific or sensitive biological marker, symptoms of chronic fatigue have been 
attributed in the psychiatric literature to the distorted perception of effort and 
avoidance of physical activity consequent to depression or somatisation. [3,4]. 
However, CFS patients can be distinguished from those with depression and indeed, 
fatigue in CFS does not respond to antidepressant therapy [2,5]. No more than 5% of 
CDC-defined CFS patients fulfil the current diagnostic criteria for somatisation 
'" 
disorder [6]. Recent clinical data also indicate that psychological co-morbidity in CFS 
is modest [7] being comparable to the psychological symptoms associated with 
chronic medical diseases such as diabetes and multiple sclerosis [8]. In a recent 
prospective study, it was shown that the pre-morbid psychiatric history did not predict 
future development of CDC-defined CFS after Epstein-Barr viral infection [9]. Thus, 
the psychiatric models of _CFS [4,10] do not adequately explain the mechanism of 
fatigue and physical limitations to exertion in appropriately defined CFS patients. 
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Table 1. Modified Centers for Disease Control (CDC) criteria for the diagnosis of 
Chronic fatigue syndrome (CFS) 
Patient must fulfil the major criteria and 4 or more minor criteria 
Major Criteria 
Clinically evaluated, unexplained, persistent or relapsing chronic fatigue that is of 
new or definite onset (has not been life long), is not the result of ongoing exertion; is 
not substantially relieved by rest; and results in substantial reduction in previous 
levels of occupational, educational, social or personal activities; and 
Minor Criteria 
The concurrent occurrence of four or more of the following symptoms, all of which 
must have persisted or recurred during six or more co~secutive months of the illness 
and must not have predated the fatigue: 
1. self-reported impairment in short-term memory or concentration severe 
enough to cause a substantial reduction in previous levels of occupational, 
educational, social or personal activities 
2. sore throat 
3. tender cervical or axillary lymph nodes 
4. muscle pain 
5. headaches of new type, pattern or severity 
6. unrefreshing sleep - _ 
7. post-exertional malaise lasting more than 24 hours 
8. mUlti-joint pain without joint swelling or redness 
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No specific treatment is currently considered effective in CFS and the claimed 
benefits of interventions such as cognitive behaviour therapy [11,12] and graded 
exercises in CFS [12,13] are debatable. 
Typically, community-acquired common viral infections trigger CFS symptoms [5] in 
previously healthy and often, physically active individuals [14]. In the past century, 
epidemic outbreaks of CFS-type symptoms were recognised after viral infections 
("atypical poliomyelitis") and were variously termed neuromyasthenia or epidemic 
myalgic encephalomyelitis (ME) [15]. These post-viral fatigue syndromes are 
considered to be neurologic diseases [16]. CFS-type fatigue is also common in post-
polio syndrome [17], Guillain Barre syndrome [18] and multiple sclerosis [19], 
conditions that are triggered by viral infections as in CFS. There is little evidence 
however to suggest that fatigue symptoms in CFS,multiple sclerosis or post-polio 
syndrome are caused by persistent infection or reactivation of the offending viruses 
[20]. However, it is recognised from the laboratory experiments that viruses can 
,-
affect more differentiated ("luxury") functions of the cells without causing cell death 
,.. 
[21]. Changes in the release, transport or receptor activation by specific 
neurotransmitters and neurohormones are some of the possible functions that may be 
affected after viral infections. 
In CFS research, it will be of considerable interest and importance if objective 
changes in normal physiological functions are identified that are of relevance to its 
symptoms. A substantial body of literature already exists on the neuroendocrine 
dysfunction and dysregulated hypothalamic-pituitary-adrenal axis in CFS [22]. A 
sUbpopulation of CFS patients has been shown to have neurally mediated hypotension 
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[23] and in particular, adolescent CFS patients are known to be highly sensitive to 
orthostatic challenge [24]. In the peripheral nervous system, chronic fatigue and 
acquired deficiency of myoadenylate deaminase deficiency have been documented 
after systemic viral infections [25]. A subgroup of CFS patients has been consistently 
shown to have altered skeletal muscle bioenergetics in the exercise studies and 31 p_ 
NMR spectroscopy [26-28] and produce excess venous lactate after subanaerobic 
exercises [29]. However, it is not known if the some of the observed abnormalities in 
the exercise tests and cardiovascular function were confounded by physical 
deconditioning and the consequent lack of fitness in CFS patients. Because there is no 
specific or sensitive diagnostic test for CFS, the case definition selects a 
heterogeneous group. The heterogeneity of patient popUlation in the research studies 
has also contributed to the conflicting results. The present research was designed to 
study the central and peripheral neurometabolic functions in CFS, to identify possible 
neurobiologic markers for fatigue and to make an attempt for clinical sub grouping of 
the CDC-defined CFS patients based on objective and reproducible criteria. 
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2. REVIEW OF THE LITERATURE: CLINICAL ASSESSMENT 
"Doctors are men who prescribe medicines ofwhich they know little, to cure diseases 
o/which they know less, in human beings of whom they know nothing" 
Voltaire (1694-1778) 
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Definition of fatigue 
Fatigue is common, yet one of the poorly understood symptoms. It is estimated that 
fatigue accounts for 10-15 million physician office visits in USA alone every year 
[30]. After pain, fatigue is probably the second commonest symptom of patients 
seeking medical attention. Because fatigue is common, it is frequently trivialised. To 
add to the difficulty, fatigue, like pain, is largely subjective and cannot be objectively 
quantified. 
Fatigue has been defined in the dictionary of the English language as "great tiredness; 
weakness or strain caused by use". In the medical literature, the term fatigue was 
introduced to characterise the rate of decline in the peak contractile force of the 
muscle fibres in the isolated nerve-muscle preparation in the laboratory. Three types 
of motor units have been distinguished according to the rate at which the skeletal 
muscle fibres fatigue (fast fatiguable, slow fatigue-resistant and fast fatigue-
resistant). All three types of motor units are found in most muscles, but in different 
". 
proportions [31]. In clinical practice, however, the term fatigue was applied to 
designate low levels of motor activity without muscle paralysis or to convey a 
sUbjective sense of lethargy, profound tiredness, lack of energy or feeling of constant 
exhaustion. It was also recognised that fatigue is sufficiently distinct from motor 
weakness because fatigue was not a major problem in a number of neuromuscular 
diseases that actually weakened muscles. Although fatigue is common in depression, 
not all fatigued patients experience low self-esteem, despair, and feelings of 
hopelessness and guilt that are frequently associated with lethargy and reduced 
12 
motivation in depressive disorders. It is therefore clear that as a symptom, fatigue is 
not the same as muscle weakness or depression. 
Subtypes of fatigue 
It may be important to distinguish between types of fatigue. In muscle physiology, 
fatigue is considered to be an inability to sustain a specified force output or work rate 
during exercise due to suboptimal muscle contractility. This has been termed 
objective fatigue [32]. Objective fatigue is characteristic of diseases that primarily 
affect muscles, neuromuscular junctions or the peripheral nerves (peripheral fatigue). 
Broadly speaking, peripheral fatigue is a physiologic measure of muscle contractility 
and is associated with primary muscle diseases and disorders of neuromuscular 
transmission. Neuromuscular disorders like myasthenia gravis and metabolic 
myopathy are the best examples of this type of fatigue. These disorders maximally 
reduce force output without causing much motor weakness. Similar objective fatigue 
may also be experienced by patients with peripheral circulatory disorders, as also in 
". 
ischemic heart disease and left ventricular failure because of a failure to augment 
blood flow to meet the requirements of the exercising muscles. 
In contrast, some patients experience difficulty in enduring normal physical as well as 
mental activities. This is characteristic of a number of chronic fatiguing disorders of 
medical aetiology. In these, !he subjective symptom of fatigue is characterised not 
only by physical, but also, by mental fatigue. This is non-neuromuscular fatigue or 
central fatigue and cannot be directly quantified directly by muscle electrophysiology 
unlike the physiological, objective fatigue [32]. 
Table 2.1 : Neurological disorders of central fatigue 
Symptomatic: 
Cerebral vasculitis and cerebrovascular diseases 
Channelopathies 
Developmental disorders (cerebral palsy, Chiari malformations) 
Dysautonomic states 
Encephalitis lethargica 
Granulomatous disorders (neurosarcoid, Wegener's granulomatosis) 
Hypothalamic and pituitary diseases 
Intracranial infections (meningitis and encephalitis) 
Metabolic encephalopathy and mitochondrial diseases 
Migraine 
Motor neuron disease 
MUltiple sclerosis 
MUltiple system atrophy 
Myotonic dystrophy 
Narcolepsy and related sleep disorders 
Paraneoplastic (limbic encephalitis, opsoclonus-myoclonus) 
Parkinson's disease and other Parkinsonian disorders 
Posterior head injury 
Post-Guillain Barre syndrome fatigue 
Post-infective fatigue states (post-polio, -Lyme disease, -Q-fever and -viral fatigue) 
Idiopathic: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) 
13 
14 
Patients with symptoms of physical and mental fatigue have no profound weakness, 
persistent or progressive cognitive decline or failure of peripheral neuromuscular 
function. Since cognitive performance during the periods of attentional tasks is a 
measure of cerebral function, these patients can be considered to have a type of 
fatigue suggestive of a dysfunction in their central nervous system, i.e. a central 
fatigue as opposed to the peripheral neuromuscular fatigue [33]. Besides CFS, 
mUltiple sclerosis and Parkinson's disease would be the two typical examples of 
central-type fatigue. Other diseases producing similar symptoms of central fatigue are 
listed in Table 2.1. 
There are several distinctive features of central fatigue that distinguish it from 
peripheral neuromuscular fatigue (Table 2.2). While peripheral fatigue appears rather 
exclusive to the neuromuscular and cardiorespiratory disorders, central fatigue is 
common in neurological disorders affecting both central and peripheral nervous 
systems, for example, mitochondrial cytopathy, B 12 deficiency, post-polio fatigue, 
ciguatera fish poisoning, motor neurone disease and myotonic dystrophy. <;entral 
fatigue is also an important symptom of certain neurological channelopathies such as 
migraine, epilepsy and paroxysmal dyskinesias [33]. 
Fatigue symptoms in CFS are closely comparable to the fatiguing neurological 
disorders of central fatigue. For example, fluctuating fatigue, paroxysms of sweating, 
and increased resting energy expenditure are common to both Parkinson's disease and 
CFS and relapsing fatigue induced by stress and exertion in CFS is similar to that seen 
in mUltiple sclerosis [2]. Unlike the symptoms of the peripheral fatigue, which are 
usually short-lived and recover by rest, symptoms of central fatigue tend to be more 
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persistent and are incompletely relieved by rest and/sleep. Central fatigue is the 
dominating feature in the symptoms of persistent or relapsing fatigue in patients with 
a clinical diagnosis ofCFS [33]. 
Chronic fatigue as a symptom 
Chronic fatigue is a symptom, not a disease. There is a long list of medical and 
psychiatric diseases associated with chronic fatigue. The pathophysiology of chronic 
fatigue is usually explained on the basis of the knowledge of the medical diseases it is 
associated with. Inflammatory and immunological disorders like rheumatoid arthritis 
provide excellent examples where cytokines may be responsible for fatigue. When 
injected in experimental animals, anti-inflammatory cytokines induce slow wave sleep 
[34]. Cytokines given as drug therapy commonly produce fatigue and myalgia. In a 
smaller proportion of patients, cytokines also induce neuro-psychiatric symptoms and 
depression. Paroxetine, an anti-depressant that selectively inhibits serotonin reuptake, 
has been successfully used in patients for the primary prevention of depression 
induced by high dose interferon-alfa therapy [35]. In a number of diseases, fatigue 
similar to CFS may be the only symptom before other signs or symptoms declare 
themselves. On the other hand, CFS-like fatigue may be the only persistent and 
disabling symptom in patients with otherwise well-controlled and treated diseases. 
Multiple sclerosis, sarcoidosis and haemachromatosis are common examples where 
fatigue can antedate other symptoms or persist despite appropriate therapy directed to 
the primary disorder. 
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Table 2.2: Characteristics of central fatigue 
• Lack of persistence of motor activity (easy fatigability) 
• Lack of persistence of mental activity (easy distractibility, impaired concentration, 
indecision) 
• Sleep disorder 
• Anomia 
• Personality changes (emotional lability and mood swings) 
• Reduced motivation or lack of motivation 
• Worsening of symptoms by physical or mental stress and chemicals (alcohol) 
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Cardiological syndrome X is an important overlap disorder of CFS. This is 
characterised by paroxysms of typical anginal chest pain with normal coronary 
angiogram. Syndrome X and CFS share many similarities including an identical 
clinical course, abnormal oxidative metabolism in skeletal muscle as found on 31 P 
nuclear magnetic resonance (NMR) spectroscopy, abnormal cerebral and cardiac 
Single Photon Emission Computed Tomographic (SPECT) scans, and increased 
lactate production [36]. 
Chronic fatigue is also a symptom of depression and is known in a number of 
psychiatric illnesses such as phobic anxiety and somatoform disorders. In the 
psychiatric literature, chronic fatigue is considered to be a "pseudoneurologic" 
symptom of somatisation. In this model, fatigue is the physical attribute of chronic 
depression and anxiety and chronic fatigue is a functional somatic disorder [4]. 
Despite overlap in some cases, however, neurogenic and somatising chronic fatigue 
may be distinguished clinically. This is usually possible on the basis of associated 
symptoms. Fatigue is seldom the first and the most important problem in psychogenic 
,. 
fatigue unlike in CFS where fatigue is the hallmark symptom. In addition, unlike CFS, 
somatising fatigue is more uniform and rarely fluctuates in severity on a day-to-day 
basis. Typically, asthenia in dissociative or somatoform disorders is frequently 
associated with generalised body and limb weakness where the strength of the 
voluntary movement is proportional or less than the resistance offered [37]. In 
addition, the severity of fati~e in functional disorders is significantly improved by 
rest or sleep and the post-exertional deterioration is maximum soon after activities 
whereas in appropriately defined CFS patients, fatigue remains unrelieved by rest or 
18 
sleep and post-exertional malaise is usually maximum after first 24 or 48 hours of 
physical activities. 
Idiopathic chronic fatigue as a clinical entity 
The concept of unexplained chronic fatigue for which there is no apparent medical 
cause has been recognised for centuries. Description of a disease complex with 
features similar to CFS exists in the papyrus Ebers and is dated circa 1400 B.c. [38]. 
The first epidemic of CFS to strike England probably dates back to the time of Henry 
VIn when one of his wives, Anne Boleyn, fell ill during this epidemic, called the 
"English Sweats" [39]. Charles Darwin was believed to suffer from CFS: a year after 
his return from the Beagle voyage, Darwin described how any fOlm of stress 
completely disabled him; two years later he gave up going out to parties because he 
found them too tiring and three years after that, in 1842, he retired to his country 
village to lead a life of permanent invalid [40]. In 1854, the very active Florence 
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Nightingale contacted an infectious disease in Crimea while organizing the field 
services for the British Army. She recovered briefly, but only to fall ill again, this 
time chronically, with chest pain, headaches and fatigue. Numerous heart specialists 
failed to find any fault with her. She was unable to walk any distance or concentrate 
when more than one person spoke to her [41]. 
In 1856, Finsen observed an epidemic of muscle rheumatism and chest pain in Iceland 
[42]. This was probably the first recorded coxsackie epidemic, later called Bornholm 
disease. The same epidemic repeated itself in a more serious fashion in the district of 
Ofjord in 1865 [42]. It was not until the full-blown poliomyelitis epidemic that swept 
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California in the summer of 1934 that CFS was considered as a separate epidemic 
illness. During that poliomyelitis epidemic, another epidemic but of different type, 
occurred among the personnel of the Los Angeles County General Hospital. [43] 
There were no deaths and 198 or more cases occurred among the doctors and other 
paramedical staff of the hospital. It is apparent that the large majority of the medical 
staff fell ill with this "new illness" after they were passively immunised with the 
prophylactic globulin prepared from the serum of patients who had fallen ill during 
this epidemic. Their symptoms were same as CFS: relapsing muscle weakness, 
unusual pain syndromes, personality changes, memory loss and anomia. The nurses in 
particular were all treated as having hysteria and several of the nurses affected in the 
1934 epidemic underwent hysterectomy, which obviously did not help [44]. This first, 
carefully recorded epidemic disease came to be called "atypical poliomyelitis" [43]. 
In the following years, a number of epidemics of CFS occurred in close association 
with the epidemics of poliomyelitis. The 1936 Wisconsin epidemic of CFS occurred 
when a· student nun returned to her cloistered school after spending sometime in 
Brooklyn with her friend who developed poliomyelitis at the same time when she fell 
ill with CFS [45]. The 1948 epidemic in Iceland started as a poliomyelitis epidemic 
and finished as a major epidemic of CFS involving 1,116 patients [46]. By 1959, 
fourteen major outbreaks ofCFS were documented [45, 47], including the Royal Free 
Hospital epidemic where the attack rate was calculated as 18.3% for nurses and 8.3% 
in the community, much higher than usually seen in poliomyelitis [48]. In most 
epidemics, the attack rate was uniform at about 6% [47] and the symptoms of the 
acute illness were consistent in over sixty recorded epidemics recorded worldwide 
[15]. In the largest Scottish outbreak of the disease between 1980 and 1983 in 
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Ayrshire [49], twenty-two patients were seen who complained of characteristic 
symptoms of CFS and had severe exhaustion most obvious after exercise. The 
disease had started in every case after an acute or subacute illness, with symptoms of 
vertigo, hyperacusis, and tinnitus or with palpitations and chest pain. Of the 
symptomatic patients, 82% had increased neutralising antibody titres to Coxsackie B 
virus [50]. 
Terminology of idiopathic chronic fatigue 
In the 19th century, neurasthenia was a popular but rather imprecise diagnosis applied 
to non-specific chronic fatigue that had a high prevalence in women [51]. However, 
the subjective nerve and muscle "fatigue" that followed the epidemic outbreaks of 
viral infections were fairly distinctive. The term neuromyasthenia has been used to 
characterise the latter syndrome since the early part of the 20th century. The clinical 
characteristics of the viral epidemic that triggered neuromyasthenia were often similar 
to non-paralytic poliomyelitis (atypical poliomyelitis)[52]. Epidemic neuromyasthenia 
had a distinctive clinical picture consisting of "headache, myalgia, myasthenia, 
encephalopathy, lymphadenopathy, morbidity and survivance" [53]. Residual 
symptoms years after included persistence of fatigue, muscle pain, nervousness and 
disturbance of cutaneous sensitivity (allodynia) [54]. Myalgic encephalomyelitis 
(ME) was the preferred name given to these patients during the 1960s [45]. This was 
considered inappropriate pathologically and hence many referred to these cases as 
having post-viral fatigue syndrome (PVFS) [5]. Many patients with a diagnosis of 
PVFS had a documented history of Epstein-Barr virus or enterovirus infections [5]. 
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Late-onset fatigue was also the commonest sequel of the polio epidemic and the 
clinical characteristics of the fatigue and related symptoms were very similar in post-
polio fatigue, epidemic neuromyasthenia, ME and PVFS. 
The term ME has been criticised because of inadequate pathological evidence for 
inflammation in the brain and spinal cord of these patients [2]. Since 1988, chronic 
fatigue syndrome (CFS) became the official designation for otherwise unexplained, 
persistent or relapsing chronic fatigue of new onset [55]. 
Chronic fatigue syndrome (CFS) 
For clinical and epidemiological purposes, patients with CFS are currently defined 
according to the modified CDC criteria which were developed by the International 
CFS Study Group and introduced in December, 1994 [1] replacing the first research 
case definition published six years' earlier [55]. According to these criteria (Table 1), 
a case ofCFS is defined as follows: 1) clinically evaluated, unexplained, persistent or 
relapsing chronic fatigue that is of new or definite onset (has not been lifelong); is not 
the result of ongoing exertion; is not substantially alleviated by rest; and results in 
substantial reduction in previous levels of occupational, social or personal activities; 
and 2) concurrent occurrence of four or more of the following symptoms, all of 
which must have persisted or recurred during 6 or more consecutive months of illness 
and must not have predated the fatigue: (i) self-reported impairment in short-term 
memory or concentration severe enough to cause substantial reduction in previous 
levels of occupational, educational, social or personal activities; (ii) sore throat; (iii) 
tender cervical or axillary lymph nodes (iv) muscle pain (v) multijoint pain without 
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joint swelling or redness; (vi) headaches of a new type, pattern or severity; (vii) 
unrefreshing sleep; and (viii) post-exertional malaise lasting more than 24 hours. 
Other definitions include prolonged fatigue, defined as self-reported persistent fatigue 
lasting 1 month or longer and chronic fatigue, defined as self-reported persistent or 
relapsing fatigue lasting 6 or more consecutive months. A case of idiopathic chronic 
fatigue is defined as clinically evaluated, unexplained chronic fatigue that fails to 
fulfil the above criteria for CFS. Presently, a diagnosis of CFS can only be made in 
exclusion of other causes since there is no specific or sensitive laboratory test for this 
condition. 
Epidemiology 
Current estimates of the CFS prevalence are 4 cases per 10,000 population [56]. It 
affects adults as well as children. Cases are approximately twice more common in 
women. The incidence in adolescents is lower than that in adults and most cases' occur 
between the ages 11-15 years although younger children (5 years and above) may 
rarely be affected. The prevalence of paediatric CFS is not known; an approximate 
estimate is 0.07% [56]. Most cases of CFS now occur sporadically. Spontaneous and 
full recovery in adults is usually limited and occurs within the first 1-2 years; indeed 
very few symptomatic adults will experience spontaneous and substantial recovery at 
a later period [57]. Clinical outcome of CFS may take any of three courses; some 
patients recover completely, some follow a relapsing course, and some are 
permanently incapacitated [8]. Levels of disability in symptomatic patients vary 
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considerably but it has been estimated that at least 25% of all CPS cases experience 
high levels of disability. 
Clinical assessment of CFS 
Onset and Precipitating factors: CPS begins abruptly in nearly one third of cases and 
is of subacute or insidious onset in the remaining two-thirds [2]. The fatigue can 
appear over a few minutes or hours. Nearly 80% cases of CPS follow an antecedent 
respiratory, gastrointestinal or other acute infection with 'flu like symptoms [58]. In 
the epidemic form of CPS, it was calculated that the illness has an incubation period 
of 5 days (range 4-10 days) [45,47]. Other cases develop after emotional or physical 
trauma such as bereavement or surgery [59]. 
Environmental agents or toxin have been implicated in a number of chronic fatigue 
disorders. A syndrome comparable to CPS is seen in some patients after immunisation 
[60], food botulism [61] and chronic lead neurotoxicity [62,63]. A neurobehavioural 
syndrome identical to CPS has been observed after ciguatera fish poisoning [64] and 
after chronic exposure to low-dose organophosphate pesticides in farmers [65,66]. 
CPS-type symptoms have been described after a prolonged period of stress [67], in 
the immunised veterans of the first Gulf-War [68], after overtraining in athletes [69], 
in individuals with multiple chemical sensitivity [70] and in women after silicone 
breast implants [71]. 
Children with history of atopy (eczema or extrinsic allergic asthma) are more prone to 
develop symptoms of post-viral CFS [72] whereas new-onset asthma has been 
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observed in both adults and children symptomatic ofCFS [59]. A proportion of male 
patients developed the illness following an attack of epididymo-orchitis [60]. There 
may be more than one precipitating factor or triggering agents. It has also been 
suggested that once an individual is exposed to a triggering agent, certain co-factors 
may playa role in increasing his susceptibility to the development of CFS symptoms 
[14]. Possible co-factors are cryptic gluten sensitivity [73], Gilbert's syndrome [58], 
atopy, prior physical exercise and preceding or concurrent history of stressful life 
events [2,14]. 
Like many patients with idiopathic epilepsy or migraine, patients who receIve a 
diagnosis of CFS will have no objective abnormality on clinical examination. 
Research studies, however, have often revealed variable and subtle neurological 
findings in CFS [74]. The diagnosis of CFS is clinical. Fatigue remains the most 
important and the central symptom in CFS. It must fulfil the characteristics as 
defined in the CDC criteria, i.e. fatigue has to be of definite or new onset, not the 
result of on-going exertion, generally unrestored by rest and sleep and results in 
substantial reduction in overall performance. Typically, there is significant post-
exertional worsening of fatigue in CFS lasting more than 24 hours and continuing for 
48-72 hours. 
Typically, a number of other neurological symptoms appear in combination with 
fatigue in CFS. Myalgia: Both diffuse muscle aches and pain as well as fibromyalgia 
are common symptoms in CFS. Similarly, patients often have joint pain in both small 
and large joints without any redness or swelling (arthralgia). Weakness: Weakness of 
sustained motor performance and skilful work are common symptoms. Sleep: Patients 
25 
are generally hypersomnolent at the beginning and can have prolonged periods of 
sleep, both during the day and night. Subsequently, these patients develop altered 
sleep rhythm with frequent, short periods of increased sleepiness during the daytime 
and have poor night time sleep with broken sleep pattern and vivid dreams. Vertigo: 
Acute vertiginous episodes are common, often lasting for a week to 10 days on 
average and then leaving the patient with a constant feeling of unsteadiness or 
dysequilibrium. Some CFS patients suffer from frequent spells of vertigo with gait 
disorder and dysequilibrium as their major physical symptom besides fatigue 
(Pedersen's syndrome) [75]. Orthostatic intolerance, tachycardia, light-headedness 
and simple faints are particularly common among young adults and women with CFS. 
Visual symptoms: Temporary visual obscuration is not uncommon and patients often 
report intense photophobia simulating meningism. 
Many CFS patients also have symptoms outside the nervous system. Development of 
asthma or worsening of pre-existing asthma is also recognised among CFS patients. 
Patients also report skin changes, usually in the form of dry skin, the new onset of 
eczema or psoriaform rashes. A large number of patients have abdominal pain, 
distension and unsatisfactory bowel movements and suffer from typical irritable 
bowel syndrome. Loss of libido and sex drive is common symptoms in both sexes. 
Male sufferers of CFS may have prostatism and women have frequent problems with 
their menstrual periods, which may be irregular, with periods of menorrhagia or 
oligomenorrhoea. Women with CFS also have an interesting association with 
idiopathic cyclic oedema. They feel overweight, with swelling of legs and sensations 
of breast engorgement. Weight changes: Though some weight loss is common in the 
early phase of illness, the majority of patients eventually recover the lost weight and 
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may even continue to gain weight, usually attributed to their sedentary lifestyle. 
Unusual food cravings, especially to chocolates or sweets, are known to develop after 
acquiring CFS may also contribute to weight gain. Alcohol intolerance: CFS patients 
characteristically develop intolerance to alcohol and even small amounts of alcohol 
dramatically worsen symptoms of fatigue and orthostatic intolerance. 
Paroxysmal attacks of chest pain and sweating are two common cardiac symptoms 
found in this condition. Some patients with CFS were originally referred by the 
cardiologists who diagnosed a condition called syndrome X (anginal chest pain with 
normal coronary arteries). Many of these patients eventually went on to develop other 
typical symptoms of CFS [76]. A sizeable proportion of CFS patients do have typical 
chest pain suggestive of angina but on further investigation, do not appear to have any 
underlying stenosis of their coronary arteries. Unexplained attacks of sweating, 
typically nocturnal, are common in these and other patients with CFS and often the 
sweating can be so profound as to necessitate a change of full clothing and bed sheets 
at night [2]. 
The most consistent neuropsychiatric findings in CFS are of mild depression, usually 
accompanied by chronic anxiety and intense introspection. Well-characterised cases 
invariably report cognitive deficits, usually anomia, impaired short-term memory and 
concentration difficulties. Self-reported cognitive impairment, particularly in tasks 
requiring sustained attention, as well as anomia are recognised in CFS. The degree of 
symptomatology may vary, but at its most severe, patients are forced to abandon all 
intellectual pursuits and children with CFS discontinue their schooling. Some patients 
do develop hypergraphia, i.e. keeping the most detailed records and long descriptions 
27 
of all their symptoms and come to the clinic with interminable notes. Every ache and 
pain is ascribed to the illness and carefully recorded. However, patients do not have 
profound anhedonia or suicidal symptoms of typical depressive illness although a pre-
morbid psychiatric abnormality ("depression-proneness") is not uncommon [77]. In 
general, patients with CFS appear more than depressed at their inability to work at the 
level of their expectations and may develop mood swings and temper tantrums. 
Emotional lability and a tendency to tearfulness are less common and if present, these 
emotional changes are suggestive of depression that may be reactive. Overall, 
psychiatric co-morbidity in CFS is modest and is probably not in excess of, what is 
seen in other chronic medical disorders, for example, multiple sclerosis and diabetes 
mellitus [8]. 
Very occasionally, objective clinical signs may be present at the time of diagnosis in 
CFS. Cervical lymphadenopathy, if present, is one of the (minor) diagnostic criteria. 
Deep reflexes may appear pathologically (and symmetrically) brisk but plantar 
responses remain flexor. Postural fine hand tremors are, however, not uncommon. 
Occasionally, focal myokymia ("benign fasciculations") may be observed in some 
patients. Significant objective motor weakness is unusual, although CFS patients are 
unable to produce maximal voluntary effort in muscle contraction against resistance. 
Disorder of gait is usually present in patients with dysequilibrium symptoms 
(Pedersen's syndrome). Rare patients do develop mild Parkinsonian features (poor 
facial expression, hypomimia and minimal hypokinesia [74]. 
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13. REVIEW OF THE LITERATURE: CFS RESEARCH 
"Disease is very old and nothing about it has changed. It is we who change as we 
learn to recognize what wasformerly imperceptible" (Jean Martin Charcot, 1887) 
.".,.' 
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More than 4000 papers have been published in the peer-reviewed journals on CFS. In 
these, peripheral and central mechanisms of fatigue have been extensively explored. 
Changes in the hypothalamic-pituitary-adrenal axis and other neuroendocrine 
responses have been identified to have important implications in the pathogenesis of 
fatigue [78]. Abnormalities have been reported in the skeletal muscle metabolism, 
cardiovascular response, neuroendocrine function and in the nervous system [2]. CFS 
has also been attributed to physical deconditioning, abnormal illness behaviour, 
chronic multiple functional symptoms and due to chronic anxiety and depression in 
the psychiatric literature [4]. The wide divergence of opinion in the literature may 
have been influenced by the difference in the selection criteria applied to the patients 
receiving a diagnosis of CFS. It is generally accepted that prevalence of CFS is at 
least higher in the population when broader definitions (e.g. Oxford criteria) have 
been used (2-4%) [79]. Because by definition, CFS patients do not have any known 
fatiguing medical disease, broader definitions are likely to select a substantially higher 
proportion of patients with functional symptoms and medically unexplained chronic 
fatigue. The variability of case selection make it difficult to compare research findings 
and it is also likely that CFS patients do not conform to a single clinical entity (80]. 
Research on peripheral aspects of fatigue 
Symptoms reported by many CFS patients relate to peripheral tissues, such as muscle, 
with prominent fatigue and pain at rest and on minimal exercise. It may be the case 
that these patients suffer from a predominantly peripheral type of fatigue. While some 
studies have been unable to confirm metabolic abnormalities [81], others found some 
CFS patients to have a moderate reduction in oxidative capacity, as measured by the 
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rate of recovery of phosphocreatine after submaximal exercise [26,28]. It has been 
proposed that the CFS patients can be classified into those with a high (and normal) 
oxidative capacity or those with a low (and abnormal) oxidative capacity. Recent 
work however indicates that autonomic dysregulation is common in CFS, with reports 
suggestive of abnormalities in both sympathetic and parasympathetic functions 
[82,83]. It has been proposed that the impairment in autonomic vasomotor control 
limits the increase in the blood flow to the exercising muscles and leads to reduced 
exercise capacity in CFS [84]. 
31 P nuclear magnetic resonance spectroscopy (NMR) provides an excellent method 
for continuous, in vivo, monitoring of intracellular energy metabolism in skeletal 
muscles. NMR studies have shown a significant reduction in the exercise capacity in 
CFS, accompanied by excessively early intracellular acidification [26-28, 85,86]. The 
first positive report of a single case [85] CFS was followed by work from the same 
group showing similar features in five of six cases [86] and then 12 out of 46 patients 
[27]: six had increased acidification relative to phosphocreatine (PCr) depletion and 
six, reduced acidification. Other workers have postulated that CFS patients may have 
relatively reduced concentrations of muscle ATP. A significant reduction in aerobic 
metabolism was noted in PCr recovery [28]. Reduced oxidative muscle metabolism in 
CFS patients has been shown in a study that compared 22 CFS patients with normal 
sedentary subjects before and for two days after a maximal treadmill test [26]. Muscle 
oxidative capacity was measured as the maximal rate of post-exercise PCr resynthesis 
in the calf muscles using 311.> NMR spectroscopy. The oxidative capacity (maximal 
rate of ATP synthesis) was reduced in CFS patients as opposed to controls. No further 
changes, however, were seen in the post-exercise period. Skeletal muscle NMR 
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studies in syndrome X have reported similar abnormalities, suggesting that CFS and 
syndrome X could share a common metabolic disorder [87]. 
Muscle biopsy: No consistent abnormality has been reported in the muscle biopsies of 
CFS patients. A variety of non-specific findings, however, were noted. In about 30%, 
scattered atrophic fibres were seen and in another 30%, there was type 2 fibre 
hypertrophy and predominance [88]. Type 2 fibre atrophy was also noted in 
occasional cases. Nearly half of the biopsies were entirely normal. Of the biopsies 
with fibre type changes, rare cases revealed evidence of myoadenylate deaminase 
deficiency. At present, there is no consensus on the implications of such a finding 
except that it has been reported after a viral infection and in association with myalgia 
[25]. It has also been seen in the muscle biopsy of patients with collagen vascular 
disease, myasthenia gravis and facioscapulohumeral muscular dystrophy, as well as in 
the normal subjects [89]. Unlike congenital myoadenylate deaminase deficiency 
where the enzyme deficiency is total, loss of enzyme in acquired myoadenylate 
deaminase deficiency is partial. On electron microscopy, muscle biopsies in CFS have 
revealed, on rare occasions, changes that might be interpreted as minor mitochondrial 
abnormalities [90]. However, these changes appear non-specific and secondary and in 
general, muscle pathology in CFS is not the primary or essential part of the clinical 
syndrome. Comparable changes have been reported in the muscle biopsies of patients 
with fibromyalgia and in the symptomatic veterans of the first Gulf-War [91]. Finally, 
significant loss of muscle protein synthetic potential (defined as mean muscle RNA 
composition - mg RNNmg DNA) was noted in acute onset CFS cases by one 
research group [92]. 
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Muscle cell culture (in vitro): Aerobic metabolism was studied in the myoblast 
cultures established from muscle biopsies of 16 typical cases of CFS compared to 10 
normal controls. The lactate/pyruvate (LIP) ratio was determined by measurement of 
lactate and pyruvate production; respiratory chain function, cytochrome oxidase and 
lactate dehydrogenase were assayed. Culture from 10 of the 16 cases showed mild 
defects of aerobic metabolism. There was a statistically significant broader range of 
LIP ratios in the patients' myoblast cultures, compared to controls. Myoblasts from 
two patients had increased LIP ratios, suggestive of a defect in oxidative 
phosphorylation while eight had decreased ratios, consistent with a mild deficiency in 
pyruvate dehydrogenase. Respiratory function, cytochrome oxidase and lactic 
dehydrogenase activities were similar in two groups. Mitochondrial volume was not 
significantly increased and no mtDNA rearrangements were present. One of the 
patients with decreased LIP ratio had biopsy findings of a mild mitochondrial 
myopathy [93]. 
Exercise tests: Since by definition, CFS patients experience profound deterioration of 
their fatigue and muscle symptoms after exercises, a number of studies have looked at 
the exercise and post-exercise motor performance in these patients, [81, 95-99] often· 
with contradictory results. In an incremental treadmill protocol (walking to 
exhaustion) [94], CFS patients showed a lower V02 max (maximum volume of 
oxygen consumed) as compared with controls in the absence of any cardiopulmonary 
abnormality. In another study [95], isometric strength testing revealed conspicuous 
disparity between the prominent SUbjective complaint of muscle fatigue by the 
patients and the relatively normal contractility of their muscles. However, a later 
study by the same group [96] showed that neither the relative torque produced by 
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voluntary or electrically stimulated contractions, or the perceived exertion differed 
significantly between patients and controls. Another group could not demonstrate any 
difference between patients or controls in exercise performance and fatigability 
though about a third of CFS cases had an abnormal lactate response and tachycardia 
[97]. In a study using symptom limited exercise treadmill test with on-line gas 
analysis and blood sampling found reduced aerobic work capacity in CFS patients as 
compared to normal subjects and patients with the irritable bowel syndrome [98]. 
While some studies provided support for a central origin of fatigue, [81,95, 98, 99] 
others argued for a peripheral, i.e. metabolic muscle cause [92, 96, 97]. Using a 
repetitive isometric quadriceps exercise (knee extension against fixed resistance) in a 
well-characterised group of CFS patients and comparing their performance with 
matched controls, no significant difference was observed between the two groups on 
the day of exercise itself, a marked and more rapid decline in quadriceps tension was 
evident in the patient group on the following day (after 24 hours) [100]. 
Overall, . these findings are consistent with the view that mild defects in skeletal 
muscle metabolism may be present in some CFS patients although presence of these 
abnormalities are not an obligate part of the disorder. Measurements of oxidative 
metabolism are not only a function of oxygen delivery to the working muscles, but 
also of mitochondrial phosphorylation. Early intracellular acidosis during submaximal 
exercise in the CFS muscles may have several explanations, including accelerated 
glycolysis relative to oxidative metabolism, deficiency of mitochondrial rich type 1 
muscle fibres, impaired autoregulation of muscle blood flow and secondary muscle 
changes consequent to physical deconditioning induced by chronic fatigue 
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Research on central fatigue in CFS 
Changes in the central nervous system may account for fatigue and neuropsychiatric 
symptoms in CFS. One of the important observations supporting a dominant role of 
central fatigue in CFS comes from a study that showed CFS patients were unable to 
fully activate skeletal muscles during intense sustained exercise despite evidence of 
normal muscle function [81]. In other studies, patients demonstrated an increased 
perception of effort during exercise with an exercise-related decrease in central motor 
drive as measured by the motor evoked potential following transcranial magnetic 
stimulation [101,102]. Post-exercise facilitation of motor evoked potential was also 
delayed in CFS, suggestive of depressed cortical excitability [103] 
Neuroimaging: Anatomical visualisation ofneuroaxis has been always normal in CFS 
patients. No specific abnormality in the conventional CT and MRI scans is diagnostic 
of CFS. However, regional cerebral hypoperfusion has been noted in the Single 
Photon Emission Computed Tomographic (SPECT) scans of CFS patients [104-106] 
The hypoperfused areas were both cortical and subcortical, typically involving the 
temporal lobes in one study [104] while hypoperfusion of the brain stem was reported 
by others [105]. There has not been any consistent pattern but what is clear is that 
CFS patients, both adults [104] and children [106], may have multiple areas of 
regional cerebral hypoperfusion that are neither specific nor unifocal [107]. In the 
absence of any demonstrable ischemic lesions in the CT or MRI scans in any CFS 
patients, these hypoperfused areas in the SPECT images are likely to be a 
consequence of metabolic or vasomotor changes influencing regional cerebral blood 
flow. Positron emission tomographic (PET) scans have also been performed in 
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patients with CFS and compared to those with major depressive disorder, CFS 
patients have lower metabolic rates in the hippocampus and amygdala, as well as in 
the caudate nucleus, the premotor cortex and the anterior cerebellum [108, 109]. 
Hypothalamus and hYfJothalamic-pituitary-adrenal (HP A) axis in CFS: 
Hypothalamus is the seat of autonomic regulation, affecting both parasympathetic and 
sympathetic nervous system functions in health and diseases. A large body of 
evidence has been derived implicating the hypothalamus in the control systems which 
are critically involved in many other physiological, endocrine and behavioural 
processes. Among these are feeding and drinking, temperature, fatigue, reproduction 
and the regulation of sleep-wake cycle [110]. The pre-optic region of the 
hypothalamus is implicated in the neural control of endocrine functions and in the 
temporal organisation of a wide spectrum of biological rhythms. Hypothalamus also 
modifies both humoral and cell-mediated immune processes utilising an extensive 
network of endocrine, autonomic and related pathways [111]. 
Hypothalamic disorders are known to be associated with clinical symptoms of 
profound fatigue. Hypothalamic tumours may present with symptoms of fatigue, 
forgetfulness and irritability [112] but eventually these disorders give rise to a variety 
of endocrine abnormalities and intracranial pressure symptoms because of their 
anatomical locations. Overwhelming fatigue is also a common symptom after 
hypophysectomy. Symptoms that suggest_hypothalamic involvement in CFS are (a) 
fatigue; (b) sleep disorders -(somnolence and sleep-rhythm reversal); (c) abnormal 
sweating; (d) altered temperature; (e) poikilothermia (feeling hot and cold); (f) mood 
disorder; (g) changes in appetite and craving for certain foods; (h) weight changes and 
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idiopathic cyclic oedema; and (i) frequently reported abnormalities in menstrual 
function. 
Abnormal hypothalamic arginine-vasopressin secretion and water metabolism have 
been previously documented in CFS. Secretion of arginine-vasopressin (A VP) was 
erratic in these patients as shown by lack of correlation between serum and urine 
osmolality and the corresponding plasma A VP levels. When compared with control 
subjects, patients with CFS as a group had significantly low baseline A VP levels and 
showed evidence of increased total body water content [113]. An abnormal water 
loading test in CFS has also been documented [114]. Changes in the hypothalmic-
pituitary-adrenal axis in CFS have been confirmed by a number of workers. In the 
original study by Demirack and others [115], CFS patients were found to have a 
supersensitivity of cortisol response to exogenous adrenocorticotrophic hormone 
(ACTH) suggestive of a pituitary deficient hypocortisolic syndrome. All patients had 
normal levels of circulating ACTH but the evening plasma ACTH levels were higher 
in patients than controls. The pituitary ACTH release was blunted in response to the 
exogenous corticotrophin releasing hormone (CRH) in CFS patients [115]. ."-
CRH resistance of pituitary ACTH, however, is not unique to CFS since this has been 
found in related conditions associated with stress such as the overtrained athlete 
syndrome [70]. Presumably, this reflects a lack of adaptation of the HPA axis to 
chronic stress and implicates a relative dissociation of the normal harmony between 
the hypothalamic and pituitary control of endocrine functions. Both physical stress 
(such as operative trauma) and emotional stress (such as bereavement) is known to 
precipitate CFS [59]. Stress directly activates the HPA-axis and modifies the immune 
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system [116]. Chronic or repeated complex stress can be associated with a loss of 
diurnal rhythm and a relatively normal circulating concentration of ACTH and 
glucocorticoids [117]. A paradoxical fall in CRR mRNA in the paraventricular 
nucleus of the hypothalamus has been described in animal models exposed to chronic 
inflammatory stress, suggesting chronic stress (as opposed to acute stress) can depress 
HPA-axis, [118] a finding similar to that observed in CFS. 
In summary, the HP A axis is hypoactive in CFS [119] but it is not entirely clear 
whether this is a primary or a secondary event in the syndrome. Therapeutic trials of 
corticosteroids (low dose hydrocortisone and/or fludrocortisone) have not been found 
to be effective in CFS; indeed, higher doses of exogenous steroids may lead to rapid 
suppression of HP A axis in these patients [120]. There is, however, an emerging view 
that low levels of tissue cortisol or relative hypocortisolemia may lead to the 
development of a chronic fatigue state under conditions of stress. An increase in the 
corticosteroid levels during acute illnesses, physical and psychological stress is a 
protective biological response that depends on the integrity of the HP A axis. It seems 
that low cortisol levels predict the development of post-traumatic stress disorder 
(PTSD) after serious physical and psychological trauma [121]. PTSD is characterised 
by chronic fatigue, sleep disturbance, poor concentration and depressive mood. In a 
recent study, patients with sepsis who were randomised to receive corticosteroids did 
significantly better as compared to the placebo-treated patients in terms of chronic 
fatigue and other neurobehavioural symptoms following recovery [121]. It may be 
speculated that a state of pre-existing relative hypocortisolemia sensitises the 
glucocorticoid receptors at a pivotal locus in the HP A axis and the stress response, 
and this may precipitate the development of chronic fatigue after acute illness or 
serious traumatic life events. 
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Neurotransmitter abnormalities in CFS: Neuroendocrine axis assessment has 
traditionally been considered one of the best and safest approaches for assessing 
specific neurotransmitter functions in the central nervous system [122]. The release 
of prolactin from the anterior pituitary is under the inhibitory control of dopamine. 
Prolactin release is stimulated by serotonin and buspirone is an indirect serotonin 
agonist. Normally, buspirone would induce a serotonin-mediated release of prolactin, 
which, however, is blunted in major depression [123] An altered sensitivity of the 
central serotoninergic receptors has been postulated as a possible explanation of the 
painful symptoms, fibromyalgia and depressive features in CFS [124,12S]. Serotonin 
(S-hydroxytryptamine, SHT) has a very important role in the vasomotor control and 
hypothalamic release of CRR [126,127]. In addition, serotonin is an important 
neurotransmitter in the limbic and paralimbic areas of the brain and is implicated in 
migraine headache. In one study, basal levels of plasma S-hydroxyindolacetic acid (S-
HIAA), the breakdown product of S-HT, were elevated in CFS patients as oppo~ed to 
controls [128]. 
Buspirone challenge test has been developed as a paradigm to test the sensitivity of 
the serotonin receptors in CFS. After oral administration of buspirone, a selective 
SHT-1A receptor agonist, prolactin level was estimated in CFS patients and compared 
to the results in patients with major depression. A significant augmentation of 
prolactin release seen only in CFS, both in male and female patients, suggesting an 
upregulated hypothalamic serotoninergic receptors in CFS [124]. Plasma prolactin 
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levels were also higher in response to d-fenfluramine in CFS patients as compared to 
the depressed patients matched for age, weight, sex and stage of menstrual cycle 
[125]. 
The level of the aminergic tone in the central nervous system is also considered to 
influence the level of central fatigue. Chronic fatigue, comparable to CFS, is common 
in patients with autonomic failure, multiple system atrophy, Parkinson's disease and 
other Parkinsonian syndromes. Central stimulants like pemoline, modafinil and 
methylphenidate have been used to treat symptomatic central fatigue with modest 
success in multiple sclerosis (MS) and multiple system atrophy. Amantadine, an 
indirect dopamine agonist, is effective in approximately 40-50% of fatigued MS 
patients [129]. Downregulation of adrenergic receptors in CFS patients was 
considered to be a possibility on the basis of the desipramine challenge test [78] .. 
Desipramine is a tricyclic antidepressant and acts by monoamine re-uptake inhibition. 
It indirectly stimulates the post-synaptic alpha2 adrenoceptor in the anterior pituitary 
leading to the release of growth hormone (GH). Blunted GH release in response to 
desipramine challenge was observed in CFS patients but not in the healthy controls. 
These results may indicate post-synaptic adrenergic receptor sub sensitivity in CFS, in 
keeping with a previous observation of lower levels of plasma 3-methoxy 4-
hydroxyphenethyleneglycol (3,4 MHPG) in CFS patients [128]. Anterior pituitary GH 
release is also augmented by acetylcholine. Pyridostigmine has been used as a 
standard probe to stimulate acetylcholine-mediated GH release [130]. Both depressed 
[130] and CFS patients [78] demonstrate an exaggerated GH response to oral 
pyridostigmine. 
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In summary, the research evidence in the study of neurotransmitter abnormalities in 
CFS suggests supersensitivity to serotonin and subsensitivity to monoamines such as 
dopamine and norepinephrine. Since dopamine is also the hypothalamic prolactin 
inhibitory factor, functional deficiency of dopamine in the neural system could lead to 
relative hyperprolactinaemia as observed in some CFS patients, especially women 
with amenorrhoea or idiopathic cyclic oedema, and also in patients with post-polio 
fatigue [131]. From these observations, one may speculate that in CFS, the normal 
balance of the dopaminergic and serotoninergic tone in the central nervous system is 
shifted in favour of a functionally overactive serotoninergic state. 
Other laboratory findings 
General: Routine laboratory tests seldom reveal any specific abnormality in the 
chronic phase of the illness [88, 132]. Haematology: Relative lymphocytosis, 
neutropenia, and monocytosis have been reported in small numbers «30% cases) in 
some cases. The ESR is generally within normal limits and indeed, any significant 
elevation of ESR would lead one to suspect an inflammatory muscle disease s~ch as 
polymyositis as a possible cause of fatigue and myalgia. However, in a review of 
laboratory abnormalities in CFS, ESR was found to be elevated in 18% of patients 
[132]. Occasionally, abnormal red blood cell morphology has been observed where 
the erythrocytes lose their normal appearance as biconcave discs and develop both 
surface changes and "cup forms", becoming non-discocytic erythrocytes [133]. 
Biochemistry: Plasma glucose and renal functions are always normal but between 5-
20% of patients will have elevated liver enzymes and creatinine kinase in serum, 
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usually raised to about two or threefold the nonnal value [134,135]. Deficiency in 
serum acy1carnitine has been reported in a series from Japan [136]. In a Glasgow 
study, levels of carnitine (total and free) in both peripheral blood lymphocytes (PBL) 
and sera were measured in 27 CFS patients and matched healthy controls. Though the 
serum levels of carnitine were comparable in both groups, the concentrations of total 
and free carnitine in PBLs were significantly lower in the CFS patients as compared 
to the healthy controls, suggestive of an intracellular carnitine deficiency [137]. 
Micronutrient assays: Though one study suggested that patients with CFS suffer from 
magnesium deficiency [138], in another study, patients were found to have nonnal red 
cell magnesium concentration and nonnal response to magnesium loading test 
indicating no evidence of magnesium deficiency in CFS [139]. 
Immunological findings 
Non-specific immunological abnonnalities have been widely reported in this 
condition. Tests for heterophile antibody was found to be positive in an ave;;ge of 
15% patients in a pooled data [132]. No difference has been recorded in the serology 
testing for Lyme disease (B. burgdorferi antibodies) between patients and controls 
[14]. 
Autoantibodies: Certain circulating autoantibodies may be found more frequently in 
CFS patients than in healthy individuals [88,132]. Positive anti-thyroid and anti-
reticulin (or antigliadin) antibody are the two common autoantibodies that have been 
reported in CFS, being present between 10-30% of patients. Low concentrations of 
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anti-nuclear antibodies and rheumatoid factor could be seen in some cases without 
other evidence of SLE or rheumatoid arthritis. Studies have also reported occasional 
presence of antibodies to smooth muscle, gastric parietal cells, insulin and insulin 
receptors; elevated levels of cryoglobulins, cold-agglutinins and false positive syphilis 
serology in 0-8% of cases [132,135]. A variety of subtle immunological abnormalities 
have been reported in CFS [140,141] but these do not appear to be specific or 
sensitive. 
Cellular mechanism of fatigue in CFS: 
Nearly 5% of victims of acute ciguatera poisoning develop a chronic disabling 
syndrome with persistent fatigability and weakness similar to CFS [142]. 
Ciguatoxins(CTX) are heat stable, non-protein, lipophilic toxins produced by a 
dinoflagellate (Gamberdiscus toxicus) which is associated with dead coral and algae 
and can be passed up the food chain to result in sporadic human outbreaks. These 
toxins bind sodium channel receptors in the open mode in both somatic· and 
autonomic nerves, thus producing prolonged sodium channel activation. The 
association of ciguatoxicosis and CFS-like syndrome stimulated an interest in the 
possibility that abnormal ion channel function may underlie CFS symptoms [143]. 
This hypothesis is considered compatible with the clinical observations in CFS 
patients that symptoms are worsened by certain drugs, alcohol and local anaesthetics, 
chemicals that are known to alter cell membrane ion channel function [2]. Although 
the pathogenesis of CFS is still unknown, one of the most characteristic features of 
the illness is the fluctuation in symptoms, which can be induced by physical and/or 
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mental stress. In this respect, CFS bears some resemblance with other neurological 
conditions caused by abnormal ion channels in the cell membrane [144]. These 
conditions are known as neurological channelopathies [144] and include both 
genetically determined channelopathies, e.g. hypokalemic periodic paralysis, familial 
hemiplegic migraine (FHM), episodic ataxia type 2 and acquired conditions such as 
neuromyotonia (Isaac' s syndrome) and certain forms of epilepsy. 
Syndrome X and CFS: Myocarditis, with or without Bornholm-type was a common 
symptom in an analysis of 1,000 patients with CFS who were seen in Glasgow over 
the past 20 years [5]. A number of patients who were eventually diagnosed to have 
CFS had initially experienced a severe chest pain that was considered to be a form of 
angina or atypical non-cardiac chest pain by the cardiologists. This association 
between patients who developed CFS and previously had chest pain resembling an 
acute coronary event was striking. All these patients were initially admitted to the 
medical units and had had extensive cardiological investigations, including 
electrocardiogram (ECG), cardiac enzyme assay and coronary angiogram. Other than 
minor ECG changes, all cardiac investigations were essentially normal or negative. 
During subsequent clinical follow-up of patients with this type of presentation, termed 
syndrome X, [145,146] a significant proportion progressed to develop symptoms of 
chronic fatigue that were indistinguishable from patients who had CFS following a 
typical viral infection. Patients with cardiological syndrome X closely resembled CFS 
in their clinical course. Like CFS, syndrome X is more common in women. 
Following their extensive research in this condition, Waldenstrom and his colleagues 
proposed that there could be abnormal ion channels (ionophores) in the skeletal 
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muscle and cardiac cells of patients with syndrome X [147]. These ionophores are 
capable of altering the net transport of ions across the cell membrane. This would 
eventually force the cell to upregulate its ATPase activity in order to maintain the 
transmembran.e ionic equilibrium. Eventually, this leads to a change of the adenine 
nucleotide pool inside the cell. Waldenstrom and colleagues expressed this 
abnormality by using the equation 
E Ch (EC) ATP+0.5ADP 
nergy arge = -A-r-p-+-A-D-P-+-A-M-P 
This ratio, i.e. EC, was very stable when measured from most muscle tissues biopsied 
and its value is constant at 0.9 (except uterine myometrium) but fell to values between 
0.48 and 0.70 in myocardiac and skeletal muscle biopsies in patients with syndrome X 
and abnormal thallium cardiac scans [147, 148]. Similar findings were observed in 
mouse myocardium after experimental infection with Coxsackie B3 virus [149]. 
These findings suggested low intracellular ATP levels consequent to an upregulated 
ATPase activity in syndrome X. 
.. ' 
Thallium cardiac scans in CFS: In their study of the cardiac thaIIium-201 SPECT 
scans on a series of syndrome X patients, Waldenstrom and colleagues detected 
perfusion abnormalities in a significant proportion [148]. Cardiac thaIIium-201 SPECT 
scanning involves the intravenous injection of radioactive thallium-201 which is 
rapidly accumulated intracellularly in a fashion similar to potassium. The perfusion 
abnormalities seen in the thallium cardiac scans in syndrome X were not due to any 
major coronary stenosis because all these patients had angiographicaIIy normal 
coronary systems. Waldenstrom proposed that the defects in the uptake ofthallium-201 
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could be due to a change in the cell metabolism resulting from abnormal ion leakage 
from the cells and not due to any microvascular ischemia [148]. 
Very similar changes in the cardiac thallium-201 SPECT scans were observed in a 
small group of well-characterised CFS patients with or without chest pain [150]. 
Image analysis revealed moderate perfusion defects in the left ventricles of 7 out of 
the 10 patients studied [150]. 
Resting energy expenditure in CFS: Resting energy expenditure (REE) is the energy 
expended by an awake, alert subject in the post-absorptive state [151]. REE accounts 
for between 60% and 90% of the total energy expenditure and any increases in REE, 
in the absence of compensatory increase in diet, should result in there being less 
energy available for other physical activities. 
In a pilot study, REE of female patients with CFS was measured and compared to the 
values in healthy sedentary controls [152]. REE varies with body size; therefore 
several body compartments that are potentially important in the prediction of the 
expected REE were also measured. These compartments were total body potassium 
(TBK), total body water, extracellular water and intracellular water. 
Eleven female patients with CFS were studied together with 11 healthy female control 
subjects in the same height, weight and age range. Since gross indices of body mass, 
such as height and weight are relatively poor predictors of the expected REE, TBK 
was chosen as the predictor of the expected REE in deference to the previous 
observations [153]. Using TBK as a predictor of the expected REE, a significant rise 
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in REE was observed in 5 of the 11 CFS patients as compared to controls [152]. In 
theory, it is possible that this transmembrane potassium leak leads to an overactive 
membrane membrane pump (Na+IK+- ATPase) that balances the transmembrane 
potassium and sodium fluxes essential to the function of excitable cells. The reduced 
TBK and marginally low intracellular water values as found in CFS patients in this 
study [152] support the possibility of "leaky" cell membranes, an assumption 
originally made to explain hyperbilirubinemia in patients with Gilbert's disease 
where chronic fatigue is common [154]. 
Genetics of chronic fatigue 
Like any other complex disorder, it is likely that genetic influences may modify 
clinical expressions of CFS. Several mitochondrial DNA (mtDNA) deletions were 
reported in a typical case of CFS and common mtDNA 4977 deletion in two of eight 
cases was observed [155]. In a classic twin study, concordance rates for CFS-defining 
idiopathic chronic fatigue were 55% in monozygotic twins and 19% in dizygotic 
twins. The twin study data are supportive of the familial aggregation of CFS and 
suggest that genes may playa role in the predisposition to the development of CFS 
under appropriate environmental trigger. 
Summary of CFS research review 
In summary, a review of published literature in CFS will clearly draw attention to two 
major paradigms of this disorder. A broad (and relatively non-specific) paradigm is 
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based on the psychiatric model and assumes CFS to be a functional somatic disorder 
and comparable to psychogenic illnesses like globus hystericus. From a neurological 
perspective, this model cannot be objectively researched because there is no 
biological template that corresponds to somatisation. The alternative neurobiologic 
paradigm is based on a more strictly defined population of patients with medically or 
psychiatrically unexplained chronic fatigue. In this paradigm, fatigue has been 
attributed to the functional changes in the peripheral, autonomic and lor central 
nervous system. None of these changes may be specific or sensitive for CFS, but 
some of the observations on neuroendocrine functions (hypoactive HP A axis and 
exaggerated prolactin response to oral buspirone) and muscle physiology (subgroup of 
patients showing delayed post-exertional recovery) have been reproduced by different 
workers. The psychosocial and neurobiological models of CFS are summarised in 
Box 1. No doubt the diverse and, at times, contradictory conclusions reached in many 
of the research publications make it difficult to identify specific pathophysiological 
mechanisms in CFS. 
. " 
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Box 1. Chronic fatigue syndrome: current hypotheses 
(1) The psychiatric hypothesis: CFS is a functional somatic syndrome and/or an 
illness behaviour linked to the depressive disorders. In this view, it is held that CFS 
develops when a psychologically vulnerable individual acquires an infection and 
perceives himselflherself to be physically ill even after recovery from this disease. 
The illness is perpetuated by a combination of depression, dysthymia, physical 
deconditioning, avoidance behaviour for physical activities and somatisation. The 
relative contributions of the individual components of these perpetuating factors may 
vary among patients. This hypothesis has been claimed to have been supported by the 
outcome of the intervention studies of graded exercises and cognitive behaviour 
therapy in CFS. 
(2) The neurobiologic hypothesis: CFS is primarily considered to be a disorder of the 
central nervous system (central fatigue) and the symptomatology reflects the outcome 
of a complex interaction between the cognitive, physical and neuropsychological 
changes induced by the triggering disease process (commonly a viral infection, rarely 
a toxin like ciguatera fish poison). The physical changes may affect the immune 
system, neuroendocrine regulation, ion channels, autonomic responses and the 
cerebral perfusion. Studies have consistently shown that patients with CFS do have 
some of these changes although the relative contributions of the individual 
components of these changes may differ in patients and at present, there is no 




CFS is a complex illness the pathogenesis of which is not clearly known. While it is 
reasonable to assume that like any other chronic medical and psychiatric syndromes, 
CFS will have both organic and psychosocial aetiologies, identification of reliable and 
objective dis~ase markers are considered important for several reasons. Firstly, 
specific biological markers are considered to be the signatures of a medical disease. 
Depending on the sensitivity and specificity of the marker, a disease can be reliably 
distinguished from other disorders sharing similar symptoms. Thirdly, biological 
markers reveal the disease mechanism and may lead to more effective treatment. 
Finally, biological markers may have prognostic values in the natural history of the 
disease. 
The objectives of the present research were to develop a neurobiological paradigm for 
CFS and make a search for possible biological markers that may be associated with 
CFS. Because the level of fatigue in health or in diseases is sensitive to the changes in 
metabolic functions, this research was focussed on the metabolic changes in patients 
with CDC-defined CFS. Secondary objectives in this research were sub-categorisation 
of CFS patients based on reproducible tests and developing new paradigms of 
neuroimaging that may identify metabolic and functional brain changes in CFS 
patients. 
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14.2 AIMS OF RESEARCH 
. ,. 
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The aims of this research were to answer the following questions: 
• Is there any significant alteration of intermediate metabolism in CFS? 
• Is there any change of energy utilisation and expenditure in CFS? 
• Is there any alteration in the muscle physiology of CFS patients? 
• What is the response of CFS patients to standardised, symptom-limited exercises? 
• How does the dopaminergic system in CFS respond to external pharmacological 
challenge? 




5.1 Blood and urinary metabolic markers in CFS 
Background 
Symptoms of peripheral and central fatigue are common in metabolic diseases. Fatty 
acids and other charged single chain lipids are considered to act as messenger 
molecules that target certain types of K+ channels [157]. After glucose, free fatty 
acids are the major source of energy in the tissues. Estimates suggest that the free 
fatty acids supply about 25-50% of the energy requirement in the fasting state [158]. 
The long chain unsaturated fatty acids of metabolic significance can be divided into 
non-essential and essential, the only source of the nutritionally essential fatty acid is 
diet. Palmitoleic acid (CI6:1) and oleic acid (CI8:I) are non-essential fatty acids. 
Linoleic acid (CI8:2), linolenic acid (CI8:3) and arachidonic acid (C20:4) are the 
essential fatty acids. Other C20 and C22 polyeonic fatty acids are derived from 
linoleic and linolenic acids by chain elongation [158]. The synthesis of essential fatty 
acids of the n-6 and n-3 series from the dietary precursors is shown in the adjoining 
diagram (Flow Chart 1) [159]. Linoleic acid and alpha-linolenic acid constitute the 
dietary precursors of the n-6 and the n-3 series. Although previous research has not 
identified specific metabolic disorders in CFS patients, lipid metabolism in CFS has 
not been studied in any detail. Because liver diseases affect fatty acid metabolism, 
liver function tests were also performed in these patients. 
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Flow Chart 1. Summary of the synthesis of essential fatty acids from the dietary 
precursors, linoleic acid of the n-6 series and a-linolenic acid of the n-3 series. In 
mass and also in functional terms, arachidonic acid (AA) and docosahexanoic acid 
(DHA) are the most important fatty acids. Dihomo-y-linolenic acid and 
eicosapentaeonoic acid are important for cell-signalling and enzyme regulating 
molecules [Ref. 159]. 
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Baseline blood and urine samples were collected in the morning from fulfilling the 
modified CDC definition of CFS patients after overnight fast. Clear supernatant was 
separated in each blood sample by centrifugation immediately after collection and 
was refrigerated at -70 0 C prior to analysis. 20ml of the voided urinary sample was 
taken from each patient and was deep frozen until the time of biochemical analysis. 
Fasting plasma samples were biochemically analysed for the following liver function 
markers: glutathione-S-transferase (GST), total protein (TP), albumin (Alb), globulin 
(Glb), bilirubin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), 
aspartarte aminotransferase (AST), gamma-glutamyl transpeptidase (GGT). Serum 
creatine kinase (CK), plasma lactic acid (lactate), free and total plasma camitine were 
also measured. For evaluating the lipid profile, following biochemical markers were 
analysed in the fasting venous blood sample: total cholesterol (TC), total triglyceride 
(TGL), very low density lipoprotein-cholesterol (VLDL-C), low density lipoprotein-
cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C). ~ ,< 
Plasma fatty acids were assayed as follows (Dr. R. Logan, Department of 
Biochemistry, Yorkhill Hospital). After initial solvent extraction and derivatisation to 
fatty acid methyl esters, the fatty acids were analysed by gas chromatography and 
mass spectroscopy. Individual fatty acids were reported as weight percent of the total 
-
fatty acids. The individual fatty acids included the following medium and long chain 
fatty acids: CI4:0, CI6:0, C:18:0, CI8:1, C18:2 (n-6), CI8:3(n-3), C20:3 (n-6), 
C20:4(n-6), C20:5(n-3) and C22:6(n-3). 
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Urine samples were tested for pH, urinary creatine and urinary orotic acid. 
Chromatographic analysis were performed for the following urinary metabolites and 
organic acids:. lactate, p-cresol, 3-hydroxybutyrate, acetoacetate, 4-deoxytetronate, 
cis-aconitate, homovallinate, hippurate, isocitrate and citrate. 
Results 
Thirty-five CDC-defined CFS patients completed the study. There were 17 men and 
18 women. Pooled results of the blood biochemical markers were compared with the 
standardised and existing reference ranges of the laboratory for the normal population. 
These data are shown in Tables 5.1.1 and 5.1.2 and graphs (Figures 5.1.1-5.1.6). Liver 
function tests were found to be normal in the CFS patients. Mean plasma bilirubin 
was 4.4 Ilmolll (range: 1- 17) and no patient had a high level of fasting plasma 
bilirubin consistent with Gilbert's syndrome. Mean serum creatine kinase was 64.97 
i.u.lL and all patient values were within normal reference range. Mean free and total 
plasma carnitine levels were 32.2 IlmollL (patients'range: 16-50; normal range 19-60) 
and 46.8 Ilmol/L (patients' range: 20-74; normal range 30-73) respectively. Only one 
patient had low free plasma camitine (16 IlmollL ) and total plasma camitine (20 
IlmollL). 
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Table 5.1.1 Blood biochemical profile of CFS patients ( n= 35) 
Biochemical marker Reference Range in Mean Median SD SEM 
(units) range the CFS 
(normal) patients 
GST (ull) 0- 15 1.5- 23 5.1 4.5 5.05 0.85 
TP(gll) 55-80 55-70 66.3 67 4.72 0.80 
Alb(gll) 35-55 33-48 43.9 44 3.32 0.56 
Glb(gll) 20-35 18-27 22.4 23 3.01 0.51 
Bilirubin (Jlmol/l) 5-17 1-17 4.4 3 3.12 0.53 
ALP (ull) 50-150 84-224 144.9 142 38.50 6.51 
AST(ull) 0- 35 10-47 18.9 17 7.23 1.22 
ALT (ull) 0-35 9-57 21.4 14 14.38 2.43 
GGT (ull) 0-50 7-295 29.7 14 50.94 8.61 
CK (ull) 30-150 20-142 64.9 60 35.84 6.24 
Free Cam (Jlmol/l) 19-60 16-50 32.2 32 8.28 1.40 
Total Cam (Jlmol/l) 30-73 20-74 46.8 46 10.87 1.84 
Lactate (mmol/l) 0-2 1-2.6 1.9 1.8 0.50 0.09 
TC(mmol/l) <6.5 2.7-7.3 4.7 4.7 0.98 0.17 
TGL(mmol/l) <3.0 0.5-2.6 1.2 0.9 0.71 0.12 
VLDL-C (mmol/l) <1.2 0.2-1 0.48 0.4 0.34 0.06 
LDL-C (mmol/l) <4.5 1.7-5.6 2.9 2.9 0.82 0.14 
HDL-C (mmol/l) >1.0 0.9-1.9 1.32 1.3 0.26 0.04 
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Table 5.1.2 Plasma fatty acids in CFS patients (n=35) 
Fatty acid expressed Reference Range in the Mean Median SD SEM 
as % of total fatty Range CFS patients 
acids (normative) 
Myristic (C14:0) 0.67 - 2.05 0.55 - 2.44 1.08 0.89 0.48 0.81 
Palmitic (C16:0) 19.10- 27.36 20.55 -27.39 23.99 23.76 1.46 0.25 
Palmitoleic (C16:1) 1.09 - 4.05 0.97-7.25 2.34 2.2 1.17 0.20 
Stearic (C18:0) 7.53 - 12.59 6.96-10.32 8.08 8.0 0.87 0.36 
Oleic (C18:1) 18.01-26.39 20.9-30.46 24.53 24.25 2.14 0.36 
Linoleic (C18:2) 21.18-32.96 26.84-37.0 30.99 30.88 4.34 0.73 
Linolenic (C18:3) 0.17-0.73 0.001-1.19 0.43 0.34 0.25 0.04 
Dihomogamma- 1.12 - 2.45 0.33- 2.26 1.38 1.35 0.36 0.06 
linolenic (C20:3) 
Arachidonic (C20:4) 6.19-10.41 3.64 - 8.3 5.71 5.76 1.18 0.20 
Eicosapentaenoic 0.09-0.89 0.001 -1.23 0.41 0.41 0.25 0.04 
" -(C20:5) 
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Fig 5.1.2: Bilirubin in CFS 
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Fig 5.1.3: Lipid Function in CFS 
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Fig 5.1.4: Carnitine in CFS 














Fig 5.1.5: CK Levels in CFS 
(Mean and SEM Plot) 
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Fig 5.1.6: Lactate in CFS 
(Mean and SEM Plot) 
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Overall, lipid profiles in CFS patients were found to be nonnal. Mean (± S.E.M.) 
plasma values for total cholesterol, triglyceride, VLDL-C, LDL-C and HDL-C were 
4.72 (0.17),1.12 (0.12), 0.48 (0.06), 2.92 (0.14) and 1.32 (0.04) mmollL. The ranges 
of the essential fatty acids were similar to the reference value with the exception of 
the arachidonic acid (AA) and docosahexaenoic acid (DHA) which were slightly 
lower in the CFS group. However, in the absence of a matched controlled group of 
healthy adult subjects, these observed differences were not suitable for statistical 
analysis. 
Results of urine chromatographic analysis were also nonnal in CFS patients. 
However, 5 patients had traces of ketonuria, probably due to the starvation effect. 
Organic acid chromatography of the urine samples showed minor traces of p_ 
hydroxyphenyllactate in 2 patients suggestive of subtle liver cell dysfunction. One 
patient had a positive chromatogram for 3-methylglutarate and 3-methylgluconate. 
Conclusions 
As compared to the established range of nonnative data in the control popUlation, 
there were no significant abnonnalities in the values for blood and urinary 
biochemical markers in the study population as a group. Results of minor liver cell 
dysfunction (e.g. traces of p-phenyllactate in 2 patients) were interpreted to reflect 
recent use of analgesics' (paracetamol). Presence of rare metabolites (3-
methylglutarate and 3-methylgluconate) in trace amounts in the urine sample of a 
single case could not be explained. When excreted at much higher levels, these 
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metabolites are associated with 3-methylgluataconic aminoaciduria, a disorder caused 
by the deficiency of 3-methylglutaconyl CoA hydratase in the branched chain amino 
acid metabolism. 
Lipid metabolism was generally normal in the CFS patients. There was a trend 
towards lower proportions of AA and DHA in the plasma levels of the essential fatty 
acids in CFS but there was no significance of this observation due to the lack of a 
control group. Furthermore, plasma levels of fatty acids only reflect recent dietary 
intake whereas red cell membrane fatty acids are more likely to represent longer term 
changes related to hepatic synthesis and metabolic handling. In functional terms, 
however, AA and DHA are the most important fatty acids required for brain 
phospholipid function (Flow Chart 2). The formation of AA and DHA in the liver is 
blocked by stress and viral infections, both of which have been implicated in the 
development ofCFS [159]. 
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Flow Chart 2. The routes whereby essential fatty acids require for brain function 
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5.2 Relationship between plasma glucose and insulin in CFS 
Background 
Maintenance of plasma glucose concentrations within narrow limits is an essential 
metabolic requirement in life. Glucose is also the most important source of energy. 
Glucose tolerance test has been used extensively in the diagnosis of diabetes and in 
patients with impaired glycaemic control. In normal subjects, insulin levels rise with 
increases in plasma glucose concentration. Conversely, insulin release from the 
pancreatic beta cells is inhibited when plasma glucose levels fall during the fasting 
state. In interpreting plasma insulin concentration at a given time point, absolute 
plasma insulin levels are not considered very helpful and plasma insulin levels are 
interpreted in the light of a simultaneously determined plasma glucose value. This is 
because a "normal" plasma insulin level may be abnormal in a hypoglycaemic state 
whereas a "high" plasma insulin level is appropriate if plasma glucose concentration 
is elevated. In an attempt to relate these two parameters, the concept of 
insulin: glucose ratio was developed [160] and was originally expressed as: 
insulin: glucose (I/G) ratio = plasma insulin (microunits/ml) = 0.4 or less 
plasma glucose (mgldl) 
The ratio (expressed in the conventional units) is usually 0.4 or less. This observation 
is based on in vitro models of pancreatic beta cell function where insulin secretion 
ceases if plasma glucose concentration falls below 90 mg/dl (5 mmoVL). 
67 
Adam, King and Schwartz defined the dynamic relationship between plasma insulin 
and glucose levels in a study where glucose solution was infused in the normal 
subjects intravenously at different rates with measurement of plasma insulin 
concentrations when a steady state had been reached [160J. Based on their data, 
normal relationship between plasma insulin and plasma glucose is expressed by a 
linear equation: 
y = O.4lx -34 
where y = plasma insulin in microunits/ml, and x = plasma glucose in mg/dl. 
The intercept of the x-axis in this equation for plasma glucose is 83 mg/dl 
(approximately 4.6 mmollL) when pancreatic insulin release is expected to cease in 
normal health. 
Methods 
An extend~d glucose tolerance test was performed as part of the metabolic screening 
in the same cohort of patients as in the previous experiment (5.1). Thirty-five CFS 
, 
patients M=17, F=18) were given of oral glucose solution (equivalent to 75g glucose) 
in a condition of overnight fasting. We measured plasma insulin levels simultaneously 
with plasma glucose every 30 minutes for 2.5 hours. All CFS patients (M=17, F=18) 
successfully completed the study protocol (extended glucose tolerance test). Blood 
samples for plasma glucose and plasma insulin were collected from a cannulated arm 
vein. All samples were flash frozen after plasma separation by centrifugation and 
. thawed samples were assayed biochemically in an auto analyser at the Department of 
. Biochemistry, Glasgow Royal Infirmary (Dr. C. E. Gray). 
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Results 
Analysis of plasma glucose values in CFS patients for the duration of extended 
glucose tolerance test revealed no fasting hyperglycaemia or impaired glucose 
tolerance (defined as venous plasma glucose concentration> or = 11.1 mmollL at 2 
hours and at least on one occasion during the first 2 hours of the test). None of the 
patients had any symptoms of hypo glycaemia during the test and did not have 
inappropriately high plasma insulin values at any of the pre-selected time points 
(baseline, 30 minutes, 60 minutes, 90 minutes, 120 minutes and 150 minutes). 
The relationship between simultaneous plasma glucose and insulin values was found 
to be essentially linear in the CFS patients but wIth a different slope. This 
relationship was best defined by the following regression equation: 
y = 1.33 x - 87.75 
As compared to the normal equation, the intercept of the x-axis in this equation for 
plasma glucose is 66 mg/dl (3.6 mmollL). 
The statistical analysis of the results is shown in Table 5.2. As compared to the 
temporal relationship between plasma glucose and insulin after glucose challenge in 
the normative controls, the observed relationship in the CFS patients was statistically 
significant. This significance is more relevant given that the individual plasma ratios 
of insulin: glucose at different time points were always normal «0.4) in the CFS 
patients. The regression equation of the insulin: glucose relationship in CFS patients 
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as compared to the nonnative equation is plotted in Figure 5.2.1. Figure 5.2.2 shows 
the mean (±S.E.M.) changes in the plasma insulin levels of CFS patients at different 
time points. 
Conclusions 
CFS patients do not have evidence of impaired glucose tolerance, fasting 
hypoglycaemia or hyperinsulinemia. However, it appears that CFS patients as a group 
may have pancreatic insulin release occurring at a relatively lower value of plasma 
glucose (about 1 mmollL lower than nonnal). The differential rates of absorption of 
oral glucose solution in the patients (as compared to the intravenous glucose in the 
historic controls) might explain the apparent differences in the plasma glucose: 
plasma insulin relationship seen in this study. An alternative explanation, however, is 
that the insulin release in CFS patients continues at a lower range of plasma glucose 
but witho~t any inappropriate hyperinsulinemia. 
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Table 5.2: Statistical analysis ofthe plasma insulin: glucose relationship (n=35) 
Regression Statistics 
!Multiple R 0.907 
iR Square 0.823 
~djusted R Square 0.778 
Standard Error 11.645 
Observations 6 
~NOVA 
df SS MS F lSignificance F 
iRegression 1 2515.38C 2515.38C 18.551 0.013 
Residual 4 542.384 135.596 
!.rotal 5 3057.763 
Coefficients !standard ErrOl' t Stat P-value 
ntercept -87.752 29.929 -2.932 0.043 
Glucose(X) 1.333 0.309 4.307 0.013 
The fitted linear model is: y=-87. 752+ 1.33x. The slope ofthis model is significantly 
different from the slope (0.41) of the nonnative model (p=0.0411 at .05 level of 
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5.3 Atypical autoantibodies in CFS 
Background 
Both peripheral (neuromuscular) and central fatigue are common in systemic 
autoimmune diseases many of which may be precipitated by infection. Infectious 
agents are implicated in the pathogenesis of rheumatoid arthritis (Epstein-Barr virus), 
diabetes (Coxsackie B4), and multiple sclerosis (human herpes virus type 6 and 
measles virus), Guillain-Barre syndrome (Campylobacter jejuni). CFS has been 
associated with preceding infections due to Epstein-Barr virus, Coxsackie B virus and 
human herpes virus-6. Many characteristics of CFS are comparable to the symptoms 
of autoimmune diseases (muscle and multi-joint pain, enlarged lymph nodes, fatigue, 
cognitive impairment). CFS patients also experience irritable bowel syndrome. 
Symptoms. of irritable bowel and CFS-type fatigue are common in coeliac disease. 
Standard autoantibody screen in CFS patients is usually negative; however, profiling 
for uncommon autoantibodies in CFS cases have not been studied. The following 
study was undertaken to determine the presence or absence of four atypical 
autoantibodies (anti-gliadin and anti-endomysia! antibodies, anti-acetylcholine 
receptor antibody, anti-voltage gated potassium channel antibody and antibody 
against the G-protein coupled cardiovascular receptors). 
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Methods 
Serum samples collected from CFS patients were tested for the chosen antibodies: 
anti-gliadin and anti-endomysial IgA antibody, anti- acetylcholine receptor (AChR) 
antibody, Anti-voltage gated potassium channel (VGKC) antibody, and antibody 
against G-protein coupled cardiovascular receptors (adrenergic and muscarinic). 
Serum antibody levels were measured in the regional reference laboratories 
employing in-house technologies. The samples were assayed blindly. The results were 
interpreted in comparison with the appropriate laboratory negative and positive 
controls. 
Results 
Anti-gliadin antibody and anti-endomysial IgA antibody: This was carried out in 33 
~ 
patients with symptoms of chronic fatigue by using a standardised enzyme linked 
immunoabsorbent assay (Ms. K. Kingstone, Gastrointestinal laboratory, Western 
General Hospitals NHS Trust, Edinburgh). There were 27 patients with CFS (M=9, 
F=18). Six patients had other neurological diseases with chronic fatigue. All 33 
patients had negative IgA anti-endomysial antibody and normal levels of anti gliadin 
IgA antibody «30 units/ml): -
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Anti-AChR antibody: Serum antibody levels were measured by radioimmunoassay 
(Mrs. J. Veitch, Neuroimmunology laboratory, South Glasgow University Hospitals 
NHS Trust). All 17 CFS patients (M=7, F=10) had antibody titres less than 0.1 
nmoles/l (negative). 
Anti-VGKC antibody: The serum antibody levels were measured by 
immunoprecipitation of 1251 -alpha dendrotoxin labelled VGKC extracted from human 
foetal cortex. A total of 45 samples were assayed (Prof. A. Vincent, Neuroscience 
laboratory, Oxford Radcliffe Hospital) from 18 male and 27 female CFS patients. In 4 
patients (2 M, 2F), the results were equivocal (antibody level 100-200 pmoVI); when 
the tests were repeated in three (1M, 2F) the results were negative. It was not possible 
to repeat the test in the fourth (M). In the remaining 42 samples, the assay for anti-
VGKC antibody was negative (titre <100 pmoVl) in each case. Overall, transient/low 
positivity of serum anti-VGKC antibody was detected- in 8.88% (4/45) of the CFS 
samples affecting both sexes equally (2M, 2 F). 
Antibodies against G protein coupled cardiovascular receptors: Using an enz~e­
linked immunoabsorbent assay (ELISA) previously described [161], antibodies to the 
G-protein coupled cardiovascular receptors was measured in the serum samples of 16 
patients with CFS (M=8, F=8). The results were compared with 9 control serum 
samples (Dr. M. Fu, Wallenberg Laboratory, Sahlgren's Hospital, Sweden). Two CFS 
patients (lM, IF) were found to have positive antibody levels (12.5%; 2/16). 
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Conclusions 
In this study, we found no evidence of coeliac disease or acquired neuromuscular 
junction disorder due to autoimmune myasthenia gravis in CFS patients. However, a 
small minority of CFS patients had positive VGKC antibody and G protein coupled 
adrenergic receptor antibody. The significance of these low positive antibody titres in 
CFS is unclear but these antibodies do not appear essential in the pathogenesis of 
CFS. 
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5.4 Serum immunossay for ouabain like substance (OLS) 
Background 
An endogenous, digitalis-like sodium pump inhibitor in plasma has been recently 
identified. This circulating factor is a specific inhibitor of the human erythrocyte, 
ouabain-sensitive sodium pump and is called "ouabain-like substance"(OLS). OLS 
leads to an excessive accumulation of intracellular sodium that has been implicated as 
the basic pathology in both essential hypertension and depression [162,163]. 
From a pilot study of the resting energy expenditure (REE), it was concluded that a 
proportion of CFS patients had increased levels of resting energy expenditure with 
respect to their total body potassium (REE TBK)' It was hypothesised that raised 
REETBK might reflect increased energy expenditure to maintain the transmembrane 
potassium gradient [152]. This gradient is maintained by the membrane sodium pump 
(Na+lK+ ATPase) and the membrane pump is sensitive to circulating OLS. " 
Methods 
Thirty-eight serum samples were assayed for the OLS level. These samples were 
collected from 17 CFS patients and 16 neurological patients without chronic fatigue 
and 5 patients with multiple sclerosis and fatigue. Serum OLS level was measured by 
in-house radioimmunoassay at the Department of Chemical Pathology, St. Thomas' 
77 
Hospital, London (Dr. R. Swaminathan). Annonymised serum samples of healthy 
blood donors obtained from the Regional Transfusion Service in Glasgow were used 
to derive the normal reference range for this experiment. 
Results 
In this radioimmunoassay, the laboratory reference value for mean OLS concentration 
in healthy individuals was 0.70 ±0.05 nmoVL (mean ± S.E.M). In the CFS patients, 
the mean OLS was 0.80 nmoVL (range 1.15 - 0.49 nmol/L, S.E.M. 0.07); the 
corresponding value in the healthy blood donors was 0.73 nmoVL (range O. 46 - 0.93 
nmoVL, S.E.M. 0.05). In 5 patients with multiple sclerosis, the mean OLS level was 
0.87 nmoVL (range 1.17 - 0.67 nmoVL, S.E.M. 0.09). 
The statistical analysis of these results is shown in Table 5.4. Individual group 
difference~ calculated by one-sided ANOV A were not found to be significant for a p 
value <0.05. Figure 5.4 shows the results of serum OLS in the three groups. 
Conclusions 
The mean serum OLS levels in CFS patients, healthy controls and other neurological 
patients were similar and the observed variations were not statistically significant. It is 
unlikely that CFS symptoms are related to the changes in the serum OLS levels. 
Table 5.4: ANOVA -Single factor analysis to test equality of mean serum OLS 
levels in CFS, NC and MS patients 
/Anova Single Factor 
SUMMARY 
Groups Count Sum Average Variance SEM 
K=FS 17 13.53 0.8Jl 0.08 0.07 
~C 16 11.64 0.73 0.03 0.05 
MS 5 4.37 0.81 0.04 0.09 
iANOVA 
Source of Variation SS df MS F P-value 
lBetween Groups 0.092 2 0.04~ 0.869 0.428 
Within Groups 1.855 35 0.053 
ttotal 1.952 37 
The differences among means are not significant, p=0.428 
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Fig 5.4: Study of Serum Ouabain Like Substance(OLS) 






5.5 Cerebrospinal fluid levels of an endogenous pentapeptide (QYNAD) 
Background 
CFS patients have experienced deterioration of symptoms after local anaesthetics 
given for minor procedures or surgery [2J. Lignocaine (lidocaine) has been shown to 
unmask demyelinating symptoms in multiple sclerosis and a local-anaesthetic like 
factor in the cerebrospinal fluid (CSF) was previously identified in patients with 
multiple sclerosis and Guillain-Barre syndrome where fatigue is common [164]. This 
pentapeptide with the sequence Gln-Tyr-Asn-Ala-Asp (QYNAD) exerts its blocking 
by shifting the steady state inactivation curve of the membrane sodium channels to 
more negative potentials, like most local anaesthetics [165J. The purpose of the 
experiment was to determine if CFS patients may have a higher concentration of this 
sodium blocking pentapeptide (QYNAD) in their CSF. 
Methods 
This experiment was carried out retrospectively. Stored cerebrospinal fluid (CSF) 
samples of 15 patients were used for this experiment. These samples were originally 
collected from patients in whom lumbar puncture was advised as a diagnostic test. 
The final diagnosis of these cases were CFS (n=5); presumed neuroinflammatory 
diseases (n=5) of which two -were found to have mUltiple sclerosis, two had isolated 
spinal cord demyelination (transverse myelitis) and in one case, a diagnosis of post-
encephalitic Parkinsonism was made. All five patients in the second group had 
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positive oligoclonal bands in the CSF indicative of a breakdown in their blood-brain-
barrier (BBB). The remaining 5 cases had headache syndromes due to non-
inflammatory neurological disorders. Oligoclonal bands were absent in the CSF 
samples of patients in the first (CFS) and the third (benign headache) groups. The 
putative pentapeptide (QYNAD) was assayed by the liquid chromatography as 
previously described in the Department of General Physiology, University of Ulm, 
Germany (Dr. R. Rudel). 
Results 
The mean values of micromolar QYNAD in the CSF samples were 8.4 JLmoVI in the 
CSF group (range: 4.8-11.2 JLmoVI; S.E.M. 1.39); 8.02 JLmol/l in the neuro-
inflammatory group (BBB) of neurological patients (range: 4.3-11.2 JLmoVI; S.E.M. 
1.11) and 6.58 JLmoVI (range: 3.9-11.0 JLmoVI; S.E.M. 1.42) in patients with benign 
headache syndrome. 
The statistical analysis is shown in Table 5.5. Individual group differences were not 
found to be statistically significant for p<0.05. Figure 5.5 shows the CSF levels of the 
pentapeptide (QYNAD) in the three groups (CFS, BBB and headache patients). It was 
of interest that the levels of the pentapeptide did not differ among these patients. 
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Conclusions 
Based on this experiment in a relatively small number of patients, it appears that the 
cerebrospinal fluid levels of this putative endogenous pentapeptide is not increased in 
CFS patients as compared to patients with other neurological disorders. 
Table 5.5: ANOVA -Single Factor Analysis to test equality of mean values of 




Groups Count Sum Average Variance 
CFS 5 42.0 8.1!J 
I8BB 5 40.1 8.02 
lHeadache 5 32-2 6.58 
/ANOVA 
Source 0/ Variation SS eff MS 
lBetween Groups 9.217 2 4.605 
lWithin Groups 103.416 12 8.618 
rrotal 112.633 14 
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Fig 5.5: CSF Penta peptide Study 
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5.6 Screening for familial haemochromatosis gene (HFE) mutation 
Background 
Haemochromatosis is a metabolic disease characterised by chronic fatigue, joint pain, 
endocrine insufficiency, diabetes, cutaneous hypermelanosis, diabetes and heart 
failure. However, at least four different types of disease expression have been 
associated with hereditary haemochromatosis linked to the haemochromatosis gene 
(HFE) [166]. Different phenotypic expressions of haemochromatosis are correlated 
with variabilities in the serum biochemical tests (total body iron stores, transferrin 
saturation and serum ferritin levels), age of onset and clinical forms. For example, 
juvenile haemochromatosis as a more severe clinical course characterised by an 
earlier onset of cardiac symptoms and does not show a male preponderance. Fatigue is 
a common symptom in all the clinical phenotypes of HFE that is inherited as an 
autosomal recessive disease with tight linkage to HLA-A. Based on the observation 
that 78.4% of cases ofhaemochromatosis had positive HLA A3 haplotype, a gene for 
haemochromatosis was postulated to be in chromosome 6 in linkage equilibrium-with 
HLA A locus [167]. The HFE gene was subsequently mapped to chromosome 6p21.3 
[168]. 
Nearly 10% of whites are homozygous for the HLA-linked haemochromatosis 
mutation [169]. Over 80% ofhaemochromatosis patients have a missense mutation 
in chromosome 6 that results in a substitution of cys282-to-tyr substitution (C282Y) at 
nucleotide 845. HFE is relatively common in the Caucasians, affecting more than 1 in 
300 individuals of northern European origin. It also has a strong founder effect. In 
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European populations, the frequency of C282Y mutation is highest (6.88%) among 
Celtics (Scottish/Irish) and Australian patients have been traced to a common Celtic 
ancestry. The carrier frequency of this mutation is around 6% in the Northern Europe 
with the highest frequency reported in Ireland (14%) [168]. Given the fact that 
fatigue in HFE does not correlate the severity of clinical forms of the disease, we 
wanted to test if CFS patients may have a higher frequency of HFE mutation. 
Methods 
Using polymerase chain reaction and restriction-enzyme digestion, peripheral 
leukocytes from the anticoagulated blood sample of 19 CFS patients (M=lO F=9) 
were screened for cys-282-tyr (C282Y) mutation (Dr. R. Spooner, Department of 
Biochemistry, West Glasgow University Hospitals NBS Trust). Additionally, full 
haematology screen was performed and serum ferritin level was estimated in all cases. 
Results 
17 CFS patients had normal HFE genotype. 2 CFS patients (M=l, F=l) were 
heterozygous for the C282Y mutation. Haematological indices were normal in all 19 
patients; 3 female CFS patients however had low serum ferritin levels. The carrier 
frequency of the HFE gene mutation in the CFS patients was found to be 2/19 
(10.5%) in this study. This was interpreted as the expected carrier frequency expected 
in the normal Scottish population. 
85 
Conclusions 
The frequency of HFE gene mutation in the Scottish CFS patients is not increased as 
compared to the normal frequency in the population. However, this was a small study 
and because the number of CFS patients was not large enough, a significant difference 
might have been missed (Type 2 error). Some female CFS patients may have low 
serum ferritin levels without the haematological manifestations of iron deficiency 
anaemia. Iron supplementation may be helpful in such a situation. 
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5.7 Skeletal muscle histology in CFS 
Background 
Early onset of fatigue in physical activities and post-exertional malaise are the key 
defining symptoms of CFS. In muscle physiology, exertional fatigue is considered to 
be a cardinal feature of impaired oxidative phosphorylation. Abnormalities of muscle 
oxidative phosphorylation are known to be present in a subgroup of CFS patients. In 
this study, muscle biopsies from CFS patients were analysed for changes in 
histochemistry and fibre morphology. 
Methods 
Under local anaesthesia, three cores of muscle biopsy were obtained from the right or 
left vastus lateralis muscle from 14 CFS patients (M= 7, F=7). Routine microscopy 
and ultrastructural studies were performed at the University Department of Pathology, 
West Glasgow University Hospitals NHS Trust (Prof W.M.H. Behan). 
Results 
The male patients were 32-56 years of age with an average duration of symptoms of 
CFS for 4.5 years (range: 1-14 years). Female CFS patients were between 24-50 years 
of age with a mean duration of illness of 6.2 years (range: 1-11 years). In one patient, 
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examination of the biopsied muscle was found to be entirely normal. Minor, non-
specific abnormalities were present in the 13 biopsies (M=6, F=7). Mild fibre atrophy 
was noted in 6 samples (M= 2, F=4). In an additional female patient (age: 24 years, 
CFS duration: 3 years), fibre atropy was more marked. Fibre atrophy in the muscles 
was generally paralleled by an increase in muscle lipid. The morphology and 
distribution of mitochondria, however, were normal; mild increases in mitochondrial 
number and cristae polymorphism was commented on in 8 patients (M=5, F=3). In 
ultrastructural studies, myofibrillary damage was seen in 6 biopsies some of which 
contained lysosomal debries. 
Conclusions 
Histological changes in the muscle biopsy were non-specific. The fibre type atrophy 
and lipid accumulation in half of the CFS cases were suggestive of changes due to 
physical d~conditioning. This is likely to be the consequence of the physical inactivity 
imposed by the persistent CFS symptoms. There was a definite excess of female ~FS 
patients with these changes in the muscle biopsies (F:M = 7:2). Our observations do 
not support the view that physical deconditioning itself causes CFS symptoms in 
which case atrophic changes should have been present in nearly every biopsy sample. 
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5.8 Intramuscular electrolyte distribution in CFS 
Background 
As an extension of the previous study, muscle biopsy samples from CFS patients were 
chemically analysed to determine the intramuscular concentrations sodium, potassium 
and the membrane sodium-potassium pump (Na+/K+-ATPase). The experiment was 
designed to test whether intramuscular electrolyte composition in CFS might differ 
from the normal individuals. 
Methods 
A total of 18 patient samples (M=9, F=9) were used in this experiment, including ten 
cryopreserved muscle biopsies from CFS cases in the previous study. For comparison, 
histologically normal muscle biopsy samples from 10 normal subjects (all male) were 
used as controls. The concentrations of intramuscular sodium (Na+), potassium ,(K+) 
and magnesium (Mg++) were analysed in the solution of muscle homogenates 
extracted with trichloroacetic acid. The concentration of the sodium-potassium pump 
(Na+IK+-ATPase) was· quantified as the total capacity of tritiated eH)-ouabain 
binding by using methods previously described [170]. This phase of the study was 
carried out at the laboratory of the Institute of Physiology, University of Aarhus in 
-
Denmark in collaboration with Prof T. Clausen and his colleagues. The laboratory 
experimenters were kept blinded to the clinical identities of the biopsy material. No 
participant had any known electrolyte disorders and none of them were on diuretic 
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treatment. The intramuscular concentrations of Na+, K+ and Mg++ were expressed as 
micromoVg of wet muscle tissue and the concentration of ATPase was expressed as 
picomoVg of wet muscle tissue. It was possible to measure intramuscular Mg++ 
concentration in 12 and 4 biopsy samples taken from patients and controls 
respectively. 
Results 
Mean (±S.E.M.) intramuscular concentrations of Na+ and K+ were 27.6 (1.79) 
J.LomoVg and 96.5 (2.42) J.LmoVg respectively in CFS patients and 30.4 (1.80) J.Lmol/g 
and 94 (2.80) JlomoVg in control subjects. Mean intramuscular concentration of 
Mg++ was found to be 9.2 J.Lmol/g in CFS patients and 8.9 JlmoVg in controls. The 
mean (±S.E.M) intramuscular concentrations of the membrane pump (Na+/K + 
ATPase) were 285.3 (10.7) picomoVg in CFS patients and 306 (15.2) picomol/g in the 
control subjects. 
The statistical analysis is shown in Tables 5.8.1- 5.8.3. The intramuscular 
concentrations of Na+, K+ and Na+/K+-ATPases in CFS patients and the control 
subjects are shown in the Figures 5.8.1-5.8.2. No statistically significant difference 
was noted in the intramuscular concentrations of sodium, potassium, magnesium and 
membrane pump (Na+/K +- ATPase) between patients and the control groups. 
Table 5.8.1: ANOVA -Single Factor Analysis to test equality of means of 




Groups Count Sum Average Variance SEM 
Na(CFS) 18 495.88 27.55 57.80 1.79 
Na (Controls) 12 364.99 30.42 38.85 1.80 
J\NOVA 
Source of Variation SS dL MS F P-value Fcrit 
Between Groups 59.179 I 59.179 1.175 0.288 4.196 
Within Groups 1409.976 28 50.356 
ifotal 1469.155 29 
The differences among means are not significant, p=0.288. 
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Table 5.8.2: ANOVA -Single Factor Analysis to test equality of means of 




Groups Count Sum Average Variance SEM 
K (CFS) 18 1737.51 96.53 105.59 2.42 
K (Controls) 12 1127.64 93.97 94.05 2.80 
ANOVA 
Source of Variation SS df MS F P-value Fcrit 
Between Groups 47.125 1 47.125 0.466 0.500 4.196 
lWithin Groups 2829.578 28 101.056 
Total 2876.702 29 
The differences among means are not significant, p=0.5. 
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Table 5.8.3: ANOVA -Single Factor Analysis to test equality of means of 
intramuscular concentrations of sodium-potassium ATPase in CFS and control 
subjects 
lAnova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance SEM 
ATPase (CFS) 18 5135 285.28 2059.39 10.70 
iATPase (Controls) 12 3672 306.00 2753.82 15.15 
~NOVA 
Source of Variation SS df MS F P-value 
lBetween Groups 3091.756 1 3091.756 1.326 0.25S 
lWithin Groups 65301.611 28 2332.20( 
rrotal 68393.367 29 
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Intramuscular electrolytes and Na+IK+-ATPase concentration in CFS patients are 
similar to the normal subjects. This would exclude any muscle metabolic changes in 
CFS secondary to adrenocorticoid or mineralocorticoid insufficiency. 
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5.9 A randomised, double blind, placebo controlled trial of 
dichloroacetate in CFS 
Background 
A proportion of CFS patients produce excess lactate after incremental exercise in a 
cycle ergometer to the anaerobic threshold [29]. 31 p nuclear magnetic resonance 
spectroscopy of the exercising muscles in CFS patients have shown evidence of early 
intracellular acidosis [85,86] and in an in vitro study of oxidative metabolism in 
myoblast cultures established from skeletal muscle biopsies, 10 of the 16 CFS 
samples showed mild defects of aerobic metabolism as compared to the normal 
controls [93]. These results are consistent with the view that impaired oxidative 
muscle metabolism in CFS patients might contribute to exercise intolerance. 
Dichloroacetate (DCA) exerts multiple effects on pathways of intermediate 
metabolism. By stimulating the activity of pyruvate dehydrogenase, DCA facilitates 
tissue oxidation of lactate [171]. When used in patients with lactic acidosis due to 
mitochondrial disorders, short term DCA treatment was found to improve indices of 
cerebral metabolism [172]. In addition, DCA stimulates peripheral glucose utilisation, 
--
inhibits gluconeogenesis and improves left ventricular mechanical efficiency under 
ischemic conditions. The outcomes of both acquired and congenital forms of lactic 
acidosis are improved by DCA [171]. 
Because DCA reduces lactate accumulation and improves muscle oxidative 
metabolism, we wanted to assess the effect of DCA on fatiguing muscle exercise in 
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CFS. 14 patients participated in the study (M=6, F=8), The age range of the study 
group was 27-66 years with a mean age of 44.5 years. Only CFS patients with a 
retained level of functional activity compatible with their ability to participate in the 
exercise protocol were recruited in this trial that was approved by the local Medical 
Research Ethics Committee ofthe Southern General Hospital NHS Trust, Glasgow. 
Methods 
The design of the study was randomised, double blind and placebo-controlled. 
Selected patients were randomly assigned to receive either the active drug (DCA) or 
placebo. All assessors were blind to the randomisation. Patients in the active arm 
were treated with DCA (25 mg/kg/day). The placebo group received identical gelatine 
capsules. Both DCA and the gelatine capsules were taken by patients three times daily 
for 14 days followed by a ten week washout period to remove any residual treatment 
effects. 
The fatiguing exercise consisted of repetitive, sustained contractions in the right 
quadriceps muscle in a previously established protocol of focal muscle fatiguability 
[100]. The protocol required repetitive, sustained (10 seconds) contraction of the 
muscle. Because sustained muscle contractions are known to result in lactic acid 
accumulation within the muscle, it was felt appropriate to use this protocol to test the 
therapeutic effect of DCA on muscle fatiguability and overall fatigue in CFS patients. 
Muscle fatigue and recovery were assessed at three time points: 
i. one day before commencement of DCA (or placebo); 
ii. a day after the 14 day treatment; and 
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iii. finally, after the 10 week washout period to remove any long-term effects of drug 
therapy. 
On each of these occasions, all participants were required to produce 18 maximum 
voluntary contractions (MVC) of the right quadriceps muscle in succession. This was 
then followed by single MVCs at 5,10, 15, 20, 35, 50,65, 80,110,140,170 and 200 
minutes into the recovery period and further three MVCs after 24 hours. The exercise 
protocol was administered in collaboration with the Department of Physiothearapy at 
the Therapy Centre of the Southern General Hospital (Dr. Lorna Paul, Glasgow 
Caledonian University). 
The effect of treatment on overall fatigue was assessed during the follow up visits by 
using Clinician's Global Impression (CGI) score (Table 5.9.1). A multi-dimensional 
fatigue sc~le was also developed (CFS Rating Scale, Appendix I). Patients were 
randomised to receive DCA or placebo. Both the patients and the investigators 'Yere 
blinded to the randomisation that was carried out by a computer-generated code in the 
hospital pharmacy. The randomisation code was broken only after all the participants 
had completed their final assessments. 
Table 5.9.1. Clinicians Global Impression (CGn : 7 point scale 
Compared to the patient's condition at the end of the RANDOMISATION VISIT, 
how much has the patient changed: 
o Very much improved 
o Muchimproved 
o Minimally improved 
o No change 
o Minimally worse 
o Much worse 
o Very much worse 
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Table 5.9.2: Participating subjects in the DCA trial :all patients fulfilled modified 
CDC criteria for the diagnosis ofCFS (M=male, F= female) 
Patient Number Sex Age (years) 
1 M 59 
2 F 44 
3 F 42 
4 M 26 
5 F 62 
6 M 46 
7 F 47 
8 M 36 
9 F 35 
10 F 49 
11 F 52 
12 M 27 
13 F 32 
14 M 66 
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Results 
14 CFS patients participated in this trial (Table 5.9.2). At baseline, there was no 
difference between the two arms in terms of the level of physical activity and the 
duration of CFS symptoms. Testing of the right quadriceps muscle group was 
undertaken using a KinCom dynamometer (Chatteex Corporation, Chattanooga Group 
Inc. Huxon, Tennesse, USA). Because randomisation was based on the order of entry 
of patients into the study and the assessors were blind to the nature of randomisation, 
the two groups were not matched for sex. Six of the 7 CFS patients in the DCA arm 
were male; all patients in the placebo arm were female. 
The CGI scores remained "unchanged" for all the participants in the study who were 
able to complete the treatment trial and all the assessments. One patient in the DCA 
group could not complete the duration of treatment fo~ 14 days as he felt generally 
unwell and was allowed to withdraw. Two other patients in this group had mild 
gastrointes~inal symptoms (nausea) but were able to complete the protocol. None of 
the patients in the placebo arm had any adverse symptom attributed to", the 
intervention. Three patients, one in the DCA and two in the placebo arm, did not 
reach quadriceps muscle fatiguability on the recommended exercise protocol of the 
experiment. Their exercise data were not included in the analysis. Therefore, the 
clinical data of this experiment were available from 13 patients whereas completed 
exercise data on quadriceps muscle fatiguiability were available in 5 patients from 
each of the DCA and placebo arm for the trial (Table 5.9.2). The two groups did not 
- match for sex but were of similar age and weight. 
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Table 5.9.3: Randomisation data of the participants 
DCA 25/mglkg daily x 14 days (n=7) Placebo x 14 days (n =7) 
Sex Age Weight (kg) Sex Age Weight (kg) 
Ma 59 64 F 44 68 
M 26 52 F 42 50 
M 46 82 FO 62 81 
M 36 76 F 47 56 
M 35 65 F 49 59 
Mb 66 92 Fb 52 70 
F 27 66 F 32 51 
a = withdrew because of feeling generally unwell in week 1 
b = excercise data were not analysed due to failure to fatigue during the exercise 
period 
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The maximum voluntary contractions (MVC) of the right quadriceps muscle were 
more powerful in the treatment arm at baseline and after washout, as would be 
expected in view of the fact that all males have a larger muscle bulk and therefore 
were able to generate greater force. However, the rate of decline of force during 
repetitive contractions (fatigue) and the pattern of recovery after exercise were similar 
between these two groups. After adjustment for the gender effect on the initial MVCs, 
no difference was noted in the two groups with respect to the patterns of muscle 
fatigue and recovery at 14 days and following ten-week washout period. The MVC 
data of the partcipants who had completed the exercise protocol are shown in Table 
5.9.3. 
Unpaired t tests were used to compare the mean force (in Newtons) generated by the 
quadriceps MVC in the two treatment groups after 14 days of therapy. A difference 
in the p value of> 0.05 was interpreted as non-significant. Despite a higher baseline 
quadriceps MVC in the male-dominated DCA arm, there was no statistical difference 
between t~e two groups after 14 days of treatment in terms of the force generated 
either during repetitive contractions or after 24 hours (during recovery). This,.. was 
certainly against any therapeutic effect of DCA in CFS. Indeed, the mean force 
generated during repetitive contraction of the right quadriceps muscle was statistically 
lowered in the treatment group after 14 days of DCA therapy as compared to the 
baseline value (paired t test, p= 0.01). However, this difference might not be real as 
the muscle foce during the recovery period (after 24 hours) in the treatment arm was 
similar to the baseline value. -
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Table 5.9.3 MVC data ofthe participants (mean force in Newtons ± S.E.M.) 
Assessment point DCA group Placebo group 
- (n =5, 4 M, 1 F) (n=5, 5F, 0 M) 
Before treatment: 
repetitive contractions 544.4 (±86.9) N 361.0 (±58.7) N 
recovery period 337.3 (±25.3) N 256.5 (±22.5) N 
After 14 days treatment 
repetitive contractions 434.4 (±89. 3) N 301.6 ( ±51.4) N 
recovery period 406.2 (±52.0) N 239.5 (± 19.0) N 
After washout period 
repetitive contractions 449.0 (± 77.0) N 277.2 (±42.8) N 
recovery period 322.0 (±44.0 ) N 257.9 (±27.6) N 
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Conclusions 
We concluded from this randomised, double blind controlled trial that treatment with 
DCA (25 mg/kg/day) does not improve quadriceps muscle contractility or fatigue in 
CFS. 
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5.10 Subanaerobic threshold exercise test, body composition and resting 
energy expenditure studies in CFS 
Background 
This study was designed primarily to address the issue of heterogeneity in the CFS 
population by developing both reproducible and objective data that may sub-
categorise patients into specific subgroups. Since fatigue following trivial exertion is a 
major symptom in CFS, response to a standardised sub-anaerobic threshold exercise 
test (SATET) [29] was selected as the obj ective tool to stratify the patient population 
at baseline. Additional physiological measures such as resting energy expenditure 
(REE) and body composition studies were applied to further characterise these 
patients. Total body potassium (TBK) measurement was also included because low 
TBK was previously reported in CFS [173]. Regional fat-free soft tissue mass (FFST) 
and body fat mass were measured by dual X-ray energy absorptiometry (DXA), 
offering the possibility of objectively assessing limb muscle wasting. All results from 
CFS patients were compared with normal healthy subjects (controls). 
The study was supported by a Research Grant from the Cunningham Trust, Scotland 
(UK) and was carried out in collaboration with the Department of Nuclear Medicine, 
South Glasgow University Hospitals NHS Trust (Dr. W.S. Watson). The research 
protocol was approved by the local Medical Research Ethics Committee and informed 
consent was obtained from all the participants. 
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Methods 
Case selection: 16 CFS females and 13 CFS males took part in this experiment. All 
CFS patients fulfilled the current CDC criteria and were first assessed clinically to 
exclude other fatiguing disorders. CFS patients who were clinically depressed were 
excluded. The control population consisted of a group of physically active, healthy 
volunteers (15 female controls and 14 male controls). All women subjects (CFS and 
controls) were studied during the non-menstrual phase of their ovarian cycle. Other 
than the replacement hormones and contraceptives, the study subjects were free from 
any medication for 24 hours before their tests. 
Baseline assessments: Patients and control subjects had the following tests: 
haematology (FBC, ESR), blood biochemistry (U&Es, LFTs, TSH), serum C-reactive 
protein (CRP) and urine analysis (including 24 hour collection for electrolytes, 
creatinine and nitrogen). 
Exercise study: A modified sub-anaerobic threshold exerCIse test (SATET) pn a 
bicycle ergometer was offered to the CFS patients and control subjects. In this test 
originally developed by Nashef and Lane [174], the level of exercise was set to 
achieve 90% of the pre-calculated anaerobic threshold as predicted from body weight, 
age and gender. Pulmonary gas exchange, respiratory rate, blood pressure and heart 
rate were continuously monitored for all the exercising subjects. All participating 
subjects had th~ option to withdraw at any stage before completing the test. Blood 
samples were drawn for plasma electrolytes, serum lactate and serum creatine kinase 
(CK) pre- and post-exercise. A short period of warm-up exercise (for 3 minutes) was 
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set for all the participants immediately before the 15 minute SATET in order to 
familiarise them with the equipment. Although the workload was adjusted for the 
body weight, age and gender of each subject, it was recognised that different degrees 
of fitness would result in widely different intra-group maximum end-exercise heart 
rates and end-exercise lactate responses. In order to compensate for differing fitness 
levels, multiple regression of end-exercise lactate against maximum end-exercise 
heart rate (expressed as a percentage of predicted age-adjusted maximum and gender 
(female=O, male =1) was established for the control sUbjects. An end-exercise lactate 
was then considered abnormally high only if it was greater than the upper 95% 
confidence limit predicted for the subject's maximum end-exercise heart rate and 
gender. In other words, only lactate responses that were inappropriately high for the 
subject's gender and heart rate response to exercise were considered abnormal. 
Following the exercise test, participants were asked to score their perceived effort in 
the scale of 1-10 as originally developed by Borg [175]. 
Energy expenditure study: Resting energy expenditure (REE) was measured on two 
consecutive mornings by the indirect calorimetry as previously described [152] l,lsing 
a Sensormedics Vmax 29n (Sensormedics Corporation, USA) or a Deltatrac II 
(Sensormedics Corporation, USA) calorimeter. The following parameters were 
recorded for each subject: Body Mass Index (BMI) (kglm2), body temperature (0 C), 
02 consumption (mllmin) and CO2 production (mllmin). The participants (patients 
and volunteers) fasted overnight before this test. REE was expressed as the 
percentage of the predicted REE derived from the Harris-Benedict equation [176]. All 
REE measurements were made in the fasting state prior to any exercise or 
venepuncture. No smoking was permitted prior to these measurements. 
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Body composition: This was assessed by the following methods: 
Dual Energy X-ray Absorptiometry (DXA) for measuring fat mass and regional fat-
free soft tissue mass (FFST) [177]. In order to reduce the effect of body size, age and 
gender from these results, the specific mass for the control subjects, e.g. fat, lower 
limb FFST was stepwise regressed against height, weight, age and gender. In each 
case, a predictive equation based on weight and gender was obtained. Results were 
then expressed as a percentage of the values predicted from these equations. This was 
done for fat mass, upper limb FFST, lower limb FFST and non-appendicular FFST. 
Intravenous tritiated eHzO) water dilution at 4 hours post-injection was measured for 
total body water (TBW) [178] and intravenous stable bromine dilution at 18 hours 
was measured for extracellular water (ECW) as previously described [177]. 
Total body potassium (TBK) was assessed by whole body counting of the naturally 
occurrin~ radioisotope (4oK) [179]. Intracellular potassium concentration (ICKC) 
measured indirectly as ICKC == TBK/(TBW-ECW) where (TBW-ECW) = ICW, i.e. 
intracellular water which contains over 95% of body potassium. 
TBW, ECW, ICW and TBK were expressed as percentages of predicted values as 
previously described for the body water composition [180] and TBK [181]. In this 
way, differences due to body size, gender and age are eliminated as possibly 
confounding factors. 
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Physical Activity Questionnaire: All patients and control subjects were asked to 
complete a modified Baecke Physical Activity Index for self-assessment of work, 
sport and home leisure activities [182]. 
All the assessments in patients and control subjects were carried out over one and a 
half consecutive working days. During the data analysis, non-parametric statistical 
tests such as Mann-Whitney U test and Kruskal-Wallis ANOV A (with correction for 
mUltiple comparisons by the method of Dunn) were used as appropriate (Unistat v5.0, 
Unistat Ltd, UK). 
Results 
CFS patients and control subjects were first subcategorised on the basis of their 
objective performance in the bicycle ergometer SATET. There were four groups: 
Controls (n=29, 14M, 15F):- All of the control subjects completed the 15 I1).inute 
exercise test and none had a significant end-exercise lactate rise. 
CFS patients Group 1 (9, 4M, SF: 31 %):- CFS patients who completed the 15 minute 
exercise test without any significant end-exercise lactate rise. 
CFS patients Group 2 (7, 4M, 3F: 24%):- CFS patients who completed the 15 minute 
exercise test but had significant end-exercise lactate increase. 
CFS patients Group 3 (13, 5M, SF: 45%):- CFS patients who could not complete the 
15 minute exercise test. 
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The demographic details of these four groups are presented in Table 5.10.1. The 
distributions of the end-exercise plasma lactate levels are shown in Figure 5.10.1. 
Summary of results from the exercise test: 
Perceived exertion (Borg Scale): Results are shown in Figure 5.10.2 where it can be 
seen that CFS patients as a group, had a significantly higher rate of perceived effort as 
compared to the control subjects (p<0.001). There were also significant differences 
between the control group and CFS Groups 1 and 3 ((P<0.01) and p<O.OOl 
respectively), but not between the control group and CFS Group 2. There were no 
statistically significant differences between the three CFS sub-groups. 
Modified Baecke physical activity index: The results are shown in Figure 5.10.3. 
There was a significant decrease in physical activity when controls were compared 
with the total CFS group (p<0.001). As with perceived exertion, there were 
significant differences between the control group and CFS Groups 1 and 3 (p<0.05 
and p<O.~OI respectively), but not between the control group and CFS Group 2. 
There were no significant differences between the CFS sub-groups. 
End exercise serum CK: There was no statistically significant difference between the 
control subjects and the CFS patients in any of the three groups. 
End exercise V02 (% o/predicted V02 at anaerobic threshold): The lactate-producing 
CFS patients (Group 2) had a 20% higher end-exercise V02 compared with controls 
although this failed to reach statistical significance. CFS Group 3, who failed to 
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complete the exercise, had significantly lower end-exercise V02 relative to CFS 
Group 2 (p<0.01; Figure 5.10.4). 
Cardiovascular (heart rate and blood pressure) responses during exercise: 
The heart rate during exercise was expressed as a percentage of the maximum heart 
rate, i.e. 220-age(years). As the data was recorded breath-by-breath, in order to 
examine the heart rate response at fixed time intervals, ie every 15 seconds, the heart 
rate versus time (breath-by-breath data) was interpolated using a curve-fitting utility 
[CurveExpert V1.37 (Hyams, USA)]. When response of heart rate with exercise time 
was inspected for controls, there was a gender difference in the response with control 
females recording a higher heart rate than control males. In order to eliminate this 
gender bias, all results at each time interval were expressed as T -scores defined as 
[Heart rate (%max)-mean Control Heart rate(%max)/ Control Standard Deviation] 
where the control mean and standard deviation results for males and females were 
used as appropriate. Any deviation of heart rate response for the CFS groups with 
time relat~ve to the control group will result in positive T -scores ifthe group heart rate 
response is higher than that of the controls while the T-scores will be negative jf the 
heart rate response is subnormal. 
From the results shown in Figure 5.10.5, it can be seen that the heart rate response for 
Group 1 is consistently lower than that for controls (p<0.01) while the response for 
Group 2 is consistently higher than the control response (p<0.01). The results for 
Group 3 are complicated by the fact that the patients stopped exercising at different 
times during the study. The single most significant finding in Group 3 patients was 
that the heart rate at the start of the exercise (0-30 seconds) was significantly higher 
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than normal. There were no significant differences between the three groups in terms 
of systolic or diastolic blood pressure throughout the exercise period. 
Results from the body composition studies: 
FFST in limbs (DXA study): Only the CFS patients who could not complete the 
exercise (Group 3) had a significant decrease of FFST compared to the controls in 
arms (p<0.04) and legs (p<0.02); no inter-group difference was noted for the non-
appendicular FFST (Figure 5.10.6). In terms of body fat, only Group 3 had 
significantly increased fat relative to the controls (p<0.001) indicative of physical 
underacti vity. 
Total body potassium (% predicted): CFS patients have lower TBK as compared to 
the control subjects. This difference is statistically significant in both Group 2 
(p<0.05) and Group 3 (p<0.04) patients but not in Group 1. However, intracellular 
potassium concentration (TBKlICW) was largely similar among all the three groups 
of CFS patients and the control SUbjects. No significant inter-group differences were 
seen for TBW, ECW or ICW. ~ 
Resting Energy Expenditure (REE): CFS patients in Group 3 have raised REE 
residuals as compared with patients in Group 2 (p<0.03) but not relative to the 
controls or Group 1 patients (Figure 5.10.7). 
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Figure 5. I 0.4: End-exercise V02 as % of predicted anaerobic threshold value in controls and CFS patients 
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Figure 5.10.6: Lower limb fat free soft-tissue mass in controls and CFS patients 
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Table 5.1 0.1: Summary of patients' data 
Measures Controls CFS group 1 CFS group 2 CFS group 3 
n=29(14M115F) n=9 (4M/5F) n=7 (4M/3F) n=13 (5M/8F) 
Median Range Median Range Median Range Median Range 
Age (y) 29 19 - 59 39 29 - 53 42 25 - 47 43 18 - 60 
BMI 23.91 18.76 24.21 18.39 - 26.78 21.01- 24.07 18.40 -
- 37.55 33.11 32.93 
32.35 
Borg Perceived 3 1-4 7 1 - 10 4 3-5 7 4 -10 
Exertion Score (1-
10) 
Baecke Physical 7.9 5.9- 6.6 5.2 - 8.3 7.2 5.2 - 8.9 6.0 4.9- 8.9 
Activity 10.9 
(arb units) 
Workload 63 38 - 86 61 47 -77 72 44 - 80 49 0-96 
(watts) 
End-exercise 1.84 0.54- 1.57 0.54- 4.65 2.86- 1.35 0.74 - 3.41 
lactate (mmoIlL) 0.77 2.72 6.4 
End-exercise 105 63 - 93 77 - 129 115 105 - 86 33 - 123 
V02(% pred AT 140 156 
V02) 
ArmFFST 101 76 - 99 81 - 123 89 79 - 109 88 40 - 121 
(% predicted) 132 
LegFFST 99 88 - 96 80 - 113 95 83 - 98 87 74 - 103 
(% predicted) 120 
Non-appendicular 102 86 - 98 88 - 120 95 86 -103 93 86 - 116 
FFST 111 
(% predicted) 
Body Fat (% . 101 50 - 112 59 - 188 118 105 - 120 90 - 158 
predicted) 163 143 
TBK 101.6 78 - 99 86 -106 88 75 -100 89 66.4 - 102 
(% predicted) 114 
Lymphocyte 1.8 1.15 - 1.76 1.25 - 1.9 1.13- 2.88 1.29 - 3.45 
count 3.15 2.5 2.65 
(l09/L) 
REE(%H&B 95 81 - 93 78 - 99 89 88 - 94 100 88 - 123 
_ predicted value) 112 
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Table 5.10.2 Characterisation of the CFS Groups 
Characteristics - CFS group 1 CFS group 2 CFS group 3 
Percentage 31% 24% 45% 
CFS CDC criteria yes yes Yes 
DSM-IV criteria no no No 
for depression 
Physical activity low low Low 
(Baecke index) 
Exercise (SATET) completed completed did not finish 
End-exercise normal high Normal 
serum lactate 
Perceived effort high normal High 
(Borg score) 
VOz(Llmin) normal high Low 
Heart rate (bpm) normal high high (at rest) 
Limb FFST (DXA) normal normal Reduced 
TBK normal low low 
REE normal normal high 
Possible parasympathetic reduced blood flow sympathetic 
pathophysiology overactivityllimbic to the exercising (norepinephrine) 
-basal ganglia muscles overactivity 
integration failure 





On the basis of their perfonnance in the SATET, CFS patients could be categorised 
into three distinct subgroups (central fatigue, metabolic fatigue and fatigue with 
exercise intolerance). Patients in these three subgroups did not differ significantly in 
the quality of their symptoms, duration of fatigue, physical activity index, quality of 
life and psychological co-morbidity. (Table 5.12.2) A reduced heart rate response to 
exercise was typical of CFS patients with central fatigue (31%) while those with 
presumed metabolic fatigue (24%) produced higher plasma lactate at the end of the 
exercise protocol (SATET). Exercise intolerant CFS patients (45%) were more likely 
to be women with an overactive sympathetic system, increased resting energy 
expenditure and muscle wasting. Autonomic response of CFS patients to symptom-
limited exercise is variable. CFS patients had a higher perceived effort to exercise and 
Group 3 patients were significantly physically deconditioned in the DXA measures. 
The specificity and the sensitivity of the proposed classification of the CDC-dyfined 
CFS cannot be estimated without a prospective study of a larger number of patients. 
However, sub-categorising CFS patients with objective physiologic tests like SATET 
and DXA may be of considerable value to individualise therapeutic interventions and 
plan future research in this complex disorder. 
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5.11 Proton magnetic resonance spectroscopy of basal ganglia in CFS 
Background 
A single study of proton magnetic resonance spectroscopy eH MRS) in CFS had 
shown a reduction of N-acetyl aspartate (NAA) in the right hippocampus [183]. 
Reduction of neuronal NAA has also been reported in the basal ganglia and brainstem 
among symptomatic Gulf-War veterans who experience symptoms of chronic fatigue 
[184]. Because central fatigue is postulated to be due to a failure of the integrative 
striatal function [33], lH MRS study of the basal ganglia was carried out in 8 CFS 
patients and the results were compared to a matched group of healthy controls. The 
objective of the study was to identify possible changes in the basal ganglia 
metabolites in CFS with special reference to the levels ofNAA since a reduced NAA 
is generally considered to be a marker of neuronal loss or injury. The research 
protocol was approved by the local Medical Research Ethics Committee. 
Methods 
Patients and Controls: CFS patients strictly fulfilling the modified Centers for Disease 
Control (CDC) diagnostic criteria [1] were selected for this study. There were 8 
patients (M:F = 1 :7) between the ages of 32 and 54 years (median: 42 years) with a 
duration of CFS symptoms between 2-14 years (median:4.5 years). None of these 
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patients was depressed. Sex and closely age-matched group of 8 healthy volunteers 
between the ages of28 and 59 years (median: 42.5 years) were chosen as controls. 
IH MRS: This was performed on a 1.5T Siemens Magnetom using single voxel MRS. 
Spin-echo (SE) of 1500/135 ms sequence was used and spectra were acquired with 
(256 averages) and without (1 average) water suppression (Dr. B. Condon, 
Department of Neuroradiology, Institute of Neurological Sciences) . The volume of 
interest (VOl) was positioned using three orthogonal TI (SE 500/140) weighted scans. 
It was placed on the left basal ganglia in all the subjects. Its dimensions were 
20X40X20 (sagittal, coronal, axial) mm3• Baseline and phase corrections were applied 
manually to the Fourier transform of the Fourier induction decay and a single 
observer (MRI physicist) defined the peak areas without having the knowledge of the 
participants (patients or controls). Areas of the N-acetyl aspartate (NAA), choline 
containing (Cho) and creatinine-containing (Cr) compounds were calculated under the 
curves. The area of the unsuppressed water peak was also calculated as a reference 
value to. which these metabolite areas could be compared. An independent 
neuroradiologist unaware of the diagnosis of patients or control subjects blindly 
interpreted the results. He visually examined and scored the Cho peaks in comparison 
to the Cr peaks using a simple two point scale, namely Cho>Cr, or Cho< = Cr. 
Results 
IH MRS values of the peak areas for the individual metabolites (absolute values and 
the ratios) for each of the patients and herlhis best-matched control are shown in 
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Table 9. Percentage differences in the peak ratios of CFS patients compared with 
controls are depicted in Table 5.11.1. These results showed a low NAAICho ratio and 
high CholCr ratio consistent with a higher Cho peaks in the CFS patients as compared 
to the healthy subjects matched for age and sex (Figures 5.11.1 and 5.11.2). These 
values were highly significant statistically when compared to the healthy controls 
(p<O.OOl). The blinded radiologist visually scored all volunteers as Cho = Cr but only 
two CFS patients; the other six CFS patients were scored as Cho >Cr, the difference 
between the two groups being significant at p<O.OOl. 
Conclusions 
Our observations clearly confirm an underlying neurobiological process in CFS [185]. 
Although no significant differences were found in the N-acetyl aspartate 
concentration between patients and the controls, a highly significant increase in the 
spectra from choline-containing compounds was seen in the CFS patient group 
(p<O.OO 1). In the absence of regional structural or inflammatory pathology, increased 
basal ganglia choline resonance in CFS is likely to be an indicator of higher cell 
membrane turnover due to gliosis or altered intramembrane signalling. The exquisite 
susceptibility of the basal ganglia to the viral infections and inflammatory processes 




















Table 5.11.1 Unsuppressed water and metabolite peaks in the IH MRS 
(H20 = water, NAA = N-acetyl aspartate, Cho = choline, Cr = creatine, CFS = patient 
with chronic fatigue syndrome, HC = healthy control) 
H2O NAA Cho Cr NAN NAN Cho/ NAN Cr/ Cho/ 
Cr Cho Cr H2O H2O H2O 
501 0.9 0.41 0.45 2.0 2.195 0.911 1.796 0.898 0.818 
436 0.76 0.28 0.34 2.229 2.717 0.821 1.739 0.779 0.639 
417 0.69 0.47 0.29 2.379 1.468 1.621 1.655 0.695 1.127 
396 0.76 0.32 0.33 2.296 2.346 0.979 1.919 0.836 0.818 
554 0.89 0.4 0.37 2.405 2.225 1.081 1.606 0.668 0.722 
614 0.9 0.4 0.44 2.05 2.249 0.911 1.469 0.717 0.653 
442 0.88 0.5 0.37 2.378 1.76 1.351 1.991 0.837 1.131 
466 0.67 0.31 0.36 1.893 2.154 0.879 1.442 0.762 0.669 
358 0.58 0.33 0.3 1.933 1.758 1.1 1.62 0.838 0.921 
438 0.82 0.29 0.4 2.025 2.810 0.720 1.868 0.922 0.664 
488 0.87 0.55 0.45 1.933 1.582 1.222 1.783 0.922 1.127 
266 0.62 0.22 0.3 2.066 2.902 0.712 2.346 1.135 0.808 
'" 
442 0.8 0.43 0.36 2.222 1.860 1.194 1.809 0.814 0.973 
384 0.66 0.27 0.38 1.741 2.464 0.711 1.469 0.717 0.695 
499 0.66 0.31 0.28 2.357 2.129 1.107 1.323 0.561 0.621 
351 0.67 0.25 0.34 1.988 2.720 0.731 1.915 0.963 0.704 
Table 5.11.2 : Percentage difference in the peak ratios of CFS group compared to 
HC group (ns = not statistically significant) 
Peak ratios % difference p value 
[NAA]/[Cr] 8.1 ns 
[NAA]/[Cho] -26.5 p<O.OOI 
[Cho]/[Cr] 48.5 p<O.OOI 
[NAA]/[H2O] -5.7 ns 
[Cr]/[H2O] -12.2 ns . 
[Cho ]/[H2O] 31.7 p<O.OI 
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Figure 5.11.1: IHMRS ofleft basal ganglia in a CFS patient 
Figure 5.11.2. IHMRS of left basal ganglia in a healthy control 
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5.12 Pramipexole induced prolactin suppression in CFS 
Background 
Pramipexole is a novel, non-ergo line dopamine agonist with specific affinity for 
dopamine D2 receptors of D3 subfamily. By stimulating the D2 receptors of the 
lactotrophs, dopamine tonically inhibits prolactin release from the anterior pituitary 
and is considered to be the hypothalamic prolactin inhibitory factor (PIF). In animal 
experiments, dopamine has an established role in arousal, self-stimulation and reward 
seeking behaviours [186]. Pharmacological dopamine blockade is frequently 
associated with fatigue, poor concentration and lack of motivation. Fatigue is also 
common in disease states characterised by dopamine deficiency [33]. Few studies 
have directly addressed the sensitivity of dopamine receptors in CFS patients. 
However, when compared to controls, CFS patients show exaggerated prolactin 
, 
response to oral buspirone that principally acts as a serotonin agonist but also has 
weak dopamine antagonist effect. Higher levels of plasma prolactin have been 
reported in patients with post-polio fatigue who experience symptoms of fatigue very 
similar to CFS [131]. 
This study was designed to evaluate the sensitivity of the dopamine D2 receptors in 
CFS by receptor stimulation with pramipexole, a directly acting dopamine agonist. 
Pramipexole-induced prolactin suppression test was used as a novel probe to test the 
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sensitivity of the dopamine D2 receptors. The results in CFS patients were compared 
with a healthy control population. 
Methods 
After overnight fasting, 0.25 mg ofpramipexole (equivalent to 0.18 mg ofMirapexin) 
was taken by mouth by the CFS patients and the control subjects. Female patients 
were matched with control women with respect to their menstrual week in the 
reproductive cycles. Blood samples were drawn by using an indwelling cannula 
inserted at an arm vein immediately prior to the oral administration of pramipexole. 
Blood samples were collected in the lithium heparin tubes. Samples were drawn at 
baseline (0 minute) and then for every 60 minutes for first 4 hours (at 60 minute, 120 
minute, 180 minute and 240 minute). All the patients and the control subjects were 
rested during the period of the test while kept under observation in the medical ward. 
None .of the patients or control subjects was taking any pro-dopaminergic or 
dopamine-antagonist medications .. 
All blood samples were collected in lithium heparinised tubes. Plasma was separated 
by centrifugation and stored at -70 0 C until biochemical tests were arranged. Thawed 
plasma samples were transported to the Department of Biochemistry, Southern 




The patient group consisted of 9 patients (M=5, F=4) in the age range of 26-56 years; 
the control group consisted of 9 healthy volunteers (M=5, F=4) in the similar age 
group. Baseline plasma prolactin levels showed no significant difference between 
patients and controls. Mean (±S.E.M) plama prolactin was 151.78 (15.49) mUlL in 
patients and 148.89 (22.21) mUlL in controls. In both groups, plasma prolactin fell 
from baseline values at 60 minutes and was maximally suppressed between 60-120 
minutes. The lowest mean (±S.E.M) plasma prolactin in CFS patients was 58.3 (6.99) 
mUlL at 120 minutes and the prolactin level remained suppressed at 180 minutes. In 
the control subjects, lowest mean C±S.E.M) plasma prolactin was 59.89 (9.53) mUlL 
at 180 minutes. No patient reported any adverse symptom during the test. The 
statistical analysis of the results and the graphs are shown in Tables 5.12.1-5.12.4 and 
Figures 5.12.a and S.12.b. 
Conclusions 
The results of this preliminary study of pramipexole-induced prolactin suppression 
indicate that as a group, CFS patients do not significantly differ from the healthy 
controls in their sensitivity to dopaminergic (D2) receptor stimulation as compared to 
the healthy controls. 
/-
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Table 5.12.1: ANOVA -Single Factor Analysis to test equality of mean values of 
CFS and control subjects at 0 minutes in pramipexole-induced prolactin suppression 
study. 
lAnova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance SEM 
CFS, 0 min 9 1366.0 151.78 2158.44 15.49 
Controls, 0 min 9 1340.0 148.89 4441.36 22.21 
ANOVA 
Source of Variation SS df MS F P-value Fcrit 
Between Groups 37.556 1 37.556 0.011 0.916 4.494 
~ithin Groups 52798.444 16 3299.903 
Total 52836 17 
The differences among means are not significant at 0 minutes, p=O.916. 
/-
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Table 5.12.2: ANOVA -Single Factor Analysis to test equality of mean values of 
CFS and control subjects at 60 minutes in pramipexole-induced prolactin suppression 
study. 
iAnova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance SEM 
CFS, 60 min 9 849 94.33 812.75 9.50 
Controls, 60 min 9 807 89.67 2330.50 16.09 
ANOVA 
Source of Variation SS df MS F P-value Fcrit 
Between Groups 98 1 98.000 0.062 0.806 4.494 
~ithin Groups 25146 16 1571.625 
Total 25244 17 
The differences among means are not significant at 60 minutes, p=0.806. 
Table 5.12.3: ANOV A -Single Factor Analysis to test equality of mean values of 
CFS and control subjects at 120 minutes in pramipexole-induced prolactin 
suppression study. 
[Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance SEM 
CFS, 120 min 9 525.00 58.33 439.50 6.99 
tontrols, 120 min 9 567.00 63.00 1243.00 11.75 
ANOVA 
Source 0/ Variation SS dj MS F P-value Fcrit 
Between Groups 98 1 98.000 0.116 0.737 4.494 
10{ithin Groups 13460 16 841.250 
Total 13558 17 
The differences among means are not significant at 120 minutes, p=0.737. 
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Table 5.12.4: ANOVA -Single Factor Analysis to test equality of mean values of 
CFS and control subjects at 180 minutes in pramipexole-induced prolactin 
suppression study. 
1AP:0va: Single Factor 
SUMMARY 
Groups Count Sum Average Variance SEM 
~FS, 180 min 9 541 60.11 1075.11 10.93 
Controls, 180 min 9 539 59.89 817.61 9.53 
ANOVA 
Source of Variation SS d[ MS F P-value Fcrit 
lBetween Groups 0.222 1 0.222 0.000 0.988 4.494 
~ithin Groups 15141.778 16 946.361 
!fotal 15142 17 








c 100 ~ ,or 
.. 11m CFS (Mean) u 80 ~ - ' . .!!! 






o min 60 min 120 min 180 min 
Time (mins) 
Fig 5.12.1a: Pramipexole induced prolactin suppression in 
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Fig 5.12.1b: Pramipexole induced Prolactin Suppression in 
CFS VS. Controls (Mean only) 
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5.13 A retrospective clinical analysis of pharmacotherapy with 
amantadine + low dose tricyclic antidepressants in CFS 
Background 
Phannacotherapy in CFS is considered to be generally ineffective. Since lethargy and 
lack of concentration is an important problem in CFS patients, non-selective central 
stimulants may have a role in symptomatic management of CFS. Amantadine, an 
indirect dopamine agonist, has been used with modest success to treat fatigue in 
multiple sclerosis [129]. Amitriptyline, a tricyclic antidepressant, is widely used in 
neurological practice for migraine prophylaxis and pain relief. The sedative effect of 
amitriptyline is also useful for disturbed night-time sleep or insomnia. Low doses of 
amitriptyline are widely used for symptomatic relief of pain and sleep disorder in CFS 
[8]. It was speculated that a combination of amantadine and low dose amitriptyline 
might 'be useful in the management of CFS symptoms (fatigue, pain and sleep 
~ 
disorder) that neither drug would achieve on its own and patients were recommended 
this combination therapy on clinical indications during their outpatient consultations. 
It was only considered appropriate that the treatment response of the CFS patients is 




Twenty-one CFS patients (M=10, F=ll) were included in a retrospective analysis of 
amantadine and amitriptyline therapy in CFS patients. Amantadine on its own was 
given to 6 patients (M=2, F=4). Amantadine and amitriptyline was prescribed to 13 
patients; 2 patients (M=l, F=l) were treated with a combination of amantadine and 
another tricyclic antideprssant (venlafaxine). In all cases, amantadine was commenced 
in a once daily dose of 100 mg and amitriptyline was given at bed-time in a single 
dose of 10 mg. The doses were increased to a maximum of 200 mg and 20 mg 
respectively between the third and fourth weeks of the trial period. Dose of 
venlafaxine was 37.5 mg twice daily (unchanged dose). 
Results 
The re~rospective assessment was carried out between 6-8 weeks after the therapy was 
initiated. The principal outcome measure was a self-reported change in the severity of 
fatigue. Patients were asked whether their fatigue symptom had "improved", showed 
"no change" or "worsened". Improvement in fatigue was reported by 3 patients (M=2, 
F=l), one of whom was only on amantadine monotherapy. Fatigue was reported as 
unchanged in 7 patients (M=3, F=4) on a combination of amantadine and 
amitriptyline though one patient reported an improvement in her musculoskeletal 
symptoms. Two patients "were unsure about the outcome, one of whom felt that his 
sleep and painful symptoms were better. Four patients (M=2, F=2) felt that their 
fatigue symptoms had worsened on treatment (one was only on amantadine 
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monotherapy). Two patients did not take the treatment and three other patients 
declined to rate their treatment response. 
Conclusions 
Retrospective analysis of pharmacotherapy amantadine with or without amitriptyline 
(venlafaxine in one case) did not provide sufficient evidence of any short-term 
treatment effect on fatigue in the CDC-defined CFS population. 
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5.14 Buspirone-augmented 123I_IBZM cerebral SPECT scan 
Background 
Buspirone is a serotonin agoinst (5 HT1A) with very weak dopamine D2 antagonist 
property. Previous studies have consistently shown that when compared to normal 
healthy controls or depressed individuals, buspirone-induced release of prolactin is 
exaggerated in CFS patients (both in men and women). The mechanism of 
hyperprolactinemic response to buspirone in CFS is not clear [124,125]. Dopamine is 
the hypothalamic prolactin inhibitory factor and it tonically inhibits prolactin release 
from the anterior pituitary. An exaggerated prolactin response to buspirone may 
indicate a reduced dopaminergic tone in CFS. Since prolactin release is considered to 
be a direct function of the dopamine D2 receptors, it is possible that CFS patients may 
have a reduction in the distribution or density of the dopamine D2 receptors. 
Radioiodine e23I) tagged iodobenzamide e23I-IBZM) cerebral single photon emission 
computed tomography (SPECT) is an established neuroimaging tool for assessing 
dopamine D2 receptor function in the basal ganglia [187]. 123I_IBZM binding to basal 
ganglia is a reliable indicator of free (i.e. unoccupied) and functional postsynaptic 
dopamine D2 receptors. Neuroleptics induce a lower binding of 123I_IBZM to the basal 
ganglia due to its higher affinity for postsynaptic dopamine D2 receptor occupancy 
[188]. Because buspirone stimulation in CFS patients of both sexes produces an 
/-
exaggerated prolactin release response [124], it was considered possible that 
buspirone pre-treatment modifies post-synaptic D2 receptor function in CFS patients 
in a way different from the controls. 
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This experiment was based on the hypothesis that CFS patients are more sensitive to 
the dopamine D2 receptor blocking effect of buspirone and show an exaggerated 
prolactin response as a result. We sought to measure D2 receptor occupancy in CFS 
patients and control subjects of both sexes by 123I_IBZM cerebral SPECT scan after a 
single oral dose of buspirone (45 mg). The study protocol was approved by the local 
Medical Research Ethics Committee and Administration of Radioactive Substances 
Advisory Committee (ARSAC), Oxon, UK. Informed consent was obtained from all 
participants before proceeding with this study. 
Methods 
All patients fulfilled the CDC definition of CFS. For all female participants (patients 
as well as controls) of child- bearing age, urinary pregnancy test was performed and 
the st~dy was not undertaken during the pre-menstrual and menstrual phases of their 
reproductive cycles. Participants were free from all medications known to interfere 
with dopamine receptor sensitivity for at least one week prior to the study. Persons 
with known sensitivities to buspirone, iodine and/or potassium iodide were excluded. 
After a light breakfast, all participating patients and control subjects were given 45 
mg of oral buspirone by mouth in the late morning. A thyroid-blocking dose of 
potassium iodide (120 mg) was also administered by mouth simultaneously to prevent 
any irradiating effect of the radioactive iodine in the tracer e23I-IBZM) on the thyroid 
gland. One hour later, a standard dose of 123I_IBZM (approximate radiation dose of 
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110Mbq) was injected intravenously. Cerebral SPECT imaging was performed with a 
dedicated Phillips head scanner linked to a computer system for image processing and 
analysis. Image acquisition was performed at 60 minutes and 120 minutes after 
intravenous injections of 123I_IBZM according to a standardised protocol [189]. The 
images were analysed in collaboration with Dr. J. Patterson (Department of 
Neuroradiology, Institute of Neurological Sciences). 
Attenuation correction and reconstruction of the images were performed prior to the 
analysis of 123I_IBZM binding. In each case, the ratio of striatal to non-specific 
binding was calculated in the right and left striatum and for anterior as well as 
posterior striatum on each side. Based on the standard region of interest template of 
basal ganglia, binding was also calculated for right and left basal ganglia. Mean 
uptake ratio values were calculated for each of these areas for male CFS patients, 
female CFS patients, healthy male and female controls. Values were compared with 
normal 123I_IBZM uptake ratios (i.e, unaugmented scans) for right and left striatum as 
well as basal ganglia. Finally, mean D2 receptor occupancy due to buspirone was 
calculated as a percentage of the mean uptake ratios in these areas. 
Results 
A total number of 10 CFS patients (M=5, F=5) and 4 healthy controls (M=2, F=2) had 
buspirone-augmented 123t_IBZM cerebral SPECT scans. The mean age of the male 
CFS patients was 47.4 (age range 40-55 years) with duration of CFS symptoms 
ranging between 2-12 years prior to the study. The mean age of the female CFS 
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patients was 46.2 years with duration of CFS symptoms between 3-10 years. The 
average age of the male controls was 36 years (31 and 41 years) and 46.5 years (45 
and 48 years) for the female controls. The mean group ages of the CFS patients and 
control subjects were 46.8 years and 41.3 years. Two CFS patients of both sexes each 
had mild postural hand tremors but no other features suggestive of Parkinsonism. 
The study was originally designed with 8 patients and 8 controls since it was 
estimated that this number of subjects would be required to detect a difference in 
IBZM specific/non-specific ratio of 0.1 uptake units with a statistical power of 80%. 
The experiment was also designed to idsentify any difference between the CFS 
patients and controls during buspirone stimulation, the assumption being that the CFS 
patients and controls (as groups) do not differ in the non-stimulated level of D2-
receptor density. 
Two region-of-interest (ROJ) methods were used to measure uptake in the basal 
ganglia (BG) from the JI23_IBZM SPECT scans in CFS patients and control SUbjects: 
i. a set of regions, representing the caudate (anterior striatum), putamen (posterior 
striatum) and occipital reference regions were derived from a large number of 
normal scans in previously studied subjects. These selected structures represented 
the average shape and size ofthe ROJ. 
ii. a much larger ROJ encompassing all of the uptake in the basal ganglia (caudate, 
putamen, pallidum). The uptake was corrected for the average size of the striatum. 
The advantage of this region is that it allows for changes in shape of the individual 
components of the striatum but includes some IBZM activity from surrounding 
structures (e.g. pallidum) 
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Uptake in each region was expressed as specific uptake/non-specific region. The 
mean uptake of 123I_IBZM as a ratio of total: non-specific uptake between patients and 
controls with or without adjustment for sex is shown in Table 5.14.1. The present 
results show no significant differences between the two groups, for any of the 
calculated values (including BG Right and BG Left). With only 4 controls, a 
significant difference might not have been expected. 
Receptor Occupancy (RO) values were calculated on the assumption that all subjects 
have exactly the same non-stimulated, normal 123I_ffiZM uptake value (1.72) in the 
ROI relative to the non-specific region, i.e., occipital cortex. These were not true RO 
values, which would have required a non-augmented ffiZM scan in each individual 
subject. Rather, this was simply an attempt at estimating "average" occupancy to 
show that buspirone does not have the same levels of D2 receptor occupancy as, for 
example, the neuroleptics. Recalculating the data in terms ofRO (Table 5.14.2) does 
not improve significance (or lack of it) in this experiment. 
Conclusions 
There was no diagnostic pattern of 123I_ffiZM uptake after oral buspirone in CFS 
patients as compared to the control group. 
Table 5.14.1. Buspirone 123mzM SPECT Scans 
BG = Basal Ganglia, AS= Anterior Striatum, PS= Posterior Striatum; 
CFS: Chronic fatigue syndrome; HC: Healthy controls 
Ratio of total: non-specific uptakes 
Subjects Sex Striatum Striatum BG BG AS AS 
Right Left Right Left Right Left 
CFSI M 1.66 1.67 1.82 1.96 1.64 1.62 
CFS2 M 1.60 1.79 1.87 2.13 1.59 1.81 
CFS3 M 1.65 1.57 1.83 1.86 1. 73 1.70 
CFS4 M 1.61 1.56 1.86 1.87 1.51 1.63 
CFS5 M 1.48 1.47 1.74 1.72 1.44 1.46 
CFS6 F 1.67 1.70 1.95 2.06 1.69 1.73 
CFS7 F 1.64 1.64 1.90 1.88 1.56 1.56 
CFS8 F 1.55 1.61 1.76 1.77 1.71 1.60 
CFS9 . F 1.69 1.68 1.93 1.91 1.64 1.74 
CFSI0 F 1.62 1.60 1.90 1.80 1.63 1.69 
HC1 M 1.64 1.72 2.05 2.16 1.66 1.59 
HC2 M 1.58 1.64 1.83 1.88 1.56 1.70 
HC3 F 1.52 1.58 1.84 1.89 1.62 1.51 



















Table 5.14.2: Buspirone 123IBZM SPECT Scans 
BG = Basal Ganglia, AS= Anterior Striatum, PS= Posterior Striatum; 
CFS: Chronic fatigue syndrome; HC: Healthy controls 
Mean Uptake Ratio Values 
Subjects Striatum Striatum BG BG AS AS 
Right Left Right Left Right Left 
Male 1.60 1.61 . 1.82 1.91 1.58 1.64 
CFS 
(n=5) 
Female 1.63 1.64 1.89 1.88 1.65 1.66 
CFS 
(n=5) 
Controls 1.61 1.66 1.96 2.00 1.64 1.64 
(n=4) 
All CFS 1.62 1.63 1.86 1.90 1.61 1.65 
(n=lO) 
Normal 1.72 1.72 1.96 1.96 
rnZM 
Receptor Occupancy (RO)% 
Subjects Striatum Right Striatum Left BG Right 
Male CFS 16.49 14.65 14.07 
(n=5) .. 
Female CFS 12.28 10.50 7.29 
(n=5) 























"If a man will begin with certainties, he shall end in doubts, but if he will be content 
to begin with doubts, he shall end in certainties" 
(Francis Bacon: Of the Proficience of Advancement of Learning Divine and Humane, 
1605) 
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A diagnosis of CFS is essentially made on the clinical grounds and by excluding other 
medical and psychiatric causes of persistent fatigue. The precise aetiology ofCFS and 
the pathogenesis of its symptoms are unknown. There is, as yet, no specific biological 
marker or a diagnostic test in CFS. New onset fatigue and limitation in physical 
endurance are the two most important and defining characteristics of CFS for neither 
of which there is any clear explanation. No specific pharmacological or psychological 
intervention is known to cure CFS and medical management in most cases is 
symptomatic and rehabilitative. Despite these obstacles, there is a growing 
recognition that service provisions are necessary for patients with CFS because of its 
potential morbidity, long- term disability and consequent socio-economic impact [56]. 
Appropriate diagnosis and effective intervention strategies are essential for the 
success of any health care system for patients with CFSIME. In the absence of 
consistent physical signs or disease-specific biological marker, the present case 
definition of CFS [1] essentially selects a heterogeneous group of patients. In the 
review of research literature, this heterogeneity has been considered to be one of the 
explanations for the variability in the research findings on CFS. In addition, patient 
heterogeneity reduces the cost-effectiveness of any intervention that may be useful for 
a subgroup of CFS patients but not for all. However, a fundamental issue regarding 
CFS is its recognition and understanding as a clinical condition. Many physicians and 
psychiatrists still do not believe CFS to be a distinct clinical disorder [3]. Psychiatry 
based research has proposed that idiopathic chronic fatigue is not be a "physical" 
disorder and is more likely to be a symptom of somatisation due to chronic anxiety or 
depression [4]. In the psychiatric explanation, chronic fatigue and its associated 
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symptoms are considered to be a functional somatic syndrome developing in response 
to non-specific stressors (illness behaviour), interpersonal conflicts, depression or 
anxiety [3]. Traditionally, psychiatric diseases have been characterised by complex 
symptoms in the absence of a diagnostic marker and the lack of a specific or sensitive 
test for CFS has been held against an organic, biomedical model of this disorder. 
Given that fatigue is a ubiquitous symptom, it therefore become necessary to develop 
a biological concept of fatigue before making any attempt to rationalise the symptoms 
of fatigue in CFS patients. 
Concept of fatigue 
Fatigue is not only common but in many cases, also an entirely subjective symptom 
that is part of normal day-to-day life. As an isolated symptom, fatigue is usually 
transient and self-limiting. It is only when fatigue is also associated with other illness 
symptoms then it draws attention to itsel£ Fatigue is reported by patients with 
infecti<:ms, nutritional deficiency, autoimmune diseases, cancer, anxiety, depression, 
diseases of heart, liver, respiratory and endocrine systems and as a side-effect of a 
wide variety of medications. In addition, persistent, relapsing or fluctuating fatigue is 
common in many neurological diseases like multiple sclerosis or central 
dysautonomia (multiple system atrophy). 
There is no exact definition of fatigue because of the overlap between the lay 
perception of tiredness -and the clinically significant symptom of fatigue. For 
operational purposes, fatigue is best defined as the difficulty in initiating or sustaining 
voluntary activities. A normal sense of fatigue ("physiological fatigue") is 
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experienced after strenuous physical labour as well as after intense mental activity. 
The precise neurological substrate of this physiological fatigue is not known. 
Physiological fatigue may be pleasurable, especially when the activity is linked to a 
reward (for example, winning a race). In normal health, muscle aches and pain after 
exercise are due to a combination of lactic acidosis and minor muscle fibre injury. 
Rest and sleep relieve physiological fatigue. When fatigue occurs within normal limits 
of daily activities in association with other disease symptoms or illnesses, then it is 
considered to be abnormal (pathological fatigue). 
The interplay between the various physiological control systems that regulate work 
output is shown in a schematic diagram (Flow Chart 3). To understand fatigue, it is 
helpful to consider voluntary effort as a controlled variable under the influence of 
mUltiple control systems. Perceived exertion is an important feedback control for the 
level of the applied effort. It has to be remembered that normal physical activity 
depends on the structural and functional integrity of the sensory and motor systems 
[190] .. Sensory signals from the skin, cardiorespiratory systems, muscles and joints as 
well as from the special senses (skin, eyes and ears) provide the afferent input that 
ascend through the spinal cord and brainstem to be relayed to the thalamus before 
reaching the sensory cortex. This information is processed by the association areas in 
the cerebral cortex (cognitive input) for the activation of the primary motor cortex that 
sends signals to the brainstem motor nuclei and the anterior hom cells in the spinal 
cord (efferent pathway). The signal from the lower motor neurons is carried forward 
by the peripheral nerves that proceed through a synaptic relay (neuromuscular 
junction) to excite the muscle fibres. Within the muscle, a series of metabolic events 
then provides the chemical energy for contraction. Any interruption to this complex 
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INTERPLAY OF PHYSIOLOGICAL CONTROL SYSTEMS FOR WORK OUTPUT 
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Flow Chart 3. Interplay of the physiological variables that control work output. In this 
model, work output is a dependent variable of the applied effort that is controlled by 
motivational input (internal and external) and feedback from the motor, sensory and 
cognitive systems that determines the level of the perceived exertion. Additional 
control systems that regulate work output are environmental factors like temperature 
and internal mileu (homeostasis and autonomic function). Fatigue is a failure to 
sustain work output due to a shift in the physiological set point for applied effort. This 
shift may occur in neurological conditions associated with a higher level of perceived 
exertion and/or a reduced level of motivational input for the applied physical effort. 
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chain of events will have the potential to influence the level of applied effort and 
perceived exertion. Using this model, pathological fatigue is best understood as an 
amplified sense ofnonnal (physiological) fatigue and could be induced by changes in 
one or more variables that control the work output and the level of perceived effort. 
Research approach to CFS 
The present research in CFS was aimed at answering questions regarding the function 
of some of the key variables that regulate perceived effort. Experiments were 
designed to test systemic metabolism, internal homeostasis and energy production, 
peripheral motor function at the level of the skeletal muscles, neuroendocrine changes 
and neuroimaging of brain metabolic function in the region of interest. We included 
only those patients who fulfilled the CDC-case definition. Cases with major 
psychiatric problems, history of drug and substance abuse and eating disorders, 
previous psychiatric history and somatofonn disorders were excluded (Box 2). Only 
adult men and non-pregnant women were included. All patients were neurologically 
examined and appropriate screening investigations were reviewed to make ,sure that. 
other medical and neurological disorders were excluded. Where indicated and 
considered necessary, additional investigations were undertaken to exclude other 
diseases. Same cohort of patients was studied in the first two experiments (5.1 and 
5.2) and an identical cohort was used for the experiments on muscle biopsy (5.7 and 
5.8). Other than these, all other experiments in this research were conducted on a 
different population of patients on each occasion. 
Box 2. Case definition of Chronic Fatigue Syndrome used in this research 
Essential requirements: 
• fulfils CDC criteria 
• minimum symptom duration of 6 months 
• substantial functional impairment must be present 
• cognitive or neuropsychiatric symptoms may be present 
• fatigue is the major symptom 
• four other symptoms required in addition to fatigue (Table 1) 
• symptoms must be of new onset 
Essential exclusions: 
Medical: all clinically important diseases 







somatisation (somatoform) disorders 
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The experiments that were designed for the purpose of this research fall into three 
broad groups: 
1. Assessment of the metabolic and humoral factors that may be predisposing to, or 
perpetuating the symptoms of fatigue in CFS. Experiments carried out in this area 
were general metabolic evaluation, genetic screening for haemochromatosis, tests for 
uncommon antibodies, circulating ouabain-like factor, and the cerebrospinal fluid and 
serum levels of endogenous pentapeptide (QYNAD). 
2. Evaluation of the skeletal motor function and peripheral fatigue in CFS. Tests on 
skeletal muscle biopsy (histological studies and measurements of the intramuscular 
concentrations of Na+, K+ and the membrane pump (Na+IK+- ATPase), a 
randomised, double blind, placebo-controlled trial of dichloroacetate and 
subanaerobic threshold exercise tests (SATET) were the chosen experiments in this 
area. 
3. Assessment of central fatigue and the functional role of basal ganglia. Experiments 
that were specifically undertaken in this aspect were neuroendocrine response to a 
novel. dopamine agoinst pramipexole, proton magnetic resonance spectroscopy of 
basal ganglia and buspirone-augmented 123I_IBZM cerebral SPECT scans .. in CFS 
patients. 
Interpretation of research findings: studies on metabolic and humoralfactors 
Overall, results of systemic metabolic screening in CFS patients did not differ from 
the normal control population. In particular, no abnormality was detected in the 
intermediate metabolism of fatty acids, liver functions and urinary profiles of organic 
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acids and amino acids. Serum CK levels were measured in a number of different 
experiments and in all CFS patients, serum CK values have been well within the 
normal reference range. Elevations in serum CK appear to be uncharacteristic of CFS. 
In a patient with exertional fatigue and raised serum CK, a primary muscle disease is 
a more likely diagnosis than CFS. 
A possible marker of CFS susceptibility is considered to be Gilbert's syndrome. The 
prevalence of Gilbert's syndrome is estimated to be 6% in population in some studies 
[191]. A significant proportion of patients with Gilbert's syndrome experience fatigue 
symptoms that is very similar to CFS. In this research, we were unable to identify and 
association between hyperbilirubinemia (fasting plasma bilirubin >20 mmoVL) and 
CFS. It therefore seems unlikely that as compared to the general popUlation, the 
frequency of Gilbert's disease is higher among the CFS patients. 
Extended glucose tolerance test (GTT) was essentially normal in CFS. This excluded 
any propensity for diabetes (pre-diabetes) in CFS patients. Fatigue is, of course, a 
recognised symptom in diabetes and this possibility needs to be excluded before a 
diagnosis of CFS is considered. What appeared to be of interest in this experiment is 
that the insulin release in CFS patients continued at a lower value of plasma glucose. 
This is clearly shown in the regression equation that was obtained for CFS patients. In 
addition, compared to the normative data, insulin level was relatively higher (but 
within physiologic range) for the corresponding values of plasma glucose at different 
time points during the ghicose tolerance test. 
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There are a number of possible explanations for this observation. Firstly, the change 
in the slope of the line representing the relationship between plasma insulin and 
glucose in our patients may just be a normal variation due to the difference in the 
popUlation characteristics of patients. Secondly, it may represent differential rates of 
glucose absorption in our patients. Only if these two possibilities are excluded, a third 
explanation is that there is a true change in the pattern of insulin release in CFS. The 
regression equation for plasma insulin and glucose in patients clearly draws attention 
to the fact that for any given range of plasma glucose, the corresponding insulin levels 
are higher, but not inappropriately high enough to cause hyperinsulinemic 
hypo glycaemia in CFS patients. This is suggestive of a "peripheral overutilisation" of 
glucose [192]. Fasting hypoglycaemia due to peripheral overutililisation of glucose 
may occur due to a number of conditions. These are usually metabolic diseases 
(systemic carnitine deficiency, deficiency in enzymes of fat oxidation, 3-hydroxy-3-
methylglutaryl CoA lyase deficiency) where insulin levels are "normal", or conditions 
where insulin levels are inappropriately increased (insulinoma, exogenous insulin, 
sepsis. and certain drugs like quinine). However, none of our patients had fasting 
hypoglycemia, carnitine deficiency or defective fat oxidation (Experiment 5.1), 
evidence of infection or history of treatment with hypoglycemic agents. One of the 
mechanisms for higher levels of plasma insulin in the absence of fasting 
hypoglycemia or hyperinsulinemic hypoglycemia is "insulin leak" from the pancreatic 
beta cells. This phenomenon was first observed with pentamidine, a drug that induces 
beta cell cytolysis [192]. It is, however, not known if "insulin leak" may occur due to 
less severe beta cell membrane injury although it is recognised that certain viral 
infections can cause beta cell inflammation ("insulinitis") leading to the development 
of autoimmune diabetes mellitus (type 1). Viruses, particularly Coxsackie B virus has 
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been associated both with the development type 1 diabetes mellitus [193] and CFS 
[194]. 
Studies on genetic susceptibility 
Like most other multifactorial and acquired diseases, genetic susceptibility will playa 
role in the selection of individuals developing CFS after an appropriate environmental 
trigger. Previous studies have consistently failed to show any specific pattern of HLA 
haplotype in CFS patients other than an association with HLA DR2 in patients with 
hypersomnolence [60]. Since haemochromatosis shares many features of CFS 
including fatigue, myalgia, arthralgia, endocrine dysfunction and cardiac abnormality 
(cardiomyopathy), a possible association of familial haemochromatosis gene (HFE) 
was explored in CFS patients. The carrier frequency of HFE gene was not increased 
in the CFS population and therefore it seems unlikely that the HFE gene is a risk 
factor for the development of CFS in the Scottish population. 
Screening for atypical autoantibodies 
Because fatigue is common in systemic autoimmune inflammatory disorders, immune 
based research has been one of the major research interests in CFS. CFS typically 
follows local or systemic infections and a number of pathogens, viruses as well as 
bacterial, have been implicated in the autoimmune diseases. For example, beta-
haemolytic streptococci have been implicated in rheumatic fever and both 
cytomegalovirus and Coxsackie B4 virus have been associated with autoimmune 
(type 1) diabetes mellitus. Coeliac disease is associated with fatigue and focal 
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neurological symptoms and cryptic gluten sensitivity has been postulated to playa 
role in neurological illnesses. Many CFS patients have bowel symptoms (abdominal 
pain, diarrhoea) usually attributed to irritable bowel and a proportion of CFS patients 
may have low levels of serum ferritin (Experiment 5.6) and! serum folate [195]. 
However, our study failed to show any significant association of cryptic coeliac 
disease with CFS. None of the tested patients were hypo-gammaglobulinemic and it is 
unlikely that an undetected deficiency of IgA was responsible for the negative results 
in the anti-IgA endomysial antibody tests. The implication of this observation is that 
the findings of positive anti-gliadin and anti-IgA antibody in a patient with chronic 
fatigue and symptoms of irritable bowel are more likely to be due to coeliac disease 
rather than due to CFS. 
Approximately 9% of CFS patients in this study were found to be positive for voltage 
gated potassium channel (VGKC) and 12.5% had positive antibody to G-protein 
coupled adrenergic receptors. Anti-VGKCs are considered to be good candidates as 
pathogenic antibodies. This is because VGKCs are located in the plasma membranes 
and are key determinants of neuronal excitability [196]. Point mutations in the human 
VGKC Kv1.1 gene can cause episodic ataxia, myokymia and epilepsy [197]. The 
radioimmunassay used for quantitating serum VGKC binds to Kv1.1, 1.2 and 1.6 
subunits that are expressed neuronally in the cerebral cortex [198]. However, anti-
VGKC antibodies are present in varying proportions throughout the brain and the 
peripheral nervous system [199]. These antibodies are positive in patients with 
peripherally restricted - neuromuscular disorder (neuromyotonia), cases with 
autoimmune limbic encephalitis affecting brain and are also found to be positive in 
Morvan's syndrome and are thought to be pathogenic. Morvan's syndrome is 
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characterised by a combination of central and peripheral neurological symptoms. 
Morvan first described this syndrome in 1890 [200] comprising of benign muscle 
fasciculations (myokymia), muscle pain, excessive sweat, saliva, tears and bronchial 
secretion in association with sleep disorder (insomnia) and neuropsychiatric 
symptoms (hallucinations and altered behaviour). The neuromuscular feature of 
Morvan's syndrome ("chorea fibrilla ire") is considered to be an example of 
continuous muscle fibre activity (neuromyotonia) and the central symptoms share 
similarities with limbic encephalitis. Anti-VGKC antibodies are pathogenic of 
Morvan's syndrome [201]. None of the CFS patients, including the antibody positive 
cases, had clinical features of neuromyotonia, Morvan's syndrome or limbic 
encephalitis. 
In the context of CFS, transient and low levels of positive autoantibody to VGKC 
make it less likely that a primary autoimmune process targeted to the plasma 
membrane potassium channels is a specific pathogenic mechanism. In general, serum 
antibodies are of relatively large molecular weight and are thought not to penetrate 
blood brain barrier. An explanation for the observation that anti-VGKC antibodies 
have low positivity in CFS is that the potassium channel subunits in the brain and/or 
peripheral nervous system have been exposed for immunological sensitisation due to 
plasma cell membrane injury. A history of infection is often present in anti-VGKC 
antibody associated autoimmune limbic encephalitis (Prof. A. Vincent, personal 
communication). It may be a possibility that plasma membrane injury from infection 
exposes a limited number· of voltage gated potassium channels for immune 
sensitisation at the early phase of the illness in CFS and these antibodies rapidly 
disappear because the sensitisation is neither specific nor sustained. 
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Like the voltage gated potassium channels, G-protein coupled cardiovascular 
receptors are also expressed at the plasma membranes. Antibodies to G-protein 
coupled adrenergic and muscarinic receptors have been observed in dilated 
cardiomyopathy [161]. None of our patients with CFS had clinical features to suggest 
cardiomyopathy. The interpretation of positive autoantibodies in 12.5% of patients in 
CFS would be similar to that of anti-VGKC antibody in that the plasma membrane 
sites of the G-protein coupled cardiovascular receptors may be affected in a 
proportion of CFS patients from cell membrane injury early in the course of the 
illness. 
The lack of significant results in the experiments on serum ouabain-like substance 
(OLS) and cerebrospinal fluid endogenous pentapeptide (QYNAD) excludes these 
candidates as important players in the pathogenesis of CFS symptoms. 
Interpretation of research findings: neuromuscular studies 
In the second group of experiments, studies on muscle histology, histochemistry and 
electron microscopy did not reveal any new information. Fibre atrophy of muscles 
with increase in lipid may indicate physical deconditioning (replacement of muscle 
fibre by lipids) and was observed in nearly half of all the patients tested for muscle 
biopsy (53.9%; 7/13). it has to be noted however that the histological changes of 
deconditioning did not correlate with the duration of CFS symptoms, being equally 
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present in patients both with the shortest (1 year) and the longest duration of illness 
(14 years). 
The experiment on muscle electrolytes and ATPase was considered in view of a 
previous study that had shown increases in the calcium ATPase activity in skeletal 
muscles of CFS patients [202]. Intramuscular sodium, potassium, magnesium and 
Na+IK+-ATPase concentrations were not significantly altered in the quadriceps 
muscle of CFS patients. These observations reinforce the view that muscle pathology 
is not a primary or essential feature of CFS. Failure of CFS patients to respond to a 
trial of dichloroacetate is, therefore, not entirely unexpected given the fact that neither 
biochemical nor histological features of mitochondrial myopathy were observed in 
other CFS patients. 
Muscle tissue electrolyte concentration is considered to be more sensitive than plasma 
electrolyte changes. Typically, chronic use of diuretics depletes intramuscular 
potassium in spite of potassium supplementation. The close correlation between 
muscle magnesium and potassium concentrations in patients on long-term- diuretic 
therapy indicates that potassium deficiency was also related to or caused by 
magnesium deficiency. In addition, these patients have a reduction in Na+1K +-
ATPase activity due to the loss of intramuscular potassium [170]. In CFS patients, 
however, normal distributions of intramuscular sodium, potassium and Na+1K +-
ATPases exclude primary sarcolemmal membrane injury in CFS. Because tissue 
electrolytes are more sensitive than serum electrolytes in chronic disorders [170], 
normal results in this experiment reliably exclude other metabolic muscle diseases 
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associated with chronic dysregulation of plasma and tissue electrolytes due to the 
deficiency of glucocorticoid or mineralocorticoid hormones. 
Subanaerobic threshold exercise test and resting energy expenditure 
The purpose of the sunanaerobic threshold exercise test (SATET) was to define more 
homogenous subgroups of CFS population and also to identify, if possible, any 
underlying pathophysiological processes specific to the identified subgroups. CFS 
Patients selected for this study were sub-categorised on the basis of SATET because it 
is objective, provides a reliable measure of the physical endurance in unselected CFS 
patients and has been validated in other studies. The resting energy expenditure (REE) 
study was an extension of the previous study where we had found some evidence of 
elevated REE in a proportion of female patients (5 out of 12) with CFS [152] who 
also had reduced total body potassium (TBK). Since muscle is the richest source of 
potassium which is predominantly intracellular, it was unclear whether the reduced 
TBK. (and REE corrected for TBK) could have been caused by physical 
deconditioning and reduced muscle mass. Body composition studies provid@ indirect 
measures of physical deconditioning and have not been previously studied in the CFS 
population in any detail. 
Objectively, the first CFS subgroup (Group 1) differed from the control subjects in the 
level of perceived exertion, consistently lower heart rate response to submaximal 
exercise and the level of physical activity. These patients did not show any obvious 
changes in their muscle metabolism in response to exercise, had normal REE and 
were not physically deconditioned. It is likely that the origin of fatigue in this group 
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of patients is in the central nervous system (central fatigue subgroup). A number of 
possible changes in the central nervous system have already been identified in CFS 
patients. These include impaired regional cerebral -blood flow in the SPECT studies, 
reduced excitability of the motor cortex and altered neuroendocrine responses. It is 
important to emphasise that none of these patients was depressed or had any other 
underlying neurological disease associated with chronic fatigue either at the time of 
their assessment or during their follow up. In the absence of prior ethical approval, no 
additional neuroimaging (anatomic or functional) was undertaken in this group that 
might have been helpful. It is noteworthy that patients in this group had a slightly 
lower heart rate response during the exercise despite being physically less active than 
the controls. A reduced heart rate response to an exercise that was perceived to be 
demanding by these patients excludes physical deconditioning as the cause of exercise 
intolerance because deconditioned subjects characteristically show a higher heart rate 
response to unaccustomed exercise. These patients clearly had a central-type fatigue 
and we postulate a possible overactivity of the parasympathetic system (i.e. 
cholinergic) to account for their reduced heart rate response during the exercise. 
Cholinergic supersensitivity is known to occur in some CFS patients [66, 203] and in 
theory, central fatigue is attributed to a failure of the autonomic and limbic integration 
of the volitional activities at the level of the basal ganglia [33]. Unlike 
antidepressants, interpersonal psychotherapy in depression has been shown to be 
effective in reversing limbic hypometabolism [204]. This may explain why some CFS 
patients benefit from cognitive behaviour therapy when administered by the trained 
therapists. 
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The results obtained in Group 2 suggested that metabolic dysfunction of the 
exercising muscles is a possible explanation for the elevated lactate response and 
consequent changes in the end-exercise heart rate observed in these patients 
(metabolic fatigue). None of these patients had any family history of muscle disease 
and did not have the common symptoms of metabolic myopathy (e.g. exercise 
cramps, myoglobinuria). Their core symptoms (muscle pain and fatigue unrelieved by 
rest or sleep) were no different from other CFS patients (Groups 1 and 3). In the 
absence of prior ethical· approval, we were unable to perform muscle biopsies in all 
these patients as a part of this study which might have been useful to detect metabolic 
muscle diseases like unsuspected mitochondrial myopathy. Clearly, an identifiable 
cause of metabolic myopathy would exclude these patients from the diagnosis of 
CDC-defined CFS. This subgroup of CFS patients did not experience significantly 
higher perceived fatigue than the physically active and healthy control population. 
The relatively higher lactate response in this subgroup is consistent with the previous 
observations by Lane and others. [29] Lane's recent data from the magnetic resonance 
spectroscopy of muscles also confirm that CFS is a heterogeneous disorder and CFS 
patients who produce abnormal lactate response to exercise (SATET +ve) is likely to 
have a peripheral component to their fatigue [205]. In metabolic disorders like 
Addison's disease, muscle fatigue is associated with both decreased endurance (a 
central effect) and altered muscle contractile function [206]. However, end-exercise 
serum lactate increase is fairly non-specific as a marker of metabolic muscle enzyme 
defect and similar changes may be observed if oxygen delivery to the exercising 
muscles is impaired due to the abnormal autonomic control of blood flow reported in 
CFS [207]. Elevated resting blood lactate levels may provide indirect evidence of a 
mitochondrial defect [208], but this was not present in any of these patients. Increased 
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levels of lactate after exercise may indicate poor tissue perfusion and both exercise 
and previous diet can result in elevated levels of lactate in nonnal subjects [209]. 
The results of our patients in Group 3 (fatigue with exercise intolerance) were more 
difficult to explain. These patients were the most severely affected and could not 
complete a customised, moderate intensity exercise for 15 minutes (SATET). Relative 
changes in the proportion of their lower limb muscle mass and fat are suggestive of 
significant physical inactivity imposed by more severe fatigue in these patients. There 
were more women were in this group as compared to the other two groups. Given the 
fact that CFS is commoner in women than in men, it is possible that this subgroup 
constitutes a substantial proportion of CFS cases. Since the level of physical activity 
(as measured by the Baecke index) in this subgroup was comparable to the CFS 
patients in the other two subgroups and yet only these patients were exercise 
intolerant and had significant evidence of decreased limb muscle mass in DXA, it is 
more likely that in these patients, exercise intolerance was the cause, rather than the 
effect, of physical deconditioning. 
There may be several possible explanations for the characteristics of Group 3 patients. 
Firstly, some of these patients maya pro-inflammatory disorder as would be expected, 
for example, in patients with rheumatoid arthritis. Cytokines are known to induce 
fatigue, increase REE and initiate catabolism of muscle proteins [210]. This pattern 
would also be consistent with the known effects of a hypoactive hypothalamic-
pituitary-adrenal axis in CFS leading to relative tissue hypocortisolemia and raised 
levels of pro-inflammatory cytokines [119]. The second possibility is that the exercise 
intolerant CFS patients (more likely to be women) suffer from orthostatic intolerance 
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and postural tachycardia due to an exaggerated noradrenergic response [211J. This is 
supported by their haemodynamic responses during the attempted exercise (Figure 
5.10.5). Patients in this subgroup had postural tachycardia, lowest physical activity 
index and raised REB. Sympathetic nervous system also plays an important part in 
regulating metabolic rate and norepinephrine increases REB due to its effect on the 
non-muscular tissues [212]. The highest rates of REB, lowest physical activity index 
and a higher resting heart rate before commencing the exercise and the similarity with 
POTS may suggest that CFS Group 3 patients could have had sympathetic 
overactivity as a result of acquired changes in the autonomic function. Another 
explanation is that the patients in this subgroup experienced unpleasant sensations 
(e.g. pain) while exercising from very early on and that the central nociceptive input 
might have limited their exercise tolerance. This mechanism has been proposed in 
women with muscle and soft tissue pain due to fibromyalgia where a reduced central 
threshold for nociceptive stimuli is considered to playa role [213]. Varicella-zoster 
virus infection has been implicated in CFS and it may be of interest that in a recent in 
vitro. model, infection with VZV was shown to confer increased norepinephrine 
sensitivity to the sensory neurons of the rat dorsal root ganglia [214J. Beta~blockers 
with or without drugs that modulate central pain perception (e.g. carbamazepine and 
low doses of tricyclic antidepressants) may be useful in improving orthostatic 
function and exercise tolerance in Group 3 patients who appear to be at a high risk of 
progressive physical deconditioning and disability. 
Analysis of results of this experiment (5.10) identifies three subgroups within the 
CDC-defined CFS popUlation. The relative distribution of patients in the three CFS 
subgroups (31 %,24% and 45% in Groups 1,2 and 3 respectively) might have differed 
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if a larger CFS population was studied. It is important to emphasise that the fatigue 
symptoms and the limitation in physical activities as measured by the Baecke physical 
activity index were very similar among patients in the three subgroups. In addition, 
there was no difference in the DXA measures relating to physical deconditioning 
(limb FFST) for Groups 1 and 2 patients. Patients who were unable to complete the 
SATET (Group 3) had some evidence of reduced muscle mass in their limbs when 
compared to the physically active control subjects. The three subgroups did not differ 
in their age, duration of CFS, range of physical symptoms, sUbjective severity of 
fatigue, range of self-reported cognitive impairment and psychological co-morbidity. 
Proven or presumed viral infection was the single common precipitant of CFS in 
patients across all subgroups. Dysregulation of the sympathetic autonomic nervous 
system as the likely explanation of the observed changes in Group 3 patients is 
consistent with the established view that sympathetic activity stimulates nociceptors 
even if they are not obviously damaged and that under some circumstances, 
sympathetic nervous system plays an active role in inflammation [215]. Interestingly, 
"vegetative neuritis" was earlier proposed to emphasise the frequent affection of the 
autonomic nervous system in CFS (cited by Holt, 1965 [53]) 
Neuroendocrine response: Dopaminergic function 
Dopaminergic system has been implicated in migraine, post-polio fatigue and CFS 
where central fatigue is common [33]. Growth hormone release from anterior pituitary 
is stimulated by dopamil1e. Bromocriptine is a dopamine agoinst with affinity for both 
dopamine DJ and D2 receptors. A previous study of bromocriptine-stimulated GH-
response in CFS could not differentiate patients from healthy controls [78]. Dopamine 
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is also the hypothalamic PIF and tonically inhibits prolactin release by the lactotrophs 
in anterior pituitary. Plasma prolactin response to pharmacologic probes has been 
traditionally accepted as a reliable and direct measure of dopamine D2 receptor 
function in the brain. Pramipexole is a synthetic dopamine agoinst with special 
affinity for D2 family of dopamine receptors. Pramipexole-induced suppression of 
prolactin response may be considered to be an indirect way to assess the sensitivity of 
the central dopamine D2 receptor system. This formed the basis of the study where we 
evaluated neuroendocrine response (inhibition of prolactin release) to pramipexole in 
CFS patients and compared the results with normal healthy controls. 
Like the bromocriptine-induced GH response [78], no significant statistical difference 
emerged from this study between the two groups (CFS and controls). There was no 
evidence for a reduced tone of pituitary dopaminergic D2 receptors in CFS. However, 
even in Parkinson's disease, hypothalamic dopamine sensitivity to GH and prolactin 
is normal when patients are challenged by apomorphine, a dopamine agonist [216]. 
This may indicate that neuroendocrine response to dopamine agonists may not be a 
sensitive test to identify patients who may have a more selective loss of dopaminergic 
function outside the pituitary-hypothalamic axis. Determination of GH response to 
dopaminergic stimulation with pramipexole may also have been useful. 
Buspirone-augmented 123I_IBZM cerebral SPECT scan 
123I_IBZM cerebral SPECT scan is widely used for nigrostriatal dopaminergic system 
and offers a reliable measure of post-synaptic D2 receptor function particularly in the 
striatum and generally, in the basal ganglia. A reduction in the normal striatal uptake 
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of the radiotracer e23I-IBZM) is characteristically associated with a reduction of 
functional post-synaptic D2 receptors due to neurodegeneration or receptor occupation 
by dopamine blocking drugs. In the absence of drug-induced dopamine receptor 
blockade, reduced striatal uptake of 123I_IBZM in the cerebral SPECT scan is 
associated with neurodegenerative disorders affecting basal ganglia, which CFS is 
not. It is rather unlikely that a significant loss of post-synaptic D2 receptors will occur 
without clinical symptoms in CFS. In addition, findings of an abnormal 123I_IBZM 
cerebral SPECT scan in a patient with chronic fatigue will probably suggest a 
fatiguing Parkinsonian disorder rather than CFS. 
It was, however, considered possible that the functional characteristics of post-
synaptic dopamine D2 receptors may be sufficiently altered in CFS to alter receptor 
sensitivity and affinity to certain neuroendocrine probes but without causing obvious 
clinical signs of basal ganglia disease. A weak dopamine receptor antagonist will be 
expected to produce longer receptor occupancy in a situation like this. Buspirone is a 
5HT 1A. agoinst but also has a weak dopamine antagonist property [217]. In contrast to 
patients with depression, CFS patients of both sexes show an exaggerated release of 
prolactin in response to buspirone and prolactin release is considered to be a reliable 
marker ofD2 receptor occupation [111]. 
Buspirone augmented 123I_IBZM cerebral SPECT scans is a novel form of functional 
brain imaging that has not been tested before. Oral buspirone is rapidly absorbed and 
pharmacokinetic studies indicate that peak plasma level of buspirone is reached at 60 
minutes [218]. The traditional dose for oral buspirone in neuroendocrine studies is 60 
mg but we used a single dose of 45 mg (rather than 60 mg) for reasons of safety 
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because it is the recommended maximum daily therapeutic dose of buspirone in 
clinical practice [218]. Because of the instructions from the regulatory authorities for 
research studies using radioactive substance (ARSAC), only patients aged 30 and 
above were included in this neuroimaging protocol. On the assumption that peak 
plasma levels of buspirone will be attained at 60 minutes after oral administration, 
intravenous injection of the radiotracer e23I-IBZM) was delayed until this point. 
Image acquisition and analysis were based on a computerised system attached to the 
SPECT scanner and results were compared independently between both sexes of 
patients and control subjects. 
Irrespective of the sex distribution, there was no statistically significant difference in 
the striatal uptake of 123I_IBZM in CFS patients and controls. However, mean uptake 
ratio values were low both in patients than controls when compared to the reference 
ratio for normal 123I_IBZM uptake (i.e. without buspirone pre-treatment). The weak 
D2 blocking effect of buspirone was also confirmed in the calculated dopamine D2 
receptor occupancy of patients and controls. Analysis for the uptake ratios and 
dopamine D2 receptor occupancy in the buspirone augmented 123I_IBZM SPECT 
scans between CFS patients and controls showed a lower mean uptake ratio values in 
control subjects; calculation for statistical significance was not possible because of the 
difference in the number of subjects that could be studied (10 CFS patients and 4 
healthy controls). The calculated percentage of dopamine D2 receptor occupancy in 
the striatum was similar between patients and controls. It is possible that because of 
unequal sizes of the patient and control groups, the results of this experiment failed to 
reach the anticipated level of significance. 
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Proton magnetic resonance spectroscopy of basal ganglia 
Proton magnetic resonance spectroscopy eH MRS) is a relatively new tool for 
imaging metabolic brain functions. Typically, IH MRS measures regional brain 
metabolite levels for N-acetyl aspartate (NAA), choline-containing compounds (Cho) 
and creatine-containing compounds (Cr). While NAA levels broadly correlate with 
the functional neuronal mass, Cr is generally considered to be an unvarying metabolic 
marker of brain function in the IH MRS. In contrast, Cho peak is considered originate 
from the cell membrane lipids. I H MRS of brain tumours shows high peaks of Cho 
reflecting mobile brain lipids due to the tissue degradation and necrosis [219]. 
Choline is acutely elevated in relapsing multiple sclerosis where lipid breakdown 
follows myelin injury [220]. However, elevated Cho is also observed in the areas of 
reactive or repairative gliosis [221] probably as a result of increased membrane 
turnover. Increments in Cho/Cr ratios in the basal ganglia were recently reported in 
patients with mild hepatitis C (but not hepatitis B) virus infection [222] and human 
immunodeficiency virus (HIV) infected patients [223]. Elevations in Cho may occur 
before [NAA] decrements in seropositive HIV patients [223] who experience 
symptoms of chronic fatigue very similar to CFS [2]. 
We chose basal ganglia as the region of interest in our study primarily because of the 
theoretical reasons [33] and also due to the fact that changes in the basal ganglia IH 
MRS were reported in the study of Gulf-War veterans symptomatic of fatigue [184]. 
CFS cases were selected carefully using strict criteria to identify the neurologically 
defined post-viral fatigue patients. Unlike the symptomatic Gulf War veterans [184], 
there was no evidence of significant loss of functional neuronal mass (reflected by 
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reduced levels of NAA and low NAAICr ratio) in the basal ganglia of our CFS 
patients. However, whether referenced to water or other metabolites, the peak: of the 
Cho-containing compounds in the I H MRS were uniformly increased in all CFS 
patients irrespective of their age or the duration of illness. The statistical strength of 
this association was extremely high (p<O.OOI). In the only other IH MRS study of the 
basal ganglia in three CFS children (ages 11, 12 and 13 years), a remarkable elevation 
of CholCr ratio was similarly observed [225]. None of these patients (ours and the 
three paediatric cases) had focal structural abnormalities of the basal ganglia in the 
MRI. In another study in adults, relative increases in the Cho peaks were observed in 
the IH MRS of the occipital cortex of non-psychiatric CFS patients as opposed to 
controls [225]. 
In general, choline peaks in the IH MRS are influenced by specific structural changes 
(tumour and demyelination), certain viral infections (e.g. hepatitis C and HIV), and 
higher rates of cell turnover (as in repairative gliosis). From this study, it appears that 
irrespective of the age of the patient or the duration of the symptoms, choline-
containing compounds are elevated in the basal ganglia of the CFS patients. However, 
CFS patients do not have any MRI evidence of structural changes in the basal ganglia 
nor serological evidence of chronic hepatitis or HIV infection. Although persistent 
Epstein Barr, enteroviral or human herpesvirus infection was proposed from time to 
time as a model for CFS, current opinion does not favour this theory [20]. A 
continuing repairative gliosis is a possibility although the precise stimulus for this 
activity in CFS is unknown at present. Because systemic metabolic studies on lipid 
and peroxisomal functions in CFS patients did not reveal any abnormality 
(Experiment 5.1), it is more likely that the increased choline spectroscopic peaks in 
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two different brain areas reported independently by us [185] and the other workers 
[225] indicate altered neural cell membrane metabolism and function in CFS. 
It has been previously hypothesised that sustained changes in cell membrane function 
may follow exposure to infections and specific neurotoxins leading to the CFS 
symptoms. [143] Ciguatera toxin is probably one of the best examples where delayed 
symptoms of chronic fatigue may be related to the alteration of the membrane ion 
channels (ciguatera toxin irreversibly inactivates sodium channels in an open mode). 
[142] It is also known that the viral membrane glycoprotein and viroporin molecules 
induce changes in the host cell membrane permeability, leading to the activation of 
phospholipases with consequent release of a number of phospholipid moieties 
including choline [226]. A common route of cellular entry shared by many bacteria, 
viruses and parasites involves lipid rich microdomains (caveolae) of the cell 
membrane. A number of microbes or their exotoxins (in the case of extracellular 
infections) co-opt the features of the host cell caveolae probably because their cognate 
receptors are localised within the lipid-rich plasmalemma of host cells [227]. 
Subsequent adaptations of the host cells to these pathogens and toxin could modify . 
cell membrane functions that may persist long after symptomatic recovery in some 
patients. 
Therapeutic interventions in CFS 
Two therapeutic trials w~re part of this research project. The first trial, a prospective, 
randomised double blind use of dichloroacetate (DCA) in CFS was without any 
benefit. There was neither an objective improvement in isometric muscle contraction 
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nor any subjective improvement of fatigue as reported by patients. The second trial 
was an open labelled retrospective observational study. Combination of amantadine 
and amitriptyline in low doses appeared to be of little benefit in terms of self-reported 
improvement of fatigue. The negative results from the prospective DCA trial 
reinforce the view that fatigue in CFS has a mechanism that is distinct from the 
muscle pathology. This is supported by the observations in a recent study of blood 
flow and muscle metabolism in CFS [228]. 
From the results of the SATET, energy expenditure and body composition studies, a 
subgroup of CFS patients (Group 3) was characterised by orthostatic intolerance, 
tachycardia, muscle wasting and raised energy expenditure probably due to an 
overactive sympathetic system.' Beta-blockers may have a potential role in these 
cases. In order to minimise the adverse effects of beta-blockers (fatigue, depression 
and peripheral circulatory compromise), a centrally active beta-blocker with intrinsic 
sympatho-mimetic activity (for example, pindolol) would be a suitable choice. Beta-
blocker may also be a possible treatment for those CFS patients with a supersensitive 
response to clonidine (CFS type 3). 
From the IH-MRS study, increases in the regional brain levels of choline-containing 
compounds suggest that membrane stabilising treatment may have a place in CFS 
pharmacotherapy. Clearly, the composition of the chosen product, bioavailability, side 
effect profile and target therapeutic doses are some of the key considerations for any 
likely pharamacological effect on central fatigue. Additionally, basal ganglia proton 
magnetic resonance spectroscopy has the potential to be used as an objective outcome 
measure in the research studies of therapeutic interventions in CFS. 
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A summary of positive and important negative findings 
Taken together, the research data have a number of implications. It is clear that in 
general, CFS patients do not have a defined disorder of systemic or muscle metabolic 
functions and do not have higher susceptibility to haemochromatosis or Gilbert's 
syndrome. CFS is not an autoimmune disease and we found no evidence for a higher 
prevalence of coeliac disease in the CFS population. A minority of patients may have 
transient, low levels of anti-VGKC antibodies that do not appear to playa pathogenic 
role in this disorder. There is no predisposition to diabetes or hyperinsulinemia 
although pancreatic insulin release appears to continue at relatively lower values of 
plasma glucose. Serum levels of ouabain-like substance and cerebrospinal fluid levels 
of a putative endogenous pentapeptide with local anaesthetic (sodium channel 
blocking) effect were not increased in the CFS population. 
Results from the exercise study (SATET) indicate that as a group, CFS patients have 
considerable variability in their autonomic and cardiovascular responses to symptom 
limited, sub-anaerobic exercise. Some patients have a relative overactivity of the 
parasympatheic tone and fatigue in these patients is primarily central. Nearly half of 
those patients who were able to complete the exercise protocol had increased plasma 
lactate. Although this observation may be interpreted as an evidence of metabolic 
oxidative defects in the exercising muscles, there are a number of caveats to this 
conclusion. Post-exercise rises in plasma lactate levels are fairly non-specific and may 
be influenced by diet, peripheral circulatory return and autonomic regulation of blood 
flow to the exercising muscles. Patients who fall into the category of the exercise 
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intolerant subgroup have objective evidence of muscle wasting due to physical 
deconditioning. These patients are more likely to be women and have a higher risk of 
progressive disability. 
Neuroendocrine tests did not reveal any specific or diagnostic abnormalities affecting 
the dopamine Dz receptor systems. Analysis of buspirone augmented IZ3I_IBZM 
cerebral SPECT scans indicates that dopamine Dz receptor affinity is similar in CFS 
and healthy controls, although the smaller number of the control subjects marginalises 
any meaningful interpretation of the experiment. 
Preliminary result from a novel form of metabolic neuroimaging has been a 
particularly rewarding aspect of this research. IH-MRS of left basal ganglia in CFS 
patient has shown unequivocal evidence of increased levels of choline containing 
compounds without any loss of functional neuronal mass. Because choline resonance 
in IH-MRS is derived from membrane phospholipids and CFS patients do not have 
evidence of abnormal lipid metabolism, it is likely that the spectroscopic increases in 
choline reflect remodelling or rapid turnover of neural cell membranes. It appears that 
irrespective of the age of the CFS patients or the duration of their symptoms, choline-
containing compounds are elevated in the basal ganglia. Taken together, recent IH_ 
MRS observations in appropriately defined, non-psychiatric CFS popUlation 
objectively confirm an underlying neurobiological process affecting neural cell 
membrane function. IH MRS observations in this research emphasise the need to 
explore long-term effects of viral-cell interactions on membrane functions. Minimal 
and non-specific pallidal changes were the only consistent pathological abnormality 
observed in encephalitis lethargic a [229]. 
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Developing a neurobiological paradigm in CFS 
One ofthe main objectives of our research was to develop a neurobiological paradigm 
of fatigue in CFS and account for some of the observed heterogeneity in the research 
outcome as previously reviewed. The research findings are consistent with the view 
that the clinical heterogeneity is a function of biological variables. Changes in the 
relative balance of the autonomic nervous system appear to be an important predictor 
with respect to the symptom-limited exercise endurance in CFS. It is possible that 
these changes are determined by the inherent genetic predisposition, the nature of the 
precipitant or trigger of the illness, acquired dysfunction of the brainstem or limbic 
autonomic functions and changes in synaptic inactivation of norepinephrine. This 
research has drawn attention to a neuroanatomic pathway that may be relevant to the 
genesis of central fatigue. IH MRS clearly suggests abnormal membrane metabolism 
in basal ganglia and the following section briefly reviews the role of basal ganglia in 
central fatigue [33]. 
From Denny-Brown's experimental work on caudate ablation in monkeys, it became 
clear that damage to the caudate nuclei led to a condition in which animals had 
difficulty formulating internally driven responses [230]. Under normal circumstances, 
initiation and sequential performance of a task requires an internally driven 
mechanism integrated at the level of basal ganglia to prepare the emotive, motor and 
sensory apparatus ("cues") responsible for next and the subsequent set of responses. 
It is known that some ~triatal units maybe highly specific and organised to carry 
information about the predictive value of stimuli (the preparatory cues). Disruption of 
normal basal ganglia derived algorithm of the sequential task processing mechanism 
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would not only delay the initiation, but also prevent the smooth execution of the 
intended task, a feature that is typical of patients with central fatigue. 
Observations have confirmed that parts of the basal ganglia circuitry functionally 
involved in the non-motor and emotional process are linked to the frontal lobes [231]. 
Stahl originally proposed that the basal ganglia may be divided into a neurologist's, a 
psychologist's, and a psychiatrist's portion, responsible for motor, cognitive and 
emotional or behavioural disorders respectively [232]. In his plan, the circuitry for the 
extrapyramidal motor disorders was putamen based, while the caudate-dorsolateral 
prefrontal circuit and the ventral striatopallidal system, especially nucleus accumbens, 
accounted for the cognitive and behavioural syndromes respectively. 
The dorsolateral prefrontal circuit in the caudate (psychologist'S basal ganglia) is 
involved in the dopamine loss seen in Parkinson's disease where central fatigue is 
common. Disruption of this circuitry at the level of the striatum impedes the execution 
of appropriate tasks. The ventral striopallidal system (the psychiatrist's basal ganglia) 
has a more complex relationship involving the shell of nucleus accumbens (the ventral 
striatum) and the extended amygdala, incorporating connections with olfactory 
tubercle, hypothalamus and brain stem. While amygdala is anatomically organised to 
encode the emotional significance of sensory events [233], the lateral and medial 
orbitofrontal and cingulate circuits from ventral striatum may be involved in the 
evaluation of relevance of external events. 
The ventral striatum is richly innervated with meso limbic dopaminergic inputs 
(motivational/ reinforcement pathways) as well as with the converging inputs from 
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the orbitofrontal (affective/environmental associations), anterior cingulate (affective 
response) and the amygdaloid complex (emotional reactivity). Ventral striatum also 
exerts a global regulatory influence on the dopaminergic neurotransmission in the 
entire striatum, and is considered to represent the anatomic substrate for motivational 
anchoring and reinforcement of successful experience (rewarding or self-stimulatory 
behaviour). 
Voluntary action is controlled both by motivation and cognition; basal ganglia may be 
the site where these kind of information meet. The striopallidal system and the 
striothalamo-cortical loop may be an important common neuroanatomic pathway for 
central fatigue. The data from IH MRS certainly point to this direction. 
Cell membrane function and fatigue 
In this research, a common explanation for a number of observations has been cell 
membrane injury. Ion channels and receptors are normally expressed on the cell 
membranes of the excitable tissues. Depending on the functional characterlstics of 
these cells and their localisation both within and outside the nervous system, a range 
of symptoms may be experienced that will both variable in severity and inducible 
under conditions of physiological as well as psychological stress. Even if basal 
ganglia and their interconnecting pathways are central to the genesis of fatigue as a 
brain-derived symptom, one still has to explain what triggers dysfunction in this 
neural network in the first place. From the IH-MRS data, it appears that cell 
membrane remodelling, due to gliosis or increased cell membrane turnover may 
explain the increases in choline peaks in the basal ganglia of CFS patients. The 
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statistical strength ofthis observation was particularly high (p<O.OOl) even though the 
number of cases included in this study was small (8 patients and 8 controls). 
Long term changes in the neural cell membrane may be induced by viral proteins. In 
the known models of chronic viral infections (for example, HIV), membrane bound 
phospholipases are activated by viral protein. Activated phospholipases split choline 
off the membrane phospholipids (phosphatidy1choline and phosphoglycerocholine). 
While idiopathic CFS is not due to any known chronic viral infections, it begs the 
question whether those who become symptomatic of CFS after a non-specific 
infection may have altered cell membrane function sustained as a result of complex 
interplay between genetic factors, infective agent and the subsequent adaptive 
response of the host. This paradigm is certainly supported by the CFS-like syndrome 
developing in a proportion of patients with ciguatera fish poisoning where a specific 
neurotoxin (ciguatoxin) modifies host cell function by permanent inactivation of the 
membrane sodium channels. Fatigue is recognised symptom of diseases and drugs 
that affect cell membrane and ion channel functions. 
Limitations of the present research 
A number of limitations may, however, apply to this work. For the majority of 
experiments undertaken in this research, different cohorts of CFS patients were 
recruited. The inherent heterogeneity in the clinical diagnosis of CFS, biological 
variability of the different groups of patients and controls might contribute to the 
inconsistency of findings. The choice of controls in the experiments was mostly 
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healthy (but not necessarily physically active) individuals. Ideally, one should have 
included patients with psychogenic fatigue (clinical depression) as a third control 
group. Inclusion of physically deconditioned healthy subjects as controls might have 
been ideal. The small number of cases in some of our experiments might account for 
findings of significance (positive G-protein coupled receptor antibody) or lack of 
significance (normal frequency ofHFE gene mutation). For experiments based on off-
site laboratory analysis, preservation and transportation of samples could have 
affected their qualities and final results. 
The research may also be criticised for not analysing power in the therapeutic trials 
and experiments. We consider all our experiments and the two therapeutic trials to be 
pilot studies of testing hypotheses rather than formal validation of any existing or 
proven theories. The interpretation of the present research data needs to be cautious 
and the evidence presented should be considered to provide only limited, but in some 
way useful, information for the next phase of neurobiological research in CFS. 
Neurobiological research in CFS 
Because of the overlap of CFS with depression and chronic anxiety, many physicians 
prefer to invoke a psychiatric explanation for fatigue when patient's symptoms do not 
fit a neurological diagnostic category. This is particularly true for CFS. Anxiety and 
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Flow Chart 4. A biological model of chronic fatigue based on neuroendocrine 
functions. In susceptible individuals, environmental stressors induce changes in the 
neuroendocrine axis primarily through the hypothalamic pituitary (HP A) axis and the 
norepinephrine (NE) system. Depending on the type of stressor (acute vs. repetitive/ 
chronic), responses may move in the opposite direction. Changes in synaptic 
sensitivities of the corticotrophin releasing hormone (CRR) , serotonin (5 HTIA) and 
alpha2 adrenergic receptors determine both the nature and the severity of fatigue-
associated symptoms (e.g. muscle pain, sleep disorder, orthostatic intolerance and 
anxiety). Both in men and women, prolactin is secreted from the anterior pituitary 
under conditions of stress. Prolactin secretion from pituitary is tonically suppressed 
by dopamine which is considered to be the hypothalamic prolactin-inhibitory factor. 
Prolactin release under stress is independent of, and probably occurs earlier than, the 
CRR-induced release of the pituitary adrenocorticotrophic hormone (ACTH) . 
~ 
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reactive ("exogenous") depression are associated with a number of medical disorders 
such as dysthyroid state and mUltiple sclerosis and stress is considered to be a 
common link between the biological and psychosocial events. Tissue cortisol reserve 
and the rate of synaptic inactivation of norepinephrine are important biological traits 
that may predispose to the development of chronic fatigue after significant 
physiological or psychological stress. Based on the interaction between the common 
environmental stressors and biological variables, it is possible to derive a 
neurobiological model of central fatigue (Flow Chart 4). 
A consistent feature of CFS is a higher level of perceived fatigue. Voluntary effort is 
influenced by multiple control systems and perceived fatigue in response to exertion 
is an important feedback control to the effort applied. The perception of fatigue is 
controlled by both biological and psychological variables. It appears that central 
fatigue in CFS is due to the metabolic and/or functional changes that affect the same 
neural network responsible for the normal perception of fatigue. With respect to CFS, 
higher levels of perceived fatigue may be induced by alterations in the internal 
environment either due to neuroendocrine changes or a lack of limbic integration of 
voluntary motor activities at the level of the basal ganglia. 
We had a number of aims in this research. With respect to the questions asked, we 
found no significant alteration of intermediate metabolism in CFS. There is also 
imited evidence in favour of energy utilisation and expenditure in CFS. Skeletal 
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muscle physiology is normal in CFS patients. Three distinct subgroups of the CDC-
defined CFS patients can be identified by standardised, symptom-limited exercises. 
The response of the aminergic system in CFS to external pharmacological challenge is 
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variable but the neuroendocrine tests do not show any alteration in the hypothalamic-
pituitary dopaminergic system. There is unequivocal evidence of altered regional 
brain metabolism in CFS, characterised by increased peaks of choline in the neural 
membranes of the basal ganglia. An increased choline level in the I H MRS of basal 
ganglia is a possible neurobiological marker of the central fatigue in CFS. 
Further research will hopefully define the possible pathophysiologic mechanism(s) 
within these individual subgroups and outline the interaction between the various 
physical and psychological changes. Ideally, this research should take the form of a 
prospective study, following several patients from their initial visits to the primary 
care physicians with a complaint of ill-health, right through to the diagnosis of 
chronic fatigue, CFS, and beyond. It also needs to be explored whether individual 
predispositions to the host-viral interaction may determine the consequent changes in 
the functions of the specific neurotransmitters, receptors, ion channels and/or enzymes 
at the different neuroanatomic levels of the autonomic nervous system in CFS. This 
appears to be the only way forward to disentangle CFS from the controversy that 
currently surrounds its existence and care. 
Many physicians prefer to invoke a psychiatric explanation for fatigue when patients' 
symptoms do not fit a common medical or neurological diagnostic category. The 
classical descriptions of the major psychiatric disorders have been fairly consistent 
over the years and when a patient with fatigue perfectly fits the criteria for a 
psychiatric disorder outlined in DSM-IV [234], one can certainly have confidence in 
the diagnosis. However, it is when patient's symptoms or clinical course do not fit or 
fit the diagnostic criteria poorly, one needs to be cautious. There is good evidence at 
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present that the brain-derived, central fatigue is related to the circuits that connect 
basal ganglia, amydgala, thalamus and frontal cortex. Thalamus is an important centre 
for afferent input from the reticular activating system and sensory pathways. Basal 
ganglia, through its link with amygdala, limbic system and the neocortex, especially 
frontal lobe, act as an important integrator of motivational activities. While fatigue is 
likely to follow structural lesions in this circuit, fatigue due to metabolic changes or 
neurotransmitter disturbance affecting these pathways are more common and may 
occur in the absence of obvious structural injury. Common neuropsychological 
consequences of central fatigue are reduced speed of information processing and 
attention deficit, generating a sense of excessive mental fatigues and interfering with 
performance rather than competence in dealing with the task. Symptoms like muscle 
pain, sleep disorder and co-morbid anxiety in fatigued patients may be partly 
explained by changes in the sensitivity of post-synaptic receptors that are triggered by 
the interactions between environmental stressors, genetic predisposition and the HP A 
axis responsiveness (Flow Chart 4). 
In summary, the perception of fatigue is controlled by both biological and 
psychological variables. This review underscores the importance of interpreting 
central fatigue on the basis of changes in cerebral metabolism and/or neurotransmitter 
function affecting subcortical-cortical network. It would be both incorrect and 
inappropriate to imply fatigue to be a medically unexplained, non-organic symptom in 
patients who do not have a primary psychiatric diagnosis. This likely mechanism of 
fatigue in CFS is central and while muscle metabolic abnormalities may be present in 
a few patients, there is an overall lack of evidence to suggest a peripheral 
(neuromuscular) role. Cell membrane receptors and ion channels may emerge as 
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candidate genes for future research in this area. Future research in CFS should ideally 
explore the central component of fatigue by using a combination of functional 
neurOlmagmg and neuroendocrine probes. To be sure, advances in modem 
neurOlmagmg and molecular neurosciences will offer better definition of the 
anatomical network and molecular pathophysiology of fatigue. Future development of 
drugs that act directly on the HP A axis, hypothalamic neuropeptides and the central 
glucocorticoid receptors will be important in our understanding of central fatigue and 
its cognitive and affective overlap. As in other complex medical problems, only the 
open minded, who are willing to consider observations and explanations at many 
different levels, are likely to succeed in offering the right solutions [235]. 
184 
17. CONCLUSIONS 
"Life is the art of drawing sufficient conclusions from insufficient premises" (Samuel 
Butler, 1912) 
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The findings in this research support the view that the primary origin of fatigue in 
CFS is in the central nervous system, i.e. fatigue is central in CFS. The research data 
also raise the possibility that the central fatigue in CFS correlates with altered 
signalling in the neuronal network that is connected to the basal ganglia. This 
alteration in neuronal signalling may be caused, among other possibilities, by an 
acquired dysfunction of the cell membranes with increased levels of membrane lipid 
breakdown. Central autonomic functions are also affected in CFS, probably by a 
mechanism affecting cell membrane receptor responses to the neurotransmitters and 
circulating hormones. Metabolic influences, anaesthetics and pharmacological agents 
that target membrane lipids can cause further dysregulation of transmembrane ion 
traffic and worsen fatigue. There is no evidence that specific neuronal loss is a feature 
of CFS. There is also no evidence that CFS is a muscle disease or primary muscle 
pathology is essential for CFS symptoms. The implications of the present research are 
summarised in Box 3. 
Understandably, therapeutic options for correcting cell membrane lipid breakdown are 
going to be difficult. Drugs that stabilise cell membranes, such as HUF A, centrally 
active beta-blockers, anti epileptics like carbamazepine may have some effect but 
individual responses could be highly variable and the efficacy of any intervention in 
CFS will be difficult to interpret without a randomised trial. It is also possible that 
what we define today as CFS consists of heterogeneous patients with different 
pathophysiological mechanisms awaiting better definition and segregation into 
subgroups. Once this is' achieved, there may possibly be diagnostic markers and 
therapeutic options for each of the defined subgroups of the CFS patients. 
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Box 3. What this research shows 
• CFS patients do not have any deficiency of essential fatty acids or camitine. 
CFS p_atients are not pre-diabetic or hyperinsulinemic but do show a degree of 
peripheral overutilisation of glucose possibly due to beta cell "insulin leak". 
• CFS patients do not have a genetic predisposition to haemochromatosis. 
• CFS patients do not have a specific or sensitive serum marker for autoantibody 
or ouabain-like substance. Cerebrospinal fluid levels ofNa+-channel blocking 
endogenous pentapeptide (QYNAD) are similar in CFS patients as compared 
to patients with neuroinflammatory disorder and benign headache syndromes. 
• Muscle histology in CFS patients is normal. 
• Intramuscular concentrations of Na+, K+ and Na+IK+-ATPases are normal in 
CFS. 
• Exercise response to CFS patients is influenced by the autonomic tone. Based 
on their physiological and metabolic responses to a standardised symptom-
limited exercise, CFS patients can be divided into three groups:( central 
. fatigue, metabolic fatigue and exercise intolerant fatigue). Patients with 
exercise intolerant fatigue are at high risk of progressive disability. 
• Neuroendocrine response to dopaminergic stimulation is normal III CFS. 
Buspirone-augmented 123J_IBZM SPECT scans do not suggest significant 
changes in the pallidal dopamine D2 receptor binding to buspirone in CFS. 
• lH MRS of basal ganglia is abnormal in non-psychiatrically defined adult 
cases with CFS. Significantly increased levels of choline in the basal ganglia 
lH MRS may indicate a pathology that affects the structure and/composition 
of the neural cell membranes in CFS patients. 
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In clinical practice, CFS must not be viewed in complete isolation from fatigue due to 
other medical or neurological disorders. Stereotyping CFS patients as depressed or 
somatising individuals is probably inaccurate and might jeopardise an effective 
therapeutic partnership developing between the patient and hislher physician. Failure 
to recognise fatigue or its importance in a patient may undermine the physician-
patient relationship that is vital for any successful therapeutic partnership. It is easy to 
dismiss subjective fatigue as a largely psychological phenomenon though it may be 
open to debate what precisely constitutes this psychological process. From a 
neurologist's viewpoint, fatigue may be accepted as a psychological problem 
provided "psyche" is defined as the collective force of integrative cortical function 
driven by the physiological principles of neuroscience. On the other hand, if the 
psychological process in fatigue is equated with the unsubstantiated hypotheses of 
illusory perception of effort, wrong body image, avoidance behaviour for physical 
activity or functional somatic syndrome, then it is a tragic fallibility of science. Lest 
we forget, Charcot, one of the founders of modern neurology and psychiatry, had 
emphasised more than a century ago, " When a patient calls on you, he is under no 
obligation to have a simple disease just to please you". Nothing provides a better 
example than CFS. No doubt, improving the understanding ofthe basic mechanism of 
fatigue and its treatment in CFS will have significant connotations for neurological 
patients with disorders of central fatigue. 
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19. APPENDIX: Clinical Proforma and the Glasgow Fatigue Scale 
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One difficulty that exists in the assessment of CPS patients and their response to a 
therapeutic intervention is the lack of an appropriate rating scale. Most fatigue rating 
scale used in the assessment of CPS are not specifically designed for CPS patients and 
do not take into account their fatigue symptoms and the overlapping features that 
often co-exist, such as syndrome X or irritable bowel syndrome. Since it is impossible 
to ascertain the efficacy of any therapeutic claim in CPS in the absence of a specific 
and sensitive disease marker, we have recently developed a CFS Rating Scale based 
on symptom severity. This has a total score in excess of 200 points and takes into 
account not only the symptoms of fatigue and myalgia and the activities of daily 
living but also other symptoms related to cardiac, neuropsychiatric and 
gastrointestinal changes frequently experienced by these patients. This scale has been 
used in the clinical assessment of the CDC-defined CPS patients. 
The final score in the CPS rating scale was calculated by adding all individual 
subscores and then dividing this figure by 10 and approximating the value to the 
nearest full number. Accordingly, the maximum possible score in this scale is 25. The 
scale was used in 90 CPS patients with a duration of symptoms of 1-15 years (mean 
4.5 years). The normative data was derived from 30 healthy subjects. 
In the CPS patients, the final score ranged from 3-19 (mean score: 9) out of a possible 
25. The final score in the normal subjects was always <1 (mean score: 0). Thus, the 
rating scale may reliably distinguish CPS patients from normal healthy subjects. 
However, it needs to be validated against other fatiguing disorders and depression to 
determine its specificity and sensitivity in the CDC-defined CPS population. 
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CHRONIC FATIGUE SYNDROME 
PATIENT'S PROFORMA 
A: Patient Characteristics 
Name: Sex: MIF D.O.B. 
Study No: ________ _ 
Address : 
----------
GP details: ________ _ 
B: Personal History 
Main Complaints: 
------
Hospital (Unit No.) 





C: Duration of CFS and related symptoms: 
When were you first diagnosed as CFSIME? 
Duration of fatigue: more than 5 yrs, 3-5 yrs, 2-3 yrs, 1-2 yrs, 6 months to 1 year? 
Onset offatigue: 
acute onset (can recall the precipitating event with the date), 
subacute 
gradual or insidious onset. 
How did you get it* - after a 'flu-like illness? 
- after a chest infection? 
- after diarrhoea? 
- after a stressful event? 
- after immunisation? 
- after trauma? 
* (In each of these, please specify the nature of the event, i.e. type of stress, such 
as bereavement, type of trauma such as surgical intervention, and the nature of the 
vaccine given.) 














Did you test positive for any of the following viruses or bacteria after you had the 
symptoms of CFS? 
Coxsackie AlB Infectious mononucleosis (EBV) 
Chlamydia Rubella 
Influenza Herpes simplex 
Brucella Campylobacter jejuni 
Have you had any change in weight since being diagnosed with CFS? YESINO. 
Do you have any of the following: Gilbert's syndrome 
Hepatitis B vaccination 
Jaundice 
Coeliac disease 
Irritable bowel syndrome 
Asthma! other atopic diseases 
Allergies to food or drugs (specify) 
Craving for salt, bread, sweets, or chocolate 
Chest pain 
Prostatism (in males) 
Endometriosis / Polycystic ovarian disease 
(in females) 





Is there any history of asthma or eczema in any members of your family? 
Is there anyone else in your family who suffers from CFS? 
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Did you participate in any of the studies of CFS? If yes please indicate when, where 
(which hospital) and nature of the study. 
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D: Exposure to Toxins/Chemicals: YES/NO 
If YES: 
time of exposure / / 
ddmmyy 
name of chemical/suspected toxin 
route of entry: ingestion/inhalation/skin contamination. __________ _ 
approximate duration of exposure _____ (days, weeks, months) 
symptoms: 
Laboratory tests: POSITIVEINEGATIVE 
diagnosis: CERTAINAJNCERTAIN 
treatment taken for presumed toxic exposure __________ _ 
E: Treatment History 







Newer antidepressants (e.g. RMAOI, Effexor, Edronex) 
,. 




Lamotrigine or Carbamazepine 
Gabapentin 
Complementary therapy: Fish oil, Primrose oil, Chinese herbs, St. John's 
Wort, aromatherapy, reflexotherapy, acupuncture, nutritional therapy 
Others (please specify): 
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Have your been under any kind of anaesthesia before or after the development 
ofCFS? YESINO. 
If YES, please specify the nature of the anaesthetic and whether it had 
precipitated or changed the course of the fatigue symptoms. 
Have you taken any of the following antibiotics in the course of your current 
illness due to CFS or for any other reason? 





(Erythromycin, Clarithromycin, Roxithromycin) - (please record if any of the 
antibiotics had any influence in the course of the fatigue symptoms) 
Have you taken any other medications or therapy that might have influenced 
the course of your fatigue? 
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F: Past Medical History 
Pre-morbid psychiatric disorders 1. 
---------------------------(e.g. depression, anxiety neurosis, 
hyperventilation, hypochondriasis 2. 
---------------------------
or major affective disorder) 
Endocrine disorder 
(e.g. diabetes, thyroid diseases 
including thyroiditis, hypo-
pituitarism) 
Recurrent infectious diseases 
(e.g. gastroenteritis, influenza) 
3. ___________ _ 
4. ________________________ _ 
1. _______________________ _ 
2, 
---------------------------
3 .. ___________ __ 
4. ___________ _ 
1.. ___________ _ 
2 .. _____________________ _ 
3. _______________________ _ 
4. ___________ __ 
Immunologic/hypersensitivity disorders 1. 
---------------------------(e.g. asthma, drug-sensitivity, rhinitis, 
thyroiditis, SLE, rheumatologic disorder) 2. 
'---------------------------
3., ____________________ _ 
4. 
---------------------------
GI disorders 1. ______________ _ 







Neurological disorders 1 .. _____________ _ 
(e.g. migraine, multiple sclerosis, polio 
Parkinson's disease, epilepsy) 2 .. _____________ _ 
Cardiovascular disorder 
(e.g. coronary artery disease, 
syndrome X, hypertension, 
peripheral vascular disease) 
G: Previous laboratory investigations 
3. ____________ _ 
4 .. _____________ _ 
1.. ____________ _ 
2. ____________ _ 
3. ____________ _ 
4. _______________ _ 
Full blood count (please record ifthere was any neutropaenia) 
ESR 
Urea and Electrolytes 







Any other tests: 
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H: Family History 
Do you have any member of your family suffering from asthma, eczema, irritable 
bowel syndrome, Gilbert's syndrome, haemochromatosis, cirrhosis of liver, 
Parkinson's disease, polio, Alzheimer's disease, suicidal depression, epilepsy, 
migraine or cardiovascular disease.? 
Is there anyone in your family or in close neighbourhood to you who could be 
suffering from chronic fatigue syndrome or CFS? 





first degree relatives 
(e.g. cousins) 
I: History of concomitant medications 
Name of Condition for Duration of Adverse effects 
medication which prescribed Treatment if any 
,. 
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J: Personal History 
Place of residence in the recent past (beginning with current one) 
1.. ________________________ _ 
2. __________________________ _ 
Occupation: ___________ _ EmployedlUnemployed __ _ 
Employment status in past five years (beginning with current one) 
1 _____________________________________ __ 
2, _______________________________________________ _ 
Marital status (single/married/living with partner) 
(for females between 15-45 years): contraception practiced 
If YES, mode of contraception 
Handedness: right/left/ambidextrous 
Smoker? 
If YES, number of cigarettes smoked per day 
Alcohol consumption (per week) 








Is the patient living at home/at an institution? If the patient is at home, please record: 
other family members/carers looking after the patient. 
Are the patient's home circumstances adequate for the level ofhislher disability? 
Has the patient applied for any kind of disability benefit on account of CFS? 
CFS Rating Scale 
1.1 Fatigue 
(maximum score = 20) 
20 = at rest 
15 = after getting up from restful night's sleep 
12 = after any of: bathing, dressing self, eating a meal 
9 = after daily routine household activities 
6 = after less than half (50%) of previous level of outdoor 
activity 
3 = after less than usual (but more than half of) the previous level 
of outdoor activity 
o = after strenuous activity 
1.2 Activities of daily living 
(maximum score = 20) 
20 = bed or chairbound for most of the waking period 
15 = requires support for some of the ADL 
12 = requires no support for ADL, but housebound 
9 = left job due to CFS 
6 = working at less than half (50%) of the normal capacity 
3 = working at less than previous capacity 
0= working at normal capacity 
1.3 Walking at a normal pace (unsupported) 
(maximum score = 12) 
12 = cannot walk 
9 = can walk up to 100 metres 
6 = can walk more than 100 but less than 300 metres 
3 = can walk more than 300 but less than 600 metres 
1 = can walk more than 600 metres but less than a km 
o = can walk more than a km 
1.4 Course of fatigue 
(maximum score = 6) 
6 = fluctuating fatigue, but without any clear remission 
3 = relapsing and remitting fatigue 
2 = progressive fatigue 
1 = stationary fatigue state, or fluctuation AM more than PM 
0= improving fatigue 
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1.5 Post-exertion malaise 
(maximum score = 6) 
6 = severe worsening of fatigue 
3 = moderate worsening of fatigue 
1 = mild worsening of fatigue 
0= no difference from fatigue at rest 
SECTION 1 TOTAL MAXIMUM SCORE = 64 
II Physical symptoms (other than GI or Psychological) 
ILl Myalgia in more than one limb 
(maximum score = 6) 
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For any of the upper or lower extremities 
3 = severe 
2 = moderate 
1 = mild I I I I 
11.2 Neck & shoulder pain (must be present for some time daily) 
(maximum score = 3) 
3 = severe, requires rest and analgesic 
2 = moderate, requires analgesic only 
1 = . mild and tolerable, usually analgesics not required I I I I 
11.3 Arthralgia (without joint swelling or redness) in more than one limb. 
(maximum score = 6) 
(for both upper and lower extremities, add score for individual extremity) 
For any limb 
3 ~ severe I I I I 7: :~erate 
11.4 Unexplained muscle weakness (Grade 4 or less in MRC Scale) 
(maximum score = 6) 
For any of the upper or lower extremities. 
3 ~ severe I I I I 7: :~erate 
11.5 Headache 
(maximum score = 6) 
6 = severe, throbbing headache preventing work, requiring 
complete rest. 
3 = moderately severe headache with visual symptoms or 
nausea. 
2 = daily headache requiring intermittent use of analgesics. 
1 = mild and occasional headache. 
0= mild and tolerable headache, usually analgesics not required. 
11.6 Dysequilihrium (symptoms of dizziness) 
(maximum score = 6) 
6 = symptoms of dizziness accompanied by nausea and vertigo 
present almost daily, severe, requiring rest and medication. 
3 = symptoms of nausea and vertigo present frequently (3 days a 
week), requiring rest or medication 
2 = symptoms of nausea or vertigo or dizziness present 
sometime during the week 
1 = any of the symptoms of nausea or vertogo, present 
occasionally (less than once a week. 
11.7 General physical symptoms 
(maximum score = 6) 
2 = documented fever 
2 = documented non-exudative pharyngitis 
2 = documented lymphadenopathy 
o = undocumented symptoms 
11.8 Visual symptoms 
(maximum score = 6) 
2 = photosensitivity or meningism 
2 = temporary visual obscuration or difficulty in focussing 
2 = dark spots in front of eyes or scintillating scotomas 
11.9 Sweating 
(maximum score = 6) 
6 = profuse, unexplained drenching sweats, frequent, at night 
time and daytime, necessitating change of clothing. 
3 = frequent unexplained night time and daytime sweating - no 
change of dress required 
2 = occasional unexplained night or daytime sweats 
1 = sweating due to environmental reasons. 
o = no sweating 
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I I I I 
11.10 Chest Pain (maximum score = 9) 
9 = syndrome X 
6 = frequent attacks of chest pain, diagnosed as atypical angina. 
EeGs normal or showing only mild changes 
3 = occasional attacks of precordial chest pain occurring at rest 
or on effort 
2 = attacks of precordial chest pain only on severe effort 
1 = any other chest pain (eg left inframammary chest pain) 
o = no chest pain 
11.11 Frequent 'flu' like illness/sore throat or other viral illnesses 
(maximum = 3) 
3 = > 6 attacks a year 
2 = 3 - 5 attacks a year 
1 = 1 - 2 attacks a year 
11.12 Craving for sweets/chocolateslbreads. 
(maximum score = 6) 
6= insatiable craving - must take out of meal chocolates, sweets 
or bread every day and night. 
3= strong craving - frequent consumption of chocolates and 
sweets almost daily. 
2= modest craving - feels happy to take sweets or chocolates but 
never every day. 
1 = . occasional craving. 
0= no craving. 
11.13 Change in body weight since the onset of fatigue. 
(maximum score =9) 
9= persistent (static or progressive) loss of weight 
6= cyclic weight changes throughout the month, with or without 
oedema (idiopathic cyclic oedema). 
3= initial loss of weight, followed by gain but not above the 
baseline weight. 
2= Initial loss of weight, followed by steady gain with 
substantial increase in body weight. 
1 = no loss, but steady weight gain. 
0= no change in body weight (any loss or gain). 
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11.14 Neurological signs (documented) 
(Maximum score = 15) 
3 = tremors 
3 = fasciculation and myokymia 
3 = hemisensory syndrome 
3 = alternate feelings of hot and cold. 
3 = unsteadiness of gait, Rombergism or difficulty in walking in 
tandem 
SECTION II TOTAL MAXIMUM SCORE = 93 
III GI Symptoms (Irritable Bowel Syndrome) 
111.1 Chronic abdominal pain 
(maximum score = 6) 
6 = chronic severe generalised abdominal pain interfering with 
work and social function 
3 = intennittent generalised moderately severe pain but 
associated with constipation - diarrhoea 
2 = chronic intennittent pain confined to lower abdomen, 
relieved by passage of flatus or stool -
1 = occasional pains with bloating or heartburn or waterbrash 
0= nopam 
111.2 Vomiting 
(maximum score = 6) 
6 = frequent vomiting for no apparent cause 
4 = vomiting induced by food 
3 = occasional nausea associated with abdominal pain 
2 = constant nausea 
1 = occasional nausea 
o = no vomiting or nausea 
111.3 Borborygmi 
(maximum score =~ 3) 
3 = continuous borborygmi with social embarrassment 
2 = occasional borborygmi with abdominal pain 
1 = borborygmi with abdominal distension 
o = no borborygmi 
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111.4 Abdominal distention 
(maximum score = 6) 
6 = marked distension causing discomfort in sitting, lying or 
wearing clothes 
4= distension occurring at times, i.e. before menstrual periods 
3= distension with synptoms of indigestion and heartburn 
1 = mild occasional distension alone 
o = no distension 
111.5 Change in bowel movement 
(maximum score = 6) 
6 = episodes of diarrhoea alternating with prolonged constipation 
requiring laxative or suppository 
3 = variable patterns, alternating with hard and soft stools or 
intermittent diarrhoea or constipation. 
2 = constipation alone or increased frequency of motions 
1 = transient changes in bowel habit lasting no more than one to 
two days 
o = regular bowel movement 
SECTION III TOTAL MAXIMUM SCORE = 27 
IV. Neuropsychological symptoms 
IV.l Change in sleep pattern 
(maximum score = 9) 
9 = difficulty in falling asleep, frequently broken sleep & 
increased daytime sleepiness; frequent nightmares. 
6 = broken sleep, increased daytime sleepiness but without 
nightmares. -
4 = sleeping excessively (more than 12 hours a day) or too little 
sleep ( less than 5 hours a day). 
3 = frequently falling offto sleep without any change in night 
time sleep. 
1 = slight increase or change in sleep pattern 
o = normal sleeping patters. 
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IV.2 Concentration difficulties 
(maximum score = 6) 
6 = difficulty in concentrating in all kinds of activities including 
visual and recreational with impaired attention span on 
formal testing. 
3 = inability to concentrate in visual and conversational tasks 
more than recreational activities. 
2 = some impairment in the ability to read or hold a conversation 
but usually not affecting social life; normal concentration in 
recreational activities. 
1 = intermittent difficulties in collecting one's thoughts but no 
persistent symptoms. 
o = no difficulty in concentrating 
IV.3 Apathy 
(maximum score = 3) 
3 = complete apathy: unable to do anything without help 
2 = difficulties in starting simple routine activities which are 
carried out 
with effort 
1 = difficulty in starting routine activities, but these can be 
carried out without much effort 
o = no difficulty in getting started with routine activities 
IV.4 Self-assessment of symptoms 
(m"aximum score = 3) 
3 = loss of interest in life 
2 = loss of interest in surroundings; loss of feeling for friends 
and family 
1 = reduced ability to enjoy usual interests 
o = normal interest in surroundings and in other people 
IV.5 Sadness 
(maximum score = 6) 
-
6 = looks sad and generates comments from family and friends 
that patient appears depressed. 
3 = looks sad, rarely smiles and work and duties affected 
2 = looks sad but can brighten up with appropriate social contact 
1 = feels sad but not all of the time. 
0= normal 
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IV.6 Excessive irritability 
(maximum score = 6) 
6 = highly irritable, cannot participate in usual conversation 
without frequent outbursts of temper 
4 = irritable; can converse but cannot hide anger or irritation; 
makes frequent gestures 
3 = spouse and family complain of irritability 
2 = excessive reaction at times to nonnal stimuli 
1 = occasional irritability and outbursts of temper 
o = no or transient irritability 
IV.7 Rapid changes in mood 
(maximum score = 3) 
3 = totally unpredictable mood, with changes from low to high 
several times during a day. 
2 = changes in mood at least on one occasion every day. 
1 = occasional changes in mood. 
0= no major mood changes. 
IV.S Hallucinatory symptoms 
(maximum score =3) 
3 = frequent hallucinatory symptoms (visual or auditory) 
interfering with daily life. 
2 = intennittent hallucinatory symptoms without any impact on 
daily life 
1 = occasional or transient hallucinations 
o = no hallucinations 
IV.9 Anomia 
(maximum score = 6) 
6 = excessive delay and pause in most sentences due to inability 
to name objects and persons 
5 = conspicuous difficulty in use of words and naming with 
substitution 
4 = errors in naming in routine conversation 
3 = occasional errors in naming 
2 = difficulty with names of people 
1 = minor difficulties in naming with substitution 
o = normal speech 
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IV.10 Memory impairment 
(maximum score = 6) 
6 = progressive impairment affecting short-term memory and 
interfering with daily life. 
4 = impairment of short term memory, non-progressive, but 
causing social embarrassment. 
3 = memory deficits connected by prompting 
2 = frequent difficulty in remembering recent events but without 
any interference with social or daily life. 
1 = occsasional or transient difficulty in short term memory. 
o = no impairment. 
IV.11 Intolerance to alcohol or antidepressants or antibiotics. 
(Maximum score = 6) 
2 = intolerance to alcohol 
2 = intolerance to tricyclic antidepressants 
2 = intolerance to antibiotics 
SECTION IV TOTAL MAXIMUM SCORE = 57 
Maximum Score: (Sections I -IV) = 241 
Subscores: 
Fatigue and neuropsychiatric symptoms: (I+IV) 
Musculoskeletal and gastrointestinal symptoms: (II+III) 
FATIGUE SCORE: Total score divided by 10 (range: 0-24) 
Definitions of improvement or deterioration: 
Change of Final Score by 6 or 25% of the baseline. 
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